Protocol Title: 
VRC 614 (000536): A Phase 1, Dose Escalation, Open
-
Label Clinical Trial with 
Experimental Controlled Human Malaria Infections (CHMI) to Evaluate Safety and Protective 
Efficacy of an Anti
-
Malaria Human Monoclonal Antibody, 
VRC
-
MALMAB0114
-
 
00
-
AB 
(L9LS), in Healthy, Malaria
-
Naive Adults
 
 
NCT: 
05019729
 
 
Documents:
 
·
 
IRB
-
approved Protocol (v2.0 03NOV2021) 
-
 
Statistical Analysis Considerations located 
in Section 6 of the Protocol 
 
·
 
IRB approved 
ICF (v2.0 03NOV2021) 
-
 
IRB Approval/Do
cument Date: 01DEC2021
 
 
 
 
 
 
Version 
2.0 
November 3, 
202
1
 
 
VACCINE RESEARCH CENTER
 
 
Protocol VRC 614 
NIH 
000536
 
 
 
 
 
Title: A Phase 1, Dose Escalation, Open-
Label Clinical Trial with Experimental Controlled 
Human Malaria Infections (CHMI) to Evaluate Safety and 
Protective Efficacy of an Anti
-
Malaria Human Monoclonal Antibody, VRC-
MALMAB01
14-00-
AB (
L9
LS), in Healthy, 
Malaria
-
Naive Adults
 
 
Abbreviated Title: 
L9LS 
in Healthy Adults
 
  
 
IND Sponsor
 
Vaccine Research Center (VRC)
 
National Institute of Allergy and 
Infectious Diseases (NIAID)
 
Bethesda, Maryland, US 
 
IND 
155252 
 
 
Investigational Product 
L9
LS Manufacturer:
 
Vaccine Clinical Materials Program (VCMP) operated under contract 
 
by Leidos Biomedical Research, Inc.,  
Frederick, Maryland, US
 
 
 
 
 
NIH Principal I
nvestigator:
 
Richard Wu
, M.D.
 
VRC/NIAID
 
Email: 
richard.wu2@nih.gov
 
 
 
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
2
 
of 
73
 
 
 
TABLE OF CONTENTS
 
 
TABLE OF CONTENTS
 
................................
................................
................................
.................
2
 
LIST OF TABLES
 
................................
................................
................................
...........................
5
 
ABBREVIATIONS
 
................................
................................
................................
.........................
6
 
PRINCIPAL INVESTIGATOR PROTOCOL SIGN
ATURE PAGE
 
................................
.............
8
 
PRÈCIS
 
9
 
STATEMENT OF COMPLIANCE
 
................................
................................
...............................
10
 
1.
 
INTRODUCTION
 
................................
................................
................................
......
11
 
1.1.
 
Study Rationale
 
................................
................................
................................
...........
11
 
1.1.1.
 
L9LS Development
 
................................
................................
................................
.....
11
 
1.1.2.
 
Rat
ionale for Study Design
 
................................
................................
.........................
12
 
1.1.3.
 
Addition of Intramuscular Injection Cohort in v.2.0
 
................................
..................
12
 
1.2.
 
Background
 
................................
................................
................................
.................
12
 
1.2.1.
 
Previous Human Experience
 
................................
................................
.......................
12
 
1.2.2.
 
Controlled Human Infections (CHI)
 
................................
................................
...........
13
 
1.3.
 
Laboratory Assessments of L9LS
 
................................
................................
...............
14
 
1.3.1.
 
Pharmacokinetic (PK) Analysis
 
................................
................................
..................
14
 
1.3.2.
 
Detection of Anti
-
Drug Antibody
 
................................
................................
...............
14
 
1.4.
 
Measures of mAb
-
Mediated Protection and Parasitemia
 
................................
...........
14
 
2.
 
STUDY PRODUCT AND CHMI
 
................................
................................
..............
15
 
2.1.
 
Study Product: L9LS
 
................................
................................
................................
..
15
 
2.2.
 
Preclinical Experience
 
................................
................................
................................
15
 
2.2.1
 
Tissue Cross
-
Reactivity (TCR) Study
 
................................
................................
........
15
 
2.2.2
 
Rat Toxicity Study
 
................................
................................
................................
......
15
 
2.3.
 
Clinical Experience
 
................................
................................
................................
.....
16
 
2.4.
 
Con
trolled Human Malaria Infection (CHMI)
 
................................
...........................
16
 
3.
 
STUDY OBJECTIVES
 
................................
................................
..............................
17
 
3.1.
 
Primary Objectives
 
................................
................................
................................
.....
17
 
3.2.
 
Secon
dary Objectives
 
................................
................................
................................
.
17
 
3.3.
 
Exploratory Objectives
 
................................
................................
...............................
17
 
4.
 
STUDY DESIGN AND CLINICAL PROCEDURES
 
................................
...............
18
 
4.1.
 
Study Population
 
................................
................................
................................
.........
18
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
3
 
of 
73
 
4.1.1.
 
Inclusion Criteria
 
................................
................................
................................
........
18
 
4.1.2.
 
E
xclusion Criteria
 
................................
................................
................................
.......
20
 
4.2.
 
Inclusion of Vulnerable Subjects
 
................................
................................
................
21
 
4.2.1.
 
Children
 
................................
................................
................................
......................
21
 
4.2.2.
 
Adult Subjects who Lack Capacity to Consent to Research Participation
 
.................
21
 
4.2.3.
 
NIH Employees
 
................................
................................
................................
..........
21
 
4.3.
 
Clinical Procedures and Evaluations
 
................................
................................
..........
21
 
4.3.1.
 
Recruitment and Retention
 
................................
................................
.........................
22
 
4.3.2.
 
Screening
 
................................
................................
................................
....................
22
 
4.3.3.
 
Enrollment and Study Day 0
 
................................
................................
.......................
23
 
4.3.4.
 
Product Administration
 
................................
................................
...............................
23
 
4.3.5.
 
Post
-
Product Administration Follow
-
up
 
................................
................................
.....
24
 
4.3.6.
 
Solicited Adverse Events (Reactogenicity)
 
................................
................................
24
 
4.3.7.
 
CHMI Procedures
 
................................
................................
................................
.......
25
 
4.3.8.
 
Post
-
CHMI Follow
-
Up
 
................................
................................
...............................
26
 
4.3.9.
 
Parasitemia Management
 
................................
................................
............................
26
 
4.3.
10.
 
Follow
-
Up through End of Study
 
................................
................................
...............
27
 
4.4.
 
Concomitant Medications
 
................................
................................
...........................
27
 
4.5.
 
Dose Escalation Plan
 
................................
................................
................................
..
28
 
4.6.
 
Criteria for Discontinuation of Protocol Participation
 
................................
................
28
 
4.6.1.
 
Discontinuation from Protocol Participation
 
................................
..............................
28
 
4.7.
 
Criteria for Pausing and Resuming the Study
 
................................
.............................
29
 
4.7.1.
 
Plan for Review of Pauses and Resuming Rules
 
................................
........................
29
 
5.
 
SAFETY AND ADVERSE EVENTS
 
................................
................................
........
30
 
5.1.
 
Adverse Events
 
................................
................................
................................
...........
30
 
5.2.
 
Serious Adverse Events
 
................................
................................
..............................
30
 
5.3.
 
A
dverse Event Reporting to the IND Sponsor
 
................................
...........................
31
 
5.4.
 
IND Sponsor Reporting to the FDA
 
................................
................................
...........
31
 
5.5.
 
Reporting to the Institutional Review Board
 
................................
..............................
32
 
5.5.1.
 
Unanticipated Problem
 
................................
................................
...............................
32
 
5.5.
2.
 
Non
-
Compliance
 
................................
................................
................................
.........
32
 
5.5.3.
 
Protocol Deviation
 
................................
................................
................................
......
33
 
5.5.4.
 
Death
 
................................
................................
................................
...........................
34
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
4
 
of 
73
 
5.5.5.
 
New Information
 
................................
................................
................................
.........
34
 
5.5.6.
 
Sus
pension or Termination of Research Activities
 
................................
....................
34
 
5.5.7.
 
Expedited Reporting to the IRB
 
................................
................................
.................
34
 
5.5.8.
 
Annual Reporting to the IRB
 
................................
................................
......................
34
 
6.
 
STATISTICAL CONSIDERATIONS
 
................................
................................
.......
35
 
6.1.
 
Overview
 
................................
................................
................................
.....................
35
 
6.2.
 
Sample Size and Accrual
 
................................
................................
............................
35
 
6.3.
 
Statistical Analysis
 
................................
................................
................................
......
36
 
6.3.1.
 
Analysis Variables
 
................................
................................
................................
......
36
 
6.3.2.
 
Safety Analysis
 
................................
................................
................................
...........
37
 
6.3.3.
 
Pharmacokinetics Analysis
 
................................
................................
.........................
37
 
6.3.4.
 
Efficacy Analysis
 
................................
................................
................................
........
38
 
6.3.5.
 
Interim analyses
 
................................
................................
................................
..........
39
 
7.
 
PHARMACY PROCEDURES
 
................................
................................
...................
40
 
7.1.
 
Study
 
Product
................................
................................
................................
..............
40
 
7.2.
 
Storage and Temperature Excursions
 
................................
................................
.........
40
 
7.3.
 
Labeling of Study Product Vial
 
................................
................................
..................
40
 
7.4.
 
Preparation of Study Product for Administration
 
................................
.......................
40
 
7.4.1.
 
Preparation for IV Administration
 
................................
................................
..............
40
 
7.4.2.
 
Preparation for SC or IM Administration 
 
................................
................................
..
41
 
7.4.3.
 
Handling of Prepared Product for IV, SC, or IM Administration
 
..............................
41
 
7.5.
 
Study Product Accountability
 
................................
................................
.....................
42
 
7.6.
 
Study Product Disposition
 
................................
................................
..........................
42
 
8.
 
HUMAN SUBJECT PROTECTIONS AND ETHICAL OBLIGATIONS
................
43
 
8.1.
 
Institutional Review Board
 
................................
................................
.........................
43
 
8.2.
 
Informed Consent
 
................................
................................
................................
.......
43
 
8.3.
 
Study Discontinuation and Closure
 
................................
................................
............
43
 
8.4.
 
Confidentiality and Privacy
 
................................
................................
........................
44
 
8.5.
 
Risk/Benefit Assessment
 
................................
................................
............................
45
 
8.5.1.
 
Potential Risks
 
................................
................................
................................
............
45
 
8.5.2.
 
Potential Benefits
 
................................
................................
................................
........
47
 
8.5.3.
 
A
ssessment of Potential Risks and Benefits
 
................................
...............................
47
 
8.6.
 
Plan for Use and Storage of Biological Samples
 
................................
........................
47
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
5
 
of 
73
 
8.6.1.
 
Use of Samples, Specimens and Data
 
................................
................................
.........
47
 
8.6.2.
 
Storage and Tracking of Blood Samples and Other Specimens
 
................................
.
47
 
8.6.3.
 
Disposition of Samples, Specimens and Data at Com
pletion of the Protocol
 
............
48
 
8.6.4.
 
Loss or Destruction of Samples, Specimens or Data
 
................................
..................
48
 
8.7.
 
Safety Oversight
 
................................
................................
................................
.........
48
 
9.
 
ADMINISTRATIVE AND OPERATIONAL OBLIGATIONS
................................
50
 
9.1.
 
Protocol Amendments and Study Termination
................................
...........................
50
 
9.2.
 
Study Documentation and Storage
 
................................
................................
.............
50
 
9.3.
 
Clinical Monitoring
 
................................
................................
................................
....
50
 
9.4.
 
Data Collection and Sharing
 
................................
................................
.......................
51
 
9.4.1.
 
Data Collection
 
................................
................................
................................
...........
51
 
9.4.2.
 
Source Documents
 
................................
................................
................................
......
51
 
9.4.3.
 
Dat
a Sharing
 
................................
................................
................................
...............
51
 
9.5.
 
Quality Assurance and Quality Control
 
................................
................................
......
51
 
9.6.
 
Language
 
................................
................................
................................
.....................
52
 
9.7.
 
Research
-
Related Injuries
 
................................
................................
...........................
52
 
9.7.1.
 
NIH
 
................................
................................
................................
.............................
52
 
9.7.2.
 
WRAIR
 
................................
................................
................................
.......................
52
 
9.8.
 
WRAIR Facility and CHMI Management
 
................................
................................
..
52
 
9.8.1.
 
Roles and Responsibilities for the CHMI
 
................................
................................
...
53
 
9.8.2.
 
WRAIR Protocol Review and Reporting Requirements
 
................................
............
53
 
10.
 
REFERENCES
 
................................
................................
................................
...........
55
 
APPENDIX I: SCHEDU
LE OF EVALUATIONS
 
................................
................................
.......
57
 
APPENDIX II: ASSESSMENT OF AE RELATIONSHIP AND SEVERITY GRADING
 
.........
69
 
APPENDIX III: STUDY PRODUCT PREPARATION
 
................................
...............................
71
 
 
L
IST OF TABLES
 
Table
 
1:
 
Study Schema
 
................................
................................
................................
.............
18
 
Table
 
2:
 
Probability of Events for Different Safety Sc
enarios (n=5 or 23)
 
..............................
35
 
Table
 
3:
 
95% Confidence Intervals for the True Rate at Possible Observed Number of 
Events (n=5 or n=23)
 
................................
................................
................................
..
36
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
6
 
of 
73
 
ABBREVIATIONS
 
 
Abbreviation
 
Definition
 
ADA
 
Anti
-
Drug Antibody
 
AE
 
Adverse event
 
ALT
 
Alanine aminotransferase
 
ANA
 
Anti
-
nuclear antibody
 
AST
 
Aspartate aminotransferase
 
CBC
 
Complete blood count
 
cGLP
 
Current Good Laboratory Practices
 
c
GMP
 
Current Good Manufacturing Practices
 
CHI
 
Controlled human infection
 
CHMI
 
C
ontrolled 
h
uman 
m
alaria 
i
nfection
 
CMP
 
Comprehensive Metabolic Panel 
 
CRF
 
Case Report Form
 
CRO
 
Contract Research Organization
 
CSP
 
Circumsporozoite protein
 
CT
P
 
Clinical Trials 
Program
 
DoD
 
Department of Defense
 
DoDI
 
Department of Defense Instruction
 
DNA
 
Deoxyribonucleic Acid
 
DOT
 
Directly observed therapy
 
EKG
 
Electrocardiogram
 
ELISA
 
Enzyme
-
linked immunosorbent assay
 
FDA
 
Food and Drug Administration
 
GCP
 
Good Clinical Practice
 
HBsAg
 
Hepatitis B surface antigen
 
HCV
 
H
epatitis C
 
virus
 
HIV
 
Human Immunodeficiency Virus
 
HRPP
 
Human Research Protections Program
 
HSBP
 
Human Subjects Protection Branch
 
ICH
 
International Conference on 
Harmonization
 
IM
 
Intramuscular
 
IND
 
Investigational New Drug Application
 
IV
 
Intravenous
 
 
LIMS
 
Laboratory Management Information System
 
m
Ab
 
Monoclonal 
A
ntibody
 
MedDRA
 
Medical dictionary for regulatory activities
 
MO
 
Medical Officer
 
NAT
 
Nucleic acid test 
 
NHP
 
Non
-
Human Primate
 
NIAID
 
National Institute of Allergy and Infectious Diseases 
 
NIH
 
National Institutes of Health
 
NIH CC
 
NIH 
Clinical Center
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
7
 
of 
73
 
Abbreviation
 
Definition
 
PBMC
 
Peripheral blood mononuclear cell
 
PCR
 
Polymerase Chain Reaction
 
Pf
 
Plasmodium falciparum
 
 
PfCSP
 
Plasmodium falciparum
 
circumsporozoite 
protein
 
PfSPZ
 
Plasmodium falciparum
 
whole
-
sporozoite
 
PI
 
Principal Investigator
 
PK
 
Pharmacokinetics
 
PSRT
 
Protocol Safety Review Team
 
QA
 
Quality Assurance
 
RBC
 
Red blood cells 
 
rPfCSP
 
Recombinant 
Plasmodium falciparum
 
circumsporozoite protein
 
SAE
 
Serious adverse event
 
SARS
-
CoV
-
2
 
Severe acute respiratory syndrome 
coronavirus 2
 
SC
 
Subcutaneous
 
SPZ
 
Sporozoite
 
SUSAR
 
Serious and unexpected suspected adverse reaction
 
TCR
 
Tissue Cross Reactivity
 
U.S.
 
United States
 
ULN
 
Upper limit of normal
 
UPnonAE
 
Unexpected Problem that is not an Adverse Event
 
VCMP
 
Vaccine Clinical Materials Program
 
VEC
 
Vaccine Evaluation Clinic 
 
VIS
 
Volunteer Infection Studies 
 
VI
P
 
Vaccine Immunology Program
 
VRC
 
Vaccine Research Center
 
WBC
 
White blood cells 
 
WHO
 
World Health Organization
 
WRAIR
 
Walter Reed Army 
Institute of Research
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
8
 
of 
73
 
PRINCIPAL INVESTIGATOR PROTOCOL SIGNATURE PAGE
 
 
VRC 61
4
: 
A Phase 1, Dose Escalation, Open
-
Label Clinical Trial with Experimental 
Controlled Human Malaria Infections (CHMI) to 
Evaluate Safety and Protective 
 
Efficacy of an Anti
-
Malaria Human Monoclonal Antibody, 
VRC
-
MALMAB01
14
-
00
-
AB 
(
L9
LS), in Healthy, Malaria
-
Na
ive Adults
 
 
I, 
the 
Principal 
Investigator 
for the study site
 
indicated 
below
, agree to conduct the study in full 
accordance with the provisions of this protocol and all applicable protocol
-
related documents. 
 
I 
agree to conduct the study in 
compliance with United States (US) Health and Human Services 
(HHS) regulations (45CFR 46); applicable US Food and Drug Administration (FDA) regulations; 
standards of the International Conference on Harmonization Guidelines for Good Clinical Practice 
(E6); 
Institutional Review Board/Ethics Committee (IRB/EC) determinations; all applicable in
-
country, state, and local laws and regulations; and other applicable requirements (e.g., US National 
Institutes of Health) and institutional policies.
 
 
I will comply wit
h all requirements regarding the 
obligations of investigators as outlined in the Statement of Investigator (Form FDA 1572), which I 
have also signed.
 
 
The protocol signature page will be signed for subsequent protocol approvals.  
 
I agree to maintain all s
tudy documentation 
pertaining to the conduct of this study, including but 
not limited to, case report forms, source documents, laboratory test results, and medication 
inventory records, 
per
 
FDA 
regulation 
(21 CFR 312.62)
 
and all applicable requirements
.  N
o study 
records will be destroyed without prior authorization from VRC/NIAID.  
 
Publication of the results of
 
this study will be governed by 
the VRC/NIAID
 
policies.
 
 
Any 
presentation, abstract, or
 
manuscript will be made available by the investigators to 
V
RC
 
Leadership for review prior to submission.
 
I have read and understand the information in this 
protocol 
and will ensure that all associates,
 
colleagues, and employees assisting in the conduct of the study are informed about the obligations
 
incurred by th
eir contribution to the study.
 
 
Richard Wu/
Clinical Fellow
 
 
 
NIH 
-
 
Vaccine Evaluation Clinic
 
____________________________
_
__    
_______________________________
___
 
Name/Title 
of Principal Investigator 
 
 
  
Study Site Name
 
 
 
_____________________________
_____
_
 
  
__________________________________
 
Signature of Principal Investigator               
 
  
Date
 
 
 
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
9
 
of 
73
 
PR
È
CIS
 
Title:
 
VRC 61
4
: A Phase 1, Dose Escalation, Open
-
Label Clinical Trial with Experimental 
Controlled Human Malaria Infections (CHMI) to Evaluate the Safety and Protective 
Efficacy of an Anti
-
Malaria Human Monoclonal Antibody, VRC
-
MALMAB01
14
-
00
-
AB 
(L9
LS), in Healthy, Malar
ia
-
Naïve Adults.
 
Design:
 
This is the first
 
in human
 
study of the VRC
-
MALMAB01
14
-
00
-
AB (
L9
LS) monoclonal 
antibody (mAb) targeting the 
Plasmodium falciparum
 
(Pf) circumsporozoite protein 
(PfCSP) in healthy adults.  This dose
-
escalation study will evaluate the safety, 
tolerability, pharmacokinetics (PK), and protective efficacy of 
L9
LS.  The primary 
hypothesis is that 
L9
LS will be safe and
 
well
 
tolera
ted
 
when 
administered by intravenous 
(IV)
,
 
subcutaneous (SC) 
or intramuscular (IM) 
routes.  The secondary hypotheses are that 
L9
LS will be detectable in human sera with a definable half
-
life and confer protection 
following a controlled human malaria infection (CHMI
).
 
Study Product:
 
VRC
-
MALMAB01
14
-
00
-
AB was isolated and developed by the Vaccine Research 
Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), National 
Institutes of Health (NIH) and binds 
an
 
epitope of the PfCSP.
 
Subjects:
 
Healthy 
adults
, 18
-
50 years of age, who are malaria
-
naive. 
 
Study Plan:
 
This 
study
 
will evaluate the 
L9LS 
doses and routes
 
of administration
 
as shown below in 
the Study Schema tabl
e
.
 
The
 
study
 
will
 
start
 
with
 
enrollment
 
into
 
Group 1
.
 
Assessment of 
safety will 
include solicited reactogenicity, clinical observation and monitoring of 
hematological and chemical parameters at clinical visits throughout the study
.
 
Interim 
safety evaluations will occur and must support continued evaluation of L9LS
 
prior to 
enrolling s
ubjects into additional dose groups.
 
L9LS recipients
 
in 
G
roups 1
-
4
 
will
 
participate in the CHMI.
 
 
Group 5 will not receive investigational product in order to
 
serve
 
as
 
the
 
control
 
group
 
for
 
the
 
CHMI.
 
 
After
 
CHMI,
 
all
 
participants
 
will
 
be
 
evaluated
 
for 
malaria parasitemia.
 
 
Subjects who develop blood stage infection will be treated as
 
soon as identified per protocol criteria.
 
Subjects in Group 6 will receive investigational 
product but will not take part in the CHMI.
 
Blood sampling for PK analysis will o
ccur
 
throughout
 
the
 
study, including
 
pre
-
 
and
 
post
-
CHMI.
 
VRC
 
614
 
Study
 
Schema
 
Group
 
Subjects
 
L9LS
 
Administration
 
CHMI
 
Dose
 
(mg/kg)
 
Route
 
1
 
5
 
1
 
IV
 
X
 
2
 
4
 
5
 
IV
 
X
 
3
 
5
 
5
 
SC
 
X
 
4
 
4
 
20
 
IV
 
X
 
5
 
6
 
Control
1
 
X
 
6
 
5
 
5
 
IM
 
N/A
 
Total
 
2
9
2
 
1
Two
 
(2)
 
additional
 
control
 
subjects
 
will
 
be
 
enrolled
 
as
 
CHMI
 
back
-
ups
 
2
Up
 
to
 
40
 
subjects
 
may
 
enroll
 
if
 
needed
 
for
 
additional
 
safety
 
or
 
efficacy
 
evaluations.
 
 
Duration
:
 
Study follow
-
up will continue through 24 weeks 
post
 
product administration or 8 weeks 
post CHMI, whichever is most stringent.
  
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
10
 
of 
73
 
STATEMENT OF COMPLIANCE
 
 
The 
trial
 
will be carried out in accordance with 
International Conference on Harmonisation 
Good 
Clinical Practice (
ICH 
GCP) 
and
 
the following
:
 
 
•
 
United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 
CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312
, and/or 21 C
FR Part 8
12) 
 
National Institutes of Health (
NIH
)
-
funded investigators and clinical trial site staff who are 
responsible
 
for the conduct, management, or
 
oversight of NIH
-
funded clinical trials
 
have 
completed Human Subjects Protection 
and ICH GCP 
Training.
 
The protocol, informed consent form(s), recruitment materials, and all participant materials will 
be submitted to the 
Institutional Review Board (
IRB
)
 
for review and approval.  Approval of both 
the protocol and the consent form must be obtained before any 
participant is enrolled.  Any 
amendment to the protocol will require review and approval by the IRB before the changes are 
implemented to the study.  
In addition, a
ll changes to the consent form will be IRB
-
approved; a 
determination will be made regarding 
whether
 
a new consent needs to be obtained from 
participants who provided consent, using a previously approved consent form
.
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
11
 
of 
73
 
1.
 
INTRODUCTION 
 
Malar
ia is a mosquito
-
borne protozoan disease
 
belonging to the genus Plasmodium that 
affects 
250
-
500
 
million
 
people, and 
kills 
approximately
 
500,000
 
individuals annually
, with
 
an enormous 
economic impact in the developing world, especially sub
-
Saharan Africa
 
[
1
-
3
]
.  The five 
recognized species of Plasmodium that cause human malaria infection are 
Plas
modium 
falciparum 
(Pf)
, 
P
. vivax, P. ovale, P. malariae, 
and
 
P. knowlesi
.  Among these, Pf
 
cause
s
 
more 
deaths in children worldwide than any other single infectious agent
.  An
 
estimated
 
30
,000 
travelers from North America, Europe, and Japan contract malari
a per year
.  
Although malaria is 
preventable with chemoprophylaxis and 
completely 
curable with early 
intervention
, 
drug 
treatment is not readily accessible 
in many parts of the world
.  Additionally, 
the use of 
antimalarial
 
drugs 
over time 
has been associat
ed with the emergence of drug
-
resistant strains
. 
 
Lack of compliance with preventive drug treatment by individuals travelling to endem
ic areas 
may also result in fatal malaria infection. 
 
The world’s first malaria vaccine, 
RTS,S/AS01
 
(Mosquirix™)
,
 
a recomb
inant protein
-
based vaccine targeting Pf,
 
was approved for use by 
European regulatory authorities in 2015.  It is currently being evaluated in immunization 
programs in sub
-
Saharan Africa despite having been found to provide only partial protection (of 
abou
t 30
-
50%) against clinical malaria to children and infants 
[
4
, 
5
]
. 
 
Therefore, the development 
of a safe and
 
more
 
effective malaria vaccine 
is an urgent priority and may t
ake many additional 
years.  Alternatively, the use of
 
antibodies 
for passive prevention of malaria provides a new and 
more immediate approach for malaria prevention that, if successful, would 
have a major impact 
on improving public health worldwide.
 
 
Recen
t development of highly potent human monoclonal 
antibodies that have changes made to improve their duration 
in vivo
 
and protect in different pre
-
clinical models will provide the first assessment of this approach.
 
1.1.
 
Study 
Rationale 
 
1.1.1.
 
L9LS
 
Development
 
The Vacci
ne Research Center (VRC),
 
National Institute of Allergy and Infectious Diseases 
(NIAID), National Institutes of Health 
(NIH) 
has
 
been investigating broadly
-
neutralizing human 
monoclonal antibodies (bNAbs) targeted at a variety of pathogens that may be util
ized in clinical 
applications including preventive and therapeutic measures.  In the case of malaria, 
prevention 
by passive immunization has potential applications for use in travelers, military personnel, 
season control and elimination campaigns in endemi
c areas.
 
L9LS (VRC
-
MALMAB0114
-
00
-
AB) is the second PfCSP
-
specific mAb the VRC plans to 
pursue in clinical development. L9
,
 
the wild
-
type parent of L9LS, was isolated by sorting
 
the
 
PfCSP
-
reactive memory B cells obtained from 
a subject immunized with 
a radi
ation
-
attenuated 
PfSPZ 
malaria vaccine in the 
VRC 314 clinical trial
 
(
[STUDY_ID_REMOVED]
)
 
using a junctional epitope 
mimic probe designed to select for “CIS43
-
like” mAbs. Epitope mapping showed L9 bound to 
NPNV motifs associated with NVDP
 
 
minor
 
repeats
 
of
 
PfCSP.
 
When
 
compared
 
to
 
a
 
published
 
panel
 
of
 
protective
 
human
 
PfCSP
 
mAbs, L9
 
protected m
ice against intravenous and mosquito 
bite SPZ challenge, and demonstrated the
 
lowest effective dose (ED)80 and effective 
concentration (EC)80 values (325.7 µg and 145.1 
µg/mL, respectively) of any mAb evaluated, 
including CIS43LS (685.92 µg and 363.93 µg/m
L,
 
respectively)
 
[
6
]
.
 
The unique preference of 
L9 for NPNV motifs was further underscored by the 
fact that
 
all
 
four NVDP tetrapeptide motifs 
had to be mutated to NANP to disrupt the recognition of
 
L9 for the NPNV motifs found in 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
12
 
of 
73
 
rPfCSP. As 100% of known 
Pf 
field isolates have one or more
 
NVDP
 
motifs,
 
these
 
data suggest
 
that
 
L9 should
 
bind
 
all circulating strains
 
of malaria
[
6
]
.
 
L9 was modified with the previously
-
described Fc
-
region LS mutatio
n (L9LS) to increase
 
neonatal Fc receptor (FcRn) binding and consequent antibody half
-
life [
2
-
5
]. 
Immune 
protection
 
and
 
half
-
life data acquired with L9 and L9LS identify L9LS as a promising clinical candidate for 
passive
 
mala
ria prophylaxis
.
 
1.1.2.
 
Rationale for 
Study
 
Design
 
This phase I trial will evaluate L9LS 
safety and PK 
at doses 1, 5 and 20 mg/kg IV
,
  
5 mg/kg SC
, 
and 5 mg/kg IM
. The study will allow 
for the achievement of
 
a range of antibody concentrations 
in vivo for determining a protective 
L9LS titer in CHMI. Because the safety and potential 
therapeutic range of this mAb is unknown, dose selection was informed by non
-
 
clinical PK data 
in non
-
human primates (NHP) compari
ng L9 and L9LS, historical dose ranges evaluated in 
clinical trials of other mAbs developed by the VRC (e.g., VRC07
-
523LS [IND133027] and 
N6LS [IND 134081]), and prior clinical experience in healthy adults with anti
-
malaria mAb 
CIS43LS (VRC 612 [NCT0420633
2] conducted under IND 142632
 
[
7
]
) where recipients were 
protected against malaria infection when challenged in CHMI at 
about 
4 weeks to 36 weeks post
-
product administration. The lack of malaria infection in participants who received a 20 or 40 
mg/kg IV dose of CIS43LS prevented the planned regression analysis to identify a threshold 
level of protection. The
 
higher participant numbers in the
 
1 mg/kg IV
 
a
nd 5 mg/kg SC groups
 
allow for more data at the lowest dose group to try to identify a protective antibody titer 
threshold and to support 
future
 
trials assessing the SC route in malarial
-
endemic regions, 
respectively.  
 
 
1.1.3.
 
Addition of Intramuscular Injection
 
Cohort in v.2.0
 
With the version 2.0 amendment, a cohort is being added to receive a 5 mg/kg dose of L9LS by 
IM injection. The purpose of this amendment is to 
evaluate
 
the 
safety, tolerability and PK of 
L9LS by the IM
 
route. 
 
Data on this route 
may
 
support develop
ment
 
of phase 2 trials 
in Africa 
as 
t
he IM 
r
oute 
may 
allow individuals, such as children, who may not have sufficient subcutaneous 
tissue or not have intravenous access, 
to be able to receive L9LS
. 
Since
 
this arm is b
eing added 
after
 
the CHMI 
has occurred
, this group will not participate in the CHMI.  
 
1.2.
 
Background
 
1.2.1.
 
Previous Human Experience 
 
There 
i
s 
no human experience with 
L9LS 
prior to this trial
. 
Prior clinical experience in 
completed and ongoing Phase 1 and 2 trials
 
of healthy adults with human mAbs manufactured 
and formulated by the VRC that recognize pathogen
-
specific epitopes (i.e., VRC01, VRC01LS, 
VRC07
-
523LS, and mAb114)
 
[
8
-
11
]
 
are used to summarize the general safety risk associated 
with mAbs. 
 
 
Treatments with these
 
mAbs have been generally well tolerated, with no reported deaths or 
serious adverse events (SAEs) assessed as related to the study products.  Typical for mAbs, the 
predominant local reactogenicity complaint has been mild pain/tenderness, although reports o
f 
mild injection site pruritus, redness and swelling have occurred at modestly higher frequencies 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
13
 
of 
73
 
with SC administration.  Malaise, muscle pain, and headache have been the most frequently 
reported solicited complaints noted in the 3 days post product admin
istration and these have also 
been mostly transient and mild in severity. 
Increased frequencies of f
ever
, 
redness, swelling and 
pain at the injection site
 
have been reported after IM administration
.
 
Urticaria and infusion 
reactions comprised of chills, rig
ors, myalgia, headache, and/or fever have been reported after IV 
infusions at product doses of 10 to 40 mg/kg; these reactions have been transient, resolved 
without sequelae within 24 hours of onset, and treated with over
-
the
-
counter analgesics and 
antipyr
etics.
 
1.2.2.
 
Controlled Human Infections (CHI) 
 
Controlled human infection (CHI) trials (also referred to as Volunteer Infection Studies (VIS)) 
result in the experimental infection of healthy subjects with the infectious agent of choice and are 
an unparalleled t
ool in infectious disease research.  CHI trials allow for the 
accelerate
d 
evaluation
 
of novel drugs and
 
vaccines
 
for po
tential efficacy, while also providing the 
opportunity to prospectively study clinical disease progression.  The first controlled human 
malaria infection (CHMI) was performed in the mid
-
1980s 
[
12
]
.
  
This process involves the 
deliberate infection with malaria parasites either by mosquito bite or direct injection
. 
 
VRC has 
successfully conducted
 
three 
Phase 1 CHMI studies
:
 
VRC 312 
[
13
]
,
 
VRC 314
 
[
14
]
, and
 
VRC 
612 
[
7
]
.
  
 
Accord
ing to a comprehensive review of CHI trials using a variety of pathogens, an estimated 
6000 subjects have received CHI 
[
15
]
.  Only four possibly
-
related SAEs have been reported, of 
which two were observed following malaria vaccination a
nd CHMI 
[
15
]
.  The first cardiac event 
of possible myocarditis, reported in 2008
 
[
16
]
, prompted recommendation by a panel of experts 
that consideration of cardiac risk be required for clinical challenge trials and that individuals 
identified as a
t increased cardiovascular risk be excluded from malaria clinical challenge trials
 
[
17
]
.  A second cardiac event was observed in 2013 following malaria vaccination and CHMI
 
[
18
]
. 
 
VRC was also informed of a possible 3
rd
, unpublished, myocarditis event in 2014. 
 
A
s a 
result of these events and the recommenda
tions, e
vidence of increas
ed cardiovascular disease 
risk or an e
lectrocardiogram (ECG) with clinically significant abnormalities
 
will preclude trial 
enrollment
 
as described in 
Section
 
4.1.2
. 
 
The challenge phase in this study will be performed
 
with Pf strain 3D7
 
[
sensitive to Chloroquine 
and Malarone (atovaquone and proguanil)
]
 
via mosquito bite, which is the natural route of 
exposure and transmission i
n the field.  While subjects will be
 
monitored closely
 
throughout 
study duration, monitoring intensity will increase
 
following 
exposure to Pf
-
infected mosquitoes 
to ensure rapid diagnosis and treatment.  Appropriate drug therapy will be used to treat 
and cure 
any subject with a confirmed Pf
 
infection
 
after diagnosis by PCR, the most sensitive assessment 
for detecting early malaria infection, in order to 
minimize
 
the risk of developing a serious 
complication
.  The
 
Pf
 
strain to be 
used 
for CHMI in this s
tudy c
an be effectively treated 
with and 
cured by the antimalarial medications to be used in this trial
 
[
19
, 
20
]
.
  
 
There is negligible risk of transmitting malaria to a person in the community since subjects are 
exposed to malaria
-
infecte
d mosquitos only during the CHMI at a contained facility.
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
14
 
of 
73
 
1.3.
 
Laboratory Assessments of 
L9LS 
 
Some laboratory assessments in this study are also designed to characterize the investigational 
product.  This includes 
PK analysis
 
and 
evaluation for anti
-
drug antib
ody (ADA) development 
after
 
product exposure
.  These are further described in the subsequent sections.  Other assays 
may also be 
performed using 
stored samples at a later date if additional assessments are needed. 
 
The VRC’s Vaccine Immunology Program (VIP
), Gaithersburg, MD, will process blood and 
store coded s
amples
,
 
and will either perform sample testing or 
ship
 
coded samples to 
designated
 
research
 
laboratories
 
at the VRC or other approved collaborators.  See 
APPENDIX I
 
for 
schedules, 
blood 
volumes and tube types to be used for research sample collection.  Research
 
assays will be performed on samples from both 
study product recipients
 
and 
CHMI
-
controls
 
at 
baseline an
d throughout the study
.
 
 
Tube types for clinical labs are according to institutional requirements and are shown in the 
Schedule of Evaluations to estimate blood volumes.  Different tubes for clinical evaluations may 
be used to meet site requirements. 
 
Rese
arch sample tube types and blood volumes must be used 
as shown or as otherwise instructed by the IND Sponsor. 
 
In some instances, coded samples may 
be transported directly by study staff to the laboratory of an approved collaborator.
 
1.3.1.
 
Pharmacokinetic (PK) Analysis
 
Concentrations of 
L9LS 
will be measured by Meso Scale Discovery (MSD) platform and similar 
methodology as previously described
 
for other VRC mAb products 
[
9
]
.  
 
1.3.2.
 
Detection of Anti
-
Drug Antibody 
 
Assays for detection of ADA will be performed at specified timepoints following product 
administration and CHMI compared to baseline status using a similar methodology as previously 
described for other VRC mAb products
 
[
9
]
.  
We will emp
loy a sequential approach 
to screen, 
confirm, and characterize ADA in the clinical serum samples according to the Food and Drug 
Administration (FDA) guidance.
 
 
Screening and confirmation will involve a
n
 
MSD 
electrochemiluminescence (ECL) bridging assay.
 
 
 
1.4.
 
Measures of mAb
-
Mediated Protection and Parasitemia
 
L9
LS
-
mediated protection will be assessed after CHMI 
outcomes are obtained 
and compared to 
control subjects
’ CHMI outcomes
.  The endpoint defining mAb
-
mediated protection for the 
CHMI is the absence of Pf
 
parasites in blood samples obtained from 
L9LS
-
recipients collected 
daily 
from Day 7 through Day 
17
 
and then on Day 21
 
post
-
CHMI.  The criteria for a case of 
malaria is confirmation of
 
parasitemia either by the Malaria real
-
time PCR assay or
 
by
 
blood 
smear
.  The Malaria real
-
time PCR assay targets the
 
18S rRNA (ribosomal RNA) gene, which is 
a DNA target.  It is the default means of monitoring for parasitemia in this protocol
; 
a single 
positive PCR result will confirm infection
 
[
13
, 
21
, 
22
]
.
 
A blood smear will be 
performed
 
by
 
the 
NIH Clinical Center Microbiology Service
 
per their 
departmental SOPs
 
for any subjec
t who develop
s
 
symptom
s
 
likely due to
 
malaria 
despite
 
hav
ing
 
a 
negative
 
PCR 
result
.
  
Laboratory personnel performing PCR and blood smear testing will be 
blinded to subject 
group and 
treatment received or lack thereof
,
 
in the case of controls.
  
Research 
blood samples may 
also 
be used 
for parasite genome analysis.  
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
15
 
of 
73
 
2.
 
STUDY PRODUCT AND CHMI 
 
2.1.
 
Study Product: 
L9
LS
 
The L9LS (
VRC
-
MALMAB01
14
-
00
-
AB
) mAb
 
was discovered and developed by the VRC, 
NIAID, NIH. 
 
The study product was
 
m
anufactured under cu
rrent Good Manufacturing Practice 
(cGMP) by the Vaccine Clinical Materials Program (VCMP) operated under contract by Leidos 
Biomedical Research, Inc., Frederick, MD
. 
 
2.2.
 
Preclinical Experience
 
To assess 
L9LS 
as a candidate for clinical tri
als, research grade mAb was 
assessed for 
in vitro
 
functional activity
 
including 
binding properties
 
and 
auto
-
reactivity
, 
in vivo
 
protection following 
challenge
 
using a mouse
 
infection model
, and 
in vivo
 
PK 
using a
n
 
NHP
 
model
.  In mice, 
L9 
was 
more 
potent than CIS43, and both L9LS and L9 mediated the same potency following challenge
.  
In NHP PK studies, 
L9LS 
exhibited substantially longer half
-
life in blood as compared to 
the 
parental 
L9 mAb 
without the LS mutation.
 
Two preclinical toxicology studies
 
were conducted with a process
-
representative developmental 
batch of L9LS.  An 
in vitro
 
tissue cross
-
reactivity (TCR) assay to screen for potential cross
-
reactivity and an 
in vivo
 
rat toxicity study to demonstrate safety were 
both 
conducted in 
compliance w
ith Title 21 of the Code of Federal Regulations Part 58 (21 CFR 58) Good 
Laboratory Practice (GLP) for Nonclinical Laboratory Studies
.
 
2.2.1
 
Tissue Cross
-
Reactivity (TCR) Study
 
The TCR assay screened a standard panel of normal human tissues (
three
 
donors per tissue) and 
Sprague Dawley rat tissues (
two
 
rats per tissue).  Mammalian cells transfected to express CSP 
were used as a tissue positive control.  Two concentrations of L9LS were tested: 1.15 µg/ml 
(selected as the concentration which saturated
 
the positive control tissue), and 11.5 µg/ml (10
-
fold excess).  A negative control IgG1
κ
 
antibody 
(GR338422
-
1, no mammalian target antigen) 
was tested at the same two concentrations. 
 
L9LS exhibited scattered specific membrane binding 
in 3/3 human salivar
y gland tissue samples
, which
 
localized to the epithelial cells lining the ducts 
and acini.  Binding was rare (1
-
5% of these epithelial cells) at 1.15 µg/ml, 
and 
rare to occasional 
(5
-
25% of these epithelial cells) at 11.5 µg/ml.  The cause of the salivary
 
epithelial cell 
membrane binding 
has not been identified
.  Specific membrane binding to salivary 
gland tissue 
was not observed for the negative control antibody
. 
 
L9LS did not bind to rat salivary epithelium. 
 
No specific membrane
-
binding to other human t
issues was observed.
 
2.2.2
 
Rat Toxicity Study
 
Sprague Dawley rats were dosed with L9LS to evaluate toxicity and toxicokinetics.  Rats 
received 0, 40, or 400 mg/kg by intravenous (IV) bolus injection twice (Day 1 and Day 11).  
Female rats were dosed with 10
 
mg/kg by subcutaneous (SC) injection once
 
(D1)
; male rats were 
dosed with 10 mg/kg SC twice (D1 and D11); both male and female rats were dosed with 100 
mg/kg SC twice (Day 1 and Day 11).  For all dose
-
levels, the main
-
group was necropsied at Day 
12 to eva
luate potential immediate effects, and recovery animals were necropsied at Day 46 to 
evaluate the potential for delayed effects and recovery.  Treated rats exhibited a transient 
increase in body temperature post
-
dose (up to + 0.5
o
C, considered 
a 
non
-
advers
e response).  
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
16
 
of 
73
 
Serum clinical chemistry 
tests 
detected slightly
-
increased globulin
,
 
consistent with the 
administration of L9LS, an IgG mAb.  For IV dosing, the no observed adverse effect level 
(NOAEL) was the high
 
dose, 400 mg/kg IV x2. For SC dosing, the N
OAEL was the high
-
dose, 
100 mg/kg SC x2.  SC injection of L9LS did not cause reactogenicity (edema, erythema, eschar) 
in any rat.  Histopathology 
evaluation 
of the SC injection site skin 
reported
 
minimal to moderate 
subcutaneous mixed cell infiltration
,
 
co
nsidered treatment
-
related and predictive for human 
volunteers.  One treated rat (in the 100 mg/kg SC group) was found dead; this 
event 
was 
attributed to a procedural error the previous day and is not considered treatment
-
related.  One 
treated female (in t
he 100 mg/kg SC recovery group) had grossly
-
visible heart enlargement 
(2
-
fold increase in both heart weight and heart:body weight compared to the control means), with 
normal heart histology.  Spontaneous cardiomyopathies are occasionally observed for the 
S
prague Dawley strain
 
of rat
.  Based on the singular incidence, this observation is not considered 
treatment
-
related.
 
With reference to the CDER 2005 Guidance for Industry Estimating the Maximum Safe Starting 
Dose in Initial Clinical Trials for Therapeutics
 
in Adult Healthy Volunteers
1
, scaling based on 
body weight is appropriate for a mAb expected to distribute mainly in the vascular space.  The 
rat IV NOAEL of 400 mg/kg x2 supports the IV clinical high
-
dose with a 20
-
fold dose margin.  
The rat SC NOAEL of
 
100 mg/kg x2 supports the SC clinical dose with a 20
-
fold dose margin.
 
The FDA provides guidance on “
the nonclinical safety studies recommended to support human 
clinical trials
” in the Guidances for Industry ICH M3(R2) 
Nonclinical Safety
 
Studies for the 
Conduct of
 
Human Clinical Trials and
 
Marketing Authorization for
 
Pharmaceuticals
2
 
and ICH 
S6 
Addendum to
 
Preclinical Safety Evaluation
 
of 
Biotechnology
-
Derived
 
Pharmaceuticals
3
.  
Taken together, the L9LS TCR and rat toxicity study results meet the safety standard set in these 
guidances and support proceeding with the proposed L9LS clinical trial.
 
2.3.
 
Clinical Experience 
 
This
 
study
 
constitutes
 
the
 
first
 
in
 
human
 
trial
 
with
 
L9LS,
 
therefore
,
 
there
 
is
 
no
 
previous
 
e
xperience
 
in humans.
  
See 
Section
 
1.2.1
 
for more information about similar VRC mAb 
products.  
As additional data about the effect of L9LS in humans is accumulated from the 
cohorts of this first
-
in
-
human Phase 1 trial
,
 
this section will be updated.
 
2.4.
 
Controlled Human Malaria Infection (CHMI) 
 
Prepa
ration of infected mosquitoes for 
CHMI
 
will be performed according to 
a 
Type II Master 
File
 
033797
, Malaria Challenge Model, Standard Operating Procedures
 
for the Pf model used
. 
 
To prepare infected mosquitoes, 
Pf
 
asexual and sexual erythrocytic stage para
sites will be grown 
in normal human erythrocytes using standard culture medium containing 10% normal human 
serum. 
 
The blood and serum for culture are purchased from a 
Food and Drug Administration
 
(
FDA
)
-
accredited blood bank. 
 
Each shipment carries a certi
ficate of analysis certifying that the 
blood products 
are
 
negative or non
-
reactive for 
immunologic evaluation and infectious disease 
testing
.
 
 
 
1
 
https://www.fda.gov/media/72309/download
 
 
2
 
https://www.fda.gov/media/71542/download
 
 
3
 
https://www.fda.gov/media/78034/download
 
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
17
 
of 
73
 
3.
 
STUDY OBJECTIVES
 
3.1.
 
Primary Objectives
 
•
 
To evaluate the safety and tolerability of L9LS administered IV at 1, 5, and 
20 mg/kg in
 
healthy,
 
malaria
-
naive adults
 
•
 
To
 
evaluate
 
the
 
safety
 
and
 
tolerability
 
of
 
L9LS
 
administered
 
SC
 
at
 
5
 
mg/kg
 
in
 
healthy,
 
malaria
-
naive
 
adults
 
•
 
To
 
evaluate
 
the
 
safety
 
and
 
tolerability
 
of
 
L9LS
 
administered
 
IM
 
at
 
5
 
mg/kg
 
in
 
healthy,
 
malaria
-
naive
 
adults
 
3.2.
 
Secondary Objectives
 
•
 
To evaluate the pharmacokinetics of 
L9
LS at each dose level throughout the study 
 
•
 
To determine if IV or SC administration of 
L9LS
 
mediates protection against infectious 
P. 
falciparum
 
following CHMI 
 
3.3.
 
Exploratory Obj
ectives
 
•
 
To determine whether anti
-
drug antibody (ADA) to 
L9LS
 
can be detected in sera of 
recipients at specific time points throughout the study
 
•
 
To assess for IgG1 allotypes and allotype
-
specific effects on
 
L9LS
 
pharmacokinetics
 
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
18
 
of 
73
 
4.
 
STUDY DESIGN
 
AND
 
CLINICAL PROCEDURES
 
This open
-
label, dose escalation study will be conducted at the VRC Vaccine Evaluation Clinic 
(VEC) in the NIH Clinical Center (NIH CC) and the CHMI will be conducted at the Walter Reed 
Army Institute of Research (WRAIR) insectary
 
with 
the oversight of NIH staff
.  The primary 
hypothesis is that 
L9LS
 
will be safe and tolerable when administered by either IV
,
 
SC
, or IM
 
routes.  The secondary hypotheses are that 
L9LS
 
will be detectable in human sera with a 
definable half
-
life and will confe
r protection following a CHMI.
  
 
This study will evaluate
 
L9LS
 
at
 
the doses and routes as shown below in the Study Schema table. 
The study will start with enrollment into Group 1
.
 
 
Assessment of safety will include solicited 
reactogenicity, clinical observ
ation and monitoring of hematological and chemical parameters at 
clinical visits throughout the study.
 
 
Interim safety evaluations will occur and must support 
continued evaluation of L9LS prior to enrolling subjects into additional dose groups.
 
 
L9LS 
recip
ients
 
in Groups 1
-
4
 
will participate in the CHMI. 
 
Group 5 will not receive investigational 
product in order to serve as the control group for the CHMI.
 
 
After CHMI,  participants
 
in 
Groups 1
-
5
 
will be evaluated for malaria parasitemia. 
 
Subjects who devel
op blood stage 
infection will be treated as soon as identified per protocol criteria.
 
Subjects in Group 6 will 
receive investigational product but will not take part in the CHMI. 
 
Blood sampling for PK 
analysis will occur throughout the study, including pr
e
-
 
and post
-
CHMI.
 
Table
 
1
:
 
Study Schema
 
 
VRC
 
614
 
Study
 
Schema
 
Group
 
Subjects
 
L9LS
 
Administration
 
CHMI
 
Dose
 
(mg/kg)
 
Route
 
1
 
5
 
1
 
IV
 
X
 
2
 
4
 
5
 
IV
 
X
 
3
 
5
 
5
 
SC
 
X
 
4
 
4
 
20
 
IV
 
X
 
5
 
6
 
Control
1
 
X
 
6
 
5
 
5
 
IM
 
N/A
 
Total
 
2
9
2
 
1
Two
 
(2)
 
additional
 
control
 
subjects
 
will
 
be
 
enrolled
 
as
 
CHMI
 
back
-
ups
.
 
2
Up
 
to
 
40
 
subjects
 
may
 
enroll
 
if
 
needed
 
for
 
additional
 
safety
 
or
 
efficacy
 
evaluations.
 
4.1.
 
Study Population
 
Subjects will 
be 
s
cr
een
ed
 
to confirm eligibility requirements for participation
 
using the 
VRC 500 
screening protocol
. 
 
The
 
screening and education process required prior to enrollment is designed 
to ensure that subjects comprehend the purpose
, 
details
 
and risks/benefits
 
of the stu
dy. 
 
 
4.1.1.
 
Inclusion Criteria
 
A subject must meet all of the following criteria to be included:
 
1.
 
Able and willing to complete the informed consent process 
 
2.
 
Able to provide proof of identity to the satisfaction of the study clinician completing the 
enrollment pro
cess
 
3.
 
Available for clinical follow
-
up through the last study visit
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
19
 
of 
73
 
4.
 
18 to 50 years of age
 
5.
 
In good general health without clinically significant medical history
 
6.
 
Physical examination without clinically significant findings within the 56 days prior to 
enrollme
nt
 
7.
 
Weight 
≤ 
115
 
kg
 
(except Group 5)
 
8.
 
Adequate venous access if assigned to an IV group or adequate subcutaneous tissue if 
assigned to a
n
 
SC group
 
9.
 
Willing to have blood samples collected, stored indefinitely, and used for research 
purposes
 
10.
 
Agrees to particip
ate in a 
controlled human malaria infection
 
(CHMI) and to comply with 
post
-
CHMI follow
-
up requirements
 
(except Group 6)
 
11.
 
Agrees to refrain from blood donation to blood banks for 3 years following 
participation 
in 
CHMI
 
(except Group 6)
 
12.
 
Agrees not to 
travel to a malaria endemic region during the entire course of study 
participation
 
(except Group 6)
 
Laboratory Criteria within 
56
 
days prior to enrollment:
 
13.
 
WBC 2,500
-
12,000/mm
3
 
14.
 
WBC differential either within institutional normal range or accompanied by the 
Principal Investigator (PI) or designee approval 
 
15.
 
Platelets = 125,000 
–
 
5
00,000/mm
3
 
 
16.
 
Hemoglobin within institutional normal range or accompanied by the PI or designee 
approval 
 
17.
 
Creatinine ≤ 1.1 x upper limit of normal (ULN) 
 
18.
 
Alanine aminotransferase (
ALT
)
 
≤1.25 x ULN 
 
19.
 
Negative for HIV infection by a
n 
FDA approved method of detection
 
Laboratory Criteria documented any time
 
during screening,
 
prior to enrollment:
 
20.
 
Negative PCR
 
for m
alaria
 
(except Group 6)
 
21.
 
Negative sickle cell screening test
 
(except Group 6)
 
22.
 
Electrocardiogram (ECG) without clinically significant abnormalities (examples may 
include: pathologic Q waves, significant ST
-
T wave changes, left ventricular 
hypertrophy, any no
n
-
sinus rhythm excluding isolated premature atrial contractions, right 
or left bundle branch block, advanced A
-
V heart block). ECG abnormalities determined 
by a cardiologist to be clinically insignificant as related to study participation do not 
preclude s
tudy enrollment
 
(except Group 6)
 
23.
 
No e
vidence of increas
ed cardiovascular disease risk; defined as >10% five
-
year risk by 
the non
-
laboratory 
method 
[
23
]
 
(except Group 6)
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
20
 
of 
73
 
Criteria Specific to Women
:
 
24.
 
Postmenopausal for at least 1 year, post
-
hysterectomy or bilateral oophorectomy, or if of 
childbearing pote
ntial:
 
a.
 
Negative
 
beta
-
human chorionic gonadotropin (β
-
HCG) 
pregnancy test (urine or 
serum) on day of enrollment
, and prior to 
product administration
 
and CHMI, and
 
b.
 
Agrees to use an effective means of birth control through the duration of study 
participation
 
4.1.2.
 
Exclusion Criteria
 
A subject will be excluded if one or more of the following conditions apply:
 
25.
 
Woman who is breast
-
feeding or planning to become pregnant during study participation
 
26.
 
Previous receipt of a malaria vaccine 
or
 
anti
-
malaria
 
monoclonal
 
antibody
 
27.
 
History of malaria infection
 
 
28.
 
Any history of a severe allergic reaction with generalized urticaria, angioedema or 
anaphylaxis prior to enrollment that has a reasonable risk of 
recurrence during the study
 
29.
 
Hypertension that is not well controlled
 
30.
 
Receipt of any investigational study product within 28 days prior to enrollment
/
p
roduct 
administration
 
(Note:
 
SARS
-
CoV
-
2
 
vaccines
 
approved
 
by
 
emergency
 
use
 
authorization
 
are
 
not
 
exclusion
ary)
 
31.
 
Receipt of any live attenuated vaccines within 28 days prior to enrollment
/
product 
administration
 
32.
 
Receipt of any 
vaccine within 2 weeks prior to enrollment/product administration
 
33.
 
Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulo
pathy, or platelet 
disorder requiring special precautions) or significant bruising or bleeding difficulties with 
intramuscular injections or blood draws
 
34.
 
History of a splenectomy, sickle cell disease or sickle cell trait
 
35.
 
History of skeeter syndrome or anaph
ylactic response to mosquito
-
bites
 
(except Group 6)
 
36.
 
Known intolerance to chloroquine phosphate, 
atovaquone or proguanil
 
(except Group 6)
 
 
37.
 
Use or planned use of any drug
, including antibiotics,
 
with antimalarial activity 
4 weeks 
prior to
 
CHMI
 
(except Group 6)
 
38.
 
History of psoriasis or porphyria, which may be exacerbated after treatment with 
chloroquine
 
(except Group 6)
 
39.
 
Anticipated use of medications known to cause drug reactions with chloroquine or 
atovaquone
-
proguanil (Malarone) such as cimetid
ine, metoclopramide, antacids, and 
kaolin
 
(except Group 6)
 
40.
 
History of Sjogren’s syndrome
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
21
 
of 
73
 
41.
 
History of
 
chronic or recurrent
 
s
alivary gland disorder diagnosed by a 
clinician
 
(note: an 
isolated occurrence of parotitis, sialadenitis, sialolithiasis, or of a sali
vary gland tumor is 
not exclusionary)
 
42.
 
History of therapeutic head or neck radiation
 
43.
 
Any other chronic or clinically significant medical condition that in the opinion of the 
investigator would jeopardize the safety or rights of the volunteer, including but 
not 
limited to: diabetes mellitus type I, chronic hepatitis; OR clinically significant forms of: 
drug or alcohol abuse, asthma, autoimmune disease,
 
infectious diseases,
 
psychiatric 
disorders, heart disease, or cancer
 
4.2.
 
Inclusion of Vulnerable Subjects 
 
4.2.1.
 
Child
ren
 
Children are not eligible to participate in this clinical trial because the study product has not been 
previously evaluated in adults.  If the product is assessed as safe for further study, other protocols 
specifically designed for children may be cond
ucted.
 
4.2.2.
 
Adult 
S
ubjects who 
L
ack 
C
apacity to 
C
onsent to 
R
esearch 
P
articipation
 
A
dults who are unable to provide initial informed consent are excluded to enroll
. Also, 
adults 
who permanently lose the capacity to provide on
-
going consent 
after 
initial consent
 
and during 
the study will be discontinued from p
rotocol 
p
articipation
 
as it is described in 
Section 
4.6
.
 
 
4.2.3.
 
NIH Employees 
 
NIH employees and members of their immediate families may participate in this protocol. 
 
We 
will follow the Guidelines for the Inclusion of Employees in NIH Research Studies and will give 
each employee a copy 
of the “NIH 
FAQs for NIH Staff Who are Considering Participation in 
NIH Research
” 
published by Office of Human Research Subjects Protections on Research 
Involving NIH Staff as Subjects, Policy 404. 
 
For NIH employee subjects, consent will be 
obtained by an
 
individual who is independent of the employee’s team.
 
 
If the individual 
obtaining consent is a co
-
worker to the subject, independent monitoring of the consent process 
will be included through the Bioethics Consultation Service.
 
 
Protocol study staff will
 
be trained 
on obtaining potentially sensitive and private information from co
-
workers or subordinates.
 
4.3.
 
Clinical Procedures and Evaluations
 
Evaluation of study product safety will include laboratory studies, medical history, physical 
assessment by clinicians, and subject self
-
assessment.  The study schedule is presented in the 
Schedule of Evaluations, 
APPENDIX I
.  Total blood volume drawn from each subject will not 
exceed the NIH Clinical Center Guidelines.
 
In response to the coronavirus disease 2019 
(COVID
-
19) pandemic and changing information related to tes
ting, all NIH CC epidemiologic 
and testing guidelines will be followed 
during 
study conduct.
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
22
 
of 
73
 
4.3.1.
 
Recruitment and Retention
 
Study enrollments will be conducted at the NIH Clinical Center.  Study subjects will be recruited 
through on
-
site and off
-
site IRB
-
approv
ed advertising done through the VRC’s screening 
protocol, VRC 500 (NCT 01375530).
 
 
Effort will be made to include women and minorities in 
proportions similar to that of the community from which they are recruited.
 
All 
volunteer
 
facing 
materials
 
used for recruitment and other purposes
 
will be submitted to 
the
 
IRB and approved 
before use.  
 
a.
 
Costs
 
There are no costs to subjects for their participation in this trial. 
 
 
b.
 
Compensation
 
Subjects will be compensated for time and inconveni
ence in accordance with the standards for 
compensation of the Clinical Research Volunteer Program.  
Compensation for 
study visit that 
includes 
IV product administration
 
is
 
$430; 
study visit that includes 
SC
 
or 
IM
 
product 
administration
 
is $375.
 
 
If enrollm
ent occurs on a different day than study product 
administration
, then
 
visit compensation will be $85.
  
Compensation will be $
200 
for scheduled 
follow
-
up 
visits that include 
venipuncture
, $
85
 
for clinic visits that do not include 
venipuncture
,
 
and $25 for t
imely completion of the electronic diary card.  Compensation for a CHMI visit 
including the pre
-
CHMI
 
clinic
 
visit 
and activities
 
is $
4
55
. 
 
T
he t
otal amount of compensation var
ies
 
depending upon group
 
and the visits completed
. 
 
Compensation 
may
 
also vary depending upon 
the number of days required for the daily 
evaluations in the period after a CHMI as those who become parasitemic early will require fewer 
days of in
-
clinic evaluation visits than those who have delayed or no parasitemia
.  C
HMI c
on
trol
 
s
ubjects will be compensated
 
similarly 
for
 
comparable visit types
.
 
4.3.2.
 
Screening
 
All s
creening 
procedures 
for this study will be completed through the VRC’s screening protocol, 
VRC 500 (NIH 11
-
I
-
0164).
 
The Recruitment Plan per NIH Policy 302 can be found 
in the NIH 
IRB approved VRC 500 protocol.
 
 
Subjects will be recruited through Institutional Review Board 
(IRB)
-
approved advertising. 
 
Screening evaluations 
are performed to confirm eligibility and will
 
include
 
medical history review, physical exam, and 
the
 
clinical laboratory tests detailed in 
APPENDIX I
.  Women presumed to be of reproductive potential will be given a pregnancy test.  
A baseline electrocardiogram (EKG) wil
l be performed. 
 
Information related to recurrent or 
persistent dry mouth or swelling of salivary glands will be 
revie
wed during screening per 
exclusion criteria.
  
Additional assessments of health may be conducted at screening 
under 
protocol VRC 500 
based 
on clinical judgment
; n
o screening procedures will be done under 
protocol
 
VRC 614
.
  
Pre
-
exposure 
research
 
b
lood samples
 
may 
be collected 
anytime 
during 
screening
 
through enrollment and will not be subject to 
the 
“
56
-
day prior to enrollment
” 
restriction
. 
 
Informed consent documents will be reviewed during screening. 
 
Counseling related to potential 
risks of the study product, pregnancy prevention, and avoiding exposure to malaria will be 
performed.  An Assessment of Understanding (AoU) will be
 
completed in association with 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
23
 
of 
73
 
enrollment
 
into VRC 
61
4
. 
 
R
ecords will be kept documenting the reason 
that 
screened 
subjects 
do 
not enroll.
 
Subjects who are not up to date on standard vaccinations may receive these, if available, during 
their participation 
in the screening protocol or at a later date during study participation
.
 
4.3.3.
 
Enrollment and Study Day 0
 
In this study, enrollment is defined as the assignment of a study identification number and 
a 
study group in the clinical database. 
 
A clinician will discus
s the target dates and timing of the 
study product administration
, CHMI, 
and sample collections before completing an enrollment to 
help ensure that the subject can comply with the projected schedule.
 
 
Informed consent must be 
obtained prior to enrollment. 
 
For
 
L9LS
 
recipients, e
nrollment will occur at Visit 
0
1R (Day 
-
28 
to Day 0) and may occur on the same day as product administration at Visit 
0
2 (Day 0) in 
advance of product administration. 
 
For
 
CHMI 
control 
subjects
, 
Visit 
0
1R 
(Day 
-
56 to Day 
-
1)
 
is 
the 
e
nrollment 
day
, which will be within 56 days prior to 
the 
CHMI
. 
 
 
For 
L9LS
 
recipients, 
Day 0 is defined as the 
day of
 
product administration.  If Day 0 does not 
coincide with enrollment, then the enrollment day may be referred to by a negative number of 
days (i.e., Day 
-
1).  For calculating elapsed days following Day 0, each subsequent calendar date 
is labeled by the next
 
sequential “Study Day” as shown in 
APPENDIX I
.  Since there may be 
more than one research sampling timepoint of interest per study day, each sample collection 
timepoint
 
has its own “Visit Number.”  For this reason, there may be more than one visit number 
recorded on the same calendar date. 
 
The study 
will start
 
with subject enrollment directly into Group 1.  Additional dose groups
 
(Groups 2, 3, 4)
 
will open 
per the dose 
escalation rules as outlined in 
Section
 
4.5
, and subjects 
will be
 
directly enrolled into the subsequent open groups.  Subjects 
in Group 5 
will
 
be
 
abl
e to 
choose to 
p
articipate in the control 
group
 
and undergo CHMI without receiving product 
administration.
 
 
In case of 
Group 5 
dropouts
 
prior to CHMI
, r
eplacement 
of control 
subjects
 
and 
enrollment of a sufficient number of backup subjects 
is allowable to ensure a total of 6 
subjects 
can serve as controls
 
on
 
the 
day of CHMI
.
 
 
Subjects in 
G
roup 6 will be enrolled after  enrollment 
in all other groups 
is complete
.
 
Because this is an open
-
label design, subjects will know what 
group they are in on the day of enrollment.  
 
Medical history and 
Day 0 evaluations 
(
prior to 
product administration, as applicable per study 
group) 
are the baseline for subsequent safety assessments
 
except that the s
creening evaluations 
will be the baseline for those only done at screening
.
 
 
4.3.4.
 
Product 
Administration 
 
All product administrations will be completed according to the assigned group.
 
On the day of, and prior to product administration, vital signs (temperature
, blood pressure, heart 
rate and respiratory rate) will be recorded, a targeted physical examination (
based on 
signs, 
reported symptoms or
 
interim
 
medical history
) may be conducted as needed, and women of 
childbearing potential must have a negative pregnan
cy test.
 
 
 
If a subject is assigned to an IV administration group, the IV access will be placed in an arm vein 
in an aseptic manner.  A different site may be used for collection of PK blood samples; however, 
the same site may be used after flushing the lin
e if another site is not available.  
L9LS
 
will be 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
24
 
of 
73
 
administered with approximately 
50
-
1
2
0 mL of normal saline IV over about 15
-
30 minutes, with 
a target of 30 minutes.  Infusions lasting longer than 30 minutes are allowed.  If the subject 
experiences side effects during the infusion, the rate of infusion may be slowed or stopped to 
alleviate 
the symptoms. 
 
If a subject is assigned to a SC administration group, the SC administration site(s) to be used 
must be assessed as acceptable by the clinician and the subject.  The preferred SC administration 
site is the abdomen, but the upper arm or thigh may be used.  
Given the weight criterion in this 
study, the maximum volume needed to administer 
a 5 mg/kg SC dose is not expected to exceed
 
3.83
 
mL. 
 
The SC dose will be administered by standard needle in a maximum volume of about 
2.5 mL per injection site.
 
 
Up to
 
two 
(
2
) SC injection sites may be used if deemed necessary by 
the clinician
.
  
SC administration sites should be at least 2 inches apart. 
 
If a subject is assigned to a IM administration group, the IM administration site(s) to be used 
must be assessed as accepta
ble 
by the clinician and the subject. 
Injections will be administered 
into
 
the 
deltoid muscle 
or 
quadriceps
 
muscle
.
 
Given the weight criterion in this study, the 
maximum volume needed to administer a 5 mg/kg IM dose is not expected to exceed 3.83 mL. 
The I
M dose will be administered by standard needle in a maximum of 
1
.0
 
m
L per injection site. 
Up
 
to
 
four
 
(
4
) IM injection sites may be used if deemed necessar
y
 
by the clinician. IM 
administration sites should be at least 2 inches apart
 
4.3.5.
 
Post
-
Product Administration 
Follow
-
up
 
 
In 
all study groups, the first subject in each dose group to receive a unique dose level (1, 5, or 20 
mg/kg) will be observed for at least 2
 
hours following completion of product administration.
 
All 
other
 
subjects will be observed for at least 1 hour following completion of product 
administration.
 
 
Collection of PK samples will be conducted according to the Schedule of 
Evaluations for the subj
ect’s study group.
 
Prior to discharge from the clinic, subjects will be assessed for local and systemic reactogenicity 
and vital signs will be recorded. 
 
Any subject who is assessed as being unwell or has ongoing 
reactogenicity symptoms will be asked to re
main in the clinic until evaluation and discharge by a 
study clinician.
  
This includes the possibility of an overnight inpatient stay to evaluate for safety.  
 
4.3.6.
 
Solicited Adverse Events
 
(Reactogenicity)
 
Each s
ubject will be given a 
7
-
day diary
 
(paper and el
ectronic
-
based available)
, a thermometer, 
and a measuring device. 
 
S
ubject
s
 
will 
use the diary to record
 
their highest temperature, local and 
systemic symptoms, and concomitant medications
 
daily
 
for 
7
 
days
 
after each product 
administration
.  Subjects will 
be 
provided training on diary completion 
and 
proper 
usage of the 
thermometer 
to measure temperature
 
and the measuring 
device
 
to measure injection site 
symptoms
.
 
 
Completion of diary training will be noted in the source documents. 
 
While the 
electronic diary is preferred, subjects will ha
ve the option to use a paper diary. 
 
The paper diary
,
 
if used, will be transcribed into the study database and stored in the subj
ect file for monitoring 
purposes.
 
 
When neither
 
paper
 
nor electronic diary is available from the subject, the study 
clinician will document the source of reactogenicity information recorded in the study database.
 
The signs and symptoms solicited by 
the 
dia
ry will include systemic events of 
temperature,
 
feeling 
unusually tired or unwell
, muscles aches, headache, chills, nausea, 
and joint pain, 
and 
local events at 
the
 
product administration
 
site 
of
 
pain/tenderness, 
swelling, redness, bruising, and 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
25
 
of 
73
 
pruritus
. 
 
Subject diaries will be reviewed by a clinician for accuracy and completeness at 
follow
-
up visits. 
 
Clinicians will follow any so
licited symptoms that 
are ongoing after
 
7
 
days
 
until they have resolved
.
 
Diary data will be available in real
-
time 
to clinician
s 
for subjects who use the electronic diary. 
 
Subjects using a paper diary will be encouraged to contact the clinic as soon as possible for any 
moderate or severe side effects that they experience in the 7 days post product administration.  A 
study
 
clinici
an may contact the subject by phone if any moderate or severe side effect is 
reported. 
 
Events that may require a clinic visit include rash, urticaria, fever of 38.6˚C (Grade 2) 
or higher lasting greater than 24 hours or significant impairment in the activ
ities of daily living 
(such as those consistent with Grade 2 or higher impairment). 
 
Additionally, other clinical 
concerns may prompt a study visit based on the judgment of a study clinician.
 
4.3.7.
 
CHMI
 
Procedures 
 
The interval between administration of study pr
oduct and CHMI will vary depending on when a 
subject is enrolled.  The CHMI will only occur following an evaluation of Day 7 safety data post 
product administration and may be administered at any time 
≥ 
8
 
days through 
12
 
weeks
 
post 
product administration.  Some flexibility around the interval between the time of 
L9LS 
administration and CHMI is permitted given the need to work with each subject’s personal 
schedule, availability of the CHMI facility and post
-
CHMI follow
-
up.  
 
Prio
r to scheduling the CHMI, a
t least two emergency contact numbers will be 
confirmed and 
verified as authentic for each subject who will participate in the challenge
. 
 
T
he clinical study 
team will review 
each subject’s
 
adherence to the schedule
 
and 
safety fo
llow
-
up to date
.  
This 
review
 
will 
attempt to identify any likelihood of unreliability on the part of the 
subject
 
during the 
CHMI
 
phase of the study
.  
Any 
subject
 
expressing inability to comply with study requirements 
may be deemed unsuitable for 
CHMI
 
and 
will be excluded from the 
CHMI
 
phase of the study
.  
Any
 
subject who receives study product
, however, will be encouraged to remain in the st
udy for 
safety follow
-
up visits.  
 
Women of childbearing potential must have a negative 
pregnancy test within 2 days 
prior to 
CHMI.  
Use of antibiotics by CHMI participants should be 
avoided 
at least 4 weeks prior to and
 
during the CHMI unless medically warranted.
 
P
rior to CHMI procedure
 
on the day of CHMI
, vital signs will be recorded 
for
 
s
ubjects 
participating in the C
HMI. An abbreviated physical examination 
will 
be performed by an 
Advanced Practitioner 
to
 
confirm
 
the subject’s ability 
to 
participate in the 
CHMI procedure.
 
CHMI will be conducted by experienced insectary and clinical staff.  M
osquitoes infected via 
membrane feeds 
in preparation for the CHMI 
contain sporozoites in their salivary glands
 
and up 
to 5 at a time
 
will be allowed to feed on 
each
 
subject under controlled conditions
. 
 
Following 
exposure, t
he mosquitoes will be 
immediatel
y 
dissected to confirm the presence of a blood meal 
and 
to 
determine the infectivity rate and the salivary gland score.
 
 
Additional mosquitoes will be 
allowed to feed until
 
5 bites
 
showing presence of a blood meal and
 
a minimum 2+ salivary gland 
score has 
been achieved
 
for each subject
.
 
Prior to discharge from 
CHMI
, subjects will be observed for a minimum of 30 minutes. 
 
Vital 
signs will be taken and 
the 
mosquito bite site will be assessed.
 
 
Subjects will be given an 
Emergency Notification card and will 
als
o 
be supplied with 
H
ydrocortisone cream
.
 
 
They will 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
26
 
of 
73
 
also be provided
 
with 
counseling and written
 
recommendations 
to reduce risk of natural 
mosquito exposure 
beginning 5 days after 
CHMI
 
and continuing until 
completion of treatment.
 
4.3.8.
 
Post
-
CHMI Follow
-
Up
 
The 
s
tudy team will be in contact with subjects at least 2 times in the first 7 days after the CHMI 
to provide close monitoring of clinical status.
 
 
Blood samples to evaluate for malaria parasitemia 
will be collected daily and run on PCR from days 7 through 
1
7
 
with a final PCR performed at 
day
 
21 
post
-
CHMI
. 
 
Malaria PCR testing is processed in the morning and results are available 
the same day
. 
 
If the
 
result is positive for malaria
,
 
the subject will be
 
contacted by phone
 
immediately.
 
 
Subject will be asked to return to the clinic
 
within two hours of notification
 
to 
initiate 
malaria 
treatment
. 
 
Prior to Day 21, r
egular parasitemia evaluations will stop 
after 
treatment is initiated for positive cases of parasitemia. 
 
In the absence of malaria infection, all 
subjects who have not already started treatment will be provided with directly observed 
definitive antimalarial treatment at Day 21.
 
During the post
-
C
HMI follow
-
up period, subjects may participate in their normal daily activities.
 
 
A study clinician will be available 24 hours a day by telephone or in person to the site staff in
 
case consultation about subject’s signs and symptoms is needed.
 
 
Any subject
 
who is assessed as
 
being unwell during the post
-
CHMI follow
-
up will be asked to remain in the clinic until
 
evaluation and discharge by a study clinician.
 
 
This includes the possibility of an overnight
 
inpatient
 
stay for evaluation
.  
 
4.3.9.
 
Parasitemia
 
Management
 
Following CHMI, a case of malaria parasitemia will be defined as
 
either a single 
positive 
PCR 
result 
or a thick blood smear 
that meet
s
 
the criteria for positivity. 
 
PCR 
allows for cases of 
malaria to be identified before gametocytes can develop
 
and thus before detection of 
gametocytes by blood smear are detectable.  Malaria infection will be treated when the criterion 
for a case is met.
 
 
 
Regardless of PCR 
or
 
blood smear 
results, all
 
CHMI participants will receive 
directly observed 
anti
malaria
l
 
treatment
 
at Day 
21 
post CHMI
, if they have not already
 
been treated for 
parasitemia by this timepoint
.  
Subjects may also be provided with treatments like antiemetics 
and ibuprofen as needed for management of symptoms. 
 
Refer to the Schedule of Evaluation
s, 
APPENDIX I
,
 
for the safety laboratory evaluations that are 
required to be performed at the onset of treatment and 
about 
2 days later.
 
Malaria i
nfections in all subject
s will be treated promptly
 
and administered as directly observed 
therapy (DOT) by a clinician until the specified course of treatment
.  Treatment regimens 
subsequently described are known to be effective against
 
the
 
Pf
 
strain
 
being used in the CHMI.
 
 
•
 
First line of treatment: a
 
standard atovaquone/proguanil (Malarone®) regimen:
 
Four Malarone Tablets (adult strength
 
tablet = 250 mg atovaquone/100 mg proguanil
; 
total daily dose 1 g atovaquone/400 mg proguanil hydrochloride) taken as a single 
dose 
daily for 3 consecutive days with food or a milky drink.
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
27
 
of 
73
 
•
 
Alternative treatment: a
 
standard chloroquine regimen: 
 
Total of 1500 mg chloroquine base (2500 mg salt) given orally in divided doses: 600 
mg base (1000 mg salt) initially, followed by 300 mg base (
500 mg salt) given 6, 24, 
and 48 hours later]
 
Alternative medications and regimens known to be effective in curing the 
Pf
 
strain administered 
for the CHMI may be used in the event of allerg
ies
,
 
intolerance
s
 
or lack of availability of 
treatments listed abov
e
. 
 
Following treatment for a positive case of malaria, cure will be documented by a PCR negative 
result at 26 days (± 5 days) after the completion of treatment
.
 
 
S
ubjects who remain 
PCR 
negative will be contacted by phone
 
at 
26
 
(days 
±5
 
days) after last n
egative PCR
.
 
4.3.10.
 
Follow
-
Up through End of Study
 
Study follow
-
up will continue via clinical visits through 
24
 
weeks after the 
product 
administration or 8 weeks
 
post final CHMI, whichever is most stringent
.  The visit schedule is 
based on intervals of time after
 
product administration
 
or CHMI.  
The schedule of visits, 
allowable windows for completing the visits, and evaluations performed at each visit are shown 
in the 
Schedule of Evaluations, 
APPENDIX I
.
  
Out of window study 
visit
s
 
will be
 
discouraged 
and recorded as protocol deviations but 
may be
 
permitted at the discretion of the PI
 
in the 
interest of obtaining safety and PK evaluations following e
xposure to the investigational study 
product or conduct of a CHMI
.
 
 
 
Any subject who receives investigational product will be required to follow the product 
administration schedule for a complete safety and research evaluation through study duration.  
Subj
ects who undergo CHMI will be required to follow the CHMI Schedule of Evaluations to 
completion.  When visits from both schedules occur on the same day, all required components of 
the required visits for each schedule must be completed.
 
S
ubjects who
 
receiv
e study product but do not 
receive
 
CHMI as scheduled 
are expected to 
continue follow
-
up according to the 
s
chedule 
for 
IV
,
 
SC
, or IM
 
group through 24 weeks, 
except 
that research sample collections 
may
 
be discontinued for pregnant women or others in which it
 
is 
contraindicated
.
 
 
Refer to 
Section
 
4.6
 
for
 
criteria for discontinuing product administration and/or study 
participation.
 
4.4.
 
Conc
o
mitant Medications
 
Only routine
 
prescription medications will be entered in the dat
abase at the time of e
nrollment.  
Subsequently, concomitant medications are only updated or recorded in the study database if 
there is an occurrence of an adverse event (AE) that requires expedited reporting
, a change to 
pre
-
existing condition treatment, 
or the develop
ment of
 
a
 
new chronic condition that requires 
ongoing medical management.  Treatment with antimalarial drugs will be recorded on a Malaria 
Endpoint Case Report Form (CRF).  Otherwise, the concomitant medication changes throughout 
the study will be recorded in the s
ubject’s chart as needed for general medical records but will 
not be recorded in the study database.  
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
28
 
of 
73
 
4.5.
 
Dose Escalation Plan
 
Th
is study will include a series of interim safety reviews to assess 
product
 
safety in a stepwise
 
manner.
 
The activation of addition
al dose groups will proceed in a staged manner that is
 
governed by the outcome of the planned interim PSRT data reviews.
 
The PSRT must assess the
 
data as showing no significant safety concerns before proceeding with group activation. If there
 
are
 
discontin
uations
 
from
 
the
 
study
 
before
 
there
 
are
 
sufficient
 
data
 
to
 
conduct
 
the
 
dose
 
escalation
 
review for a specific group, then additional subjects may be enrolled to complete the dose
 
evaluation
. 
 
The study will begin with direct enrollment of subjects into 
Group 1
, with one subject enrolled 
per day for the first 3 subjects
. 
 
The first dose escalation review (from 
1
 
mg/kg 
IV 
to
 
5
 
mg/kg
 
IV
) will occur when 3 subjects who received the 
1
 
mg/kg dose
 
by IV 
have completed the Day 7 
safety follow
-
up visit. 
 
The PSRT
 
review will determine whether enrollment into 
Group 2 
may 
begin. 
 
The second dose escalation review (from 
5
 
mg/kg 
IV 
to 
2
0 mg/kg
 
IV
) will occur when 3 subjects 
who received the 
5
 
mg/kg dose
 
by IV 
have completed the Day 7 safety follow
-
up visit. 
 
The 
PSRT 
review will determine whether enrollment into Group 
4
 
may begin.
 
Group 3 (5 mg/kg SC) can enroll at 
any time
 
and 
is
 
not contingent upon the dose escalation 
reviews for the IV 
doses
.  
 
If there are discontinuations from the study before there are sufficient
 
data to conduct the dose 
escalation
 
review for a specific group, then 
additional
 
subjects may be 
enrolled to complete the 
dose evaluation
.
 
 
Additionally, AEs assessed as related to study product at the time of a dose 
escalation review may warrant enrollment of additional subjects into a dose group to reassess 
safety before proceeding to a higher dose.  
Consultation with the IRB or FDA
 
as per 
study pause 
criteria 
may 
occur if indicated.  
 
G
roup 6 (5 mg/kg IM) 
was added after completion of the dose escalation 
process 
and 
can enroll 
at any time
.
 
4.6.
 
Criteria for Discontinuation of Protocol Participation
 
All participants who received the study product
 
will remain on study and continue safety follow
-
up
 
to 
Visit 14
 
(i.e.,
 
week 24
)
. 
Participants
 
who have completed the CHMI, but did not receive 
study product, will remain on study and continue safety follow
-
up to Visit C18.
 
Decisions by the 
PI or designee t
o discontinue a subject 
from 
protocol participation will 
be made
 
with the 
following criteria.
 
4.6.1.
 
Discontinuation 
from
 
Protocol Participation
 
A subject
 
will
 
be discontinued
 
from protocol participation for the following reasons:
 
1.
 
Subject voluntarily 
withdraws;
 
2.
 
Subject is lost to follow
-
up
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
29
 
of 
73
 
4.7.
 
Criteria for Pausing and Resuming the Study 
 
The study team will closely monitor and review study data as they become available to make 
determinations regarding the presence, severity and attribution of AEs.  Study p
roduct 
administrations and
 
new enrollments will be paused if any of the following criteria are met: 
 
•
 
One
 
(or more) subject experiences a 
SAE
 
that is assessed as related (possibly, probably or 
definitely) to the study product, or
 
•
 
T
wo
 
(or more) subjects experience the same 
Grade 3
 
or higher
 
AE
 
that is assessed as 
related (possibly, probably or definitely) to the study product (other than self
-
li
mited 
Grade 3 solicited reactogenicity).
 
4.7.1.
 
Plan for Review of Pauses and Resuming Rules  
 
In the event of a pause, the IND Sponsor 
Medical
 
Officer (
M
O) and the PSRT will be promptly 
notified.  The IND Sponsor 
M
O and PI, in consultation with the PSRT, will co
nduct a review of 
available information, including the events that lead to the pause, and will make the decision to 
resume, amend or close the study.  As part of the pause review, the reviewers may also advise on 
whether the study needs to be paused again 
for any subsequent events of the same type.  
 
Study product administrations and new enrollments would resume only if review of the AEs that 
caused the pause results in a recommendation to permit further study product administrations and 
study enrollments. 
 
Safety data reports and changes in study status will be submitted to relevant 
regulatory authorities 
in accordance with
 
Section
 
5
 
and institutional po
licy.
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
30
 
of 
73
 
5.
 
SAFETY AND ADVERSE EVENTS 
 
5.1.
 
Adverse Events
 
An adverse event (AE) is any untoward or unfavorable medical occurrence in a human subject, 
including any abnormal sign (e.g., abnormal physical exam or laboratory finding), symptom, or 
disease temporally ass
ociated with the subject’s participation in research, whether or not 
considered related to the subject’s participation in the research.  In the context of FDA
-
required 
reporting, an AE means any untoward medical occurrence associated with the use of a drug
 
in 
humans, whether or not considered drug related. 
 
•
 
Solicited AEs (
i.e.,
 
reactogenicity parameters
 
as defined in 
Section
 
4.3.6
) will be 
recorded without attribution assessments by the subject 
on
 
paper or 
an 
electronic diary 
for 
7
 
days after 
each product administration.
 
•
 
Unsolicited AEs will be recorded in the study dat
abase with attribution assessments 
during the following periods: 
 
1) from product administration through the Day 28 post
-
product administration visit; and 
 
2) from CHMI through the 
Day 28 post
-
CHMI visit
.  
 
A
fter 
and between the indicated
 
time periods, onl
y SAEs (as detailed in 
Section
 
5.3
)
 
and
 
new 
chronic medical conditions will be recorded 
as AEs 
through the last 
expected 
study 
visit or 
contact.  
 
Mala
ria and the associated signs and symptoms of parasitemia events occurring at any time 
during the study will be recorded on a Malaria Endpoint CRF and will not be recorded as an AE.
 
APPENDIX II
 
describes how attribution assessments, the relationship between an AE and the 
study product, CHMI or both, will be determined.  Also available in 
APPENDIX II
 
is the link 
to 
the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse 
Events, Corrected Version 2.1 [July 2017], which will be used to determine the severity grades 
of AEs in this protocol with several modifications as noted. 
 
5.2.
 
Serious Adverse Events
 
The term “Serious Adverse Event” (SAE) is defined in 21 CFR 312.32 as follows:  “An adverse 
event or suspected adverse reaction is considered serious if, in the view of either the investigator 
or the sponsor, it results in any of the
 
following outcomes:  Death, a life
-
threatening adverse 
event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or 
significant incapacity or substantial disruption of the ability to conduct normal life functions, or a 
con
genital anomaly/birth defect.  Important medical events that may not result in death, be life
-
threatening, or require hospitalization may be considered serious when, based upon appropriate 
medical judgment, they may jeopardize the patient or subject and ma
y require medical or 
surgical intervention to prevent one of the outcomes listed in this definition.  Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an emergency 
room or at home, blood dyscrasias or convulsio
ns that do not result in inpatient hospitalization, 
or the development of drug dependency or drug abuse.”
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
31
 
of 
73
 
“Life threatening” refers to an AE or suspected adverse reaction that represents an immediate 
risk of death to the subject.  It does not include an AE
 
or suspected adverse reaction that, had it 
occurred in a more severe form, might have caused death.  Similarly, a hospital admission for an 
elective procedure is not considered a SAE.
 
5.3.
 
Adverse Event Reporting to the IND Sponsor
 
AEs that meet SAE criteria m
ust be reported and submitted by the clinical site on an expedited 
basis to 
the IND 
Sponsor, 
VRC/NIAID/NIH
, according to sponsor guidelines as
 
follows:
 
•
 
Results in death;
 
•
 
Is life threatening (places the subject at immediate risk of death from the event as 
i
t
 
occurred);
 
•
 
Results in inpatient hospitalization or prolongation of existing hospitalization;
 
•
 
Results in a persistent or significant disability/incapacity;
 
•
 
Results in a congenital anomaly/birth defect in the offspring of a study subject; OR
 
•
 
Based 
upon app
ropriate medical judgment, may jeopardize the subject’s health and may 
require medical or surgical intervention to prevent one of the other outcomes listed in this 
definition (examples of such events include allergic bronchospasm requiring intensive 
treatm
ent in the emergency room or at home, blood dyscrasias or convulsions that do not 
result in inpatient hospitalization, or the development of drug dependency or drug abuse).
 
In addition, any event, regardless of severity, which in the judgment
 
of an investi
gator represents 
a SAE, may be reported on an expedited basis.
 
An investigator will communicate an initial SAE report within 24 hours of site awareness of 
occurrence to the IND Sponsor by data entry into the database, which triggers an alert to the IND 
Spo
nsor MO.  Within 3 working days, a written summary by the investigator should be 
submitted to the IND Sponsor.  
 
In order for the IND Sponsor to comply with regulations mandating sponsor notification of 
specified SAEs to the FDA within 7 and/or 15 calendar
 
days, the investigator must submit 
additional information as soon as it is available.
 
5.4.
 
IND Sponsor Reporting to the FDA 
 
The IND Sponsor is responsible for making the determination of which SAEs are “serious and 
unexpected suspected adverse reactions” (SUS
ARs) as defined in 21 CFR 312.32. 
 
•
 
Suspected 
A
dverse 
R
eaction
 
means any AE for which there is a reasonable possibility that 
the drug caused the AE. 
 
•
 
Unexpected Adverse Event
 
means an AE that is not listed at the specificity or severity that 
has been observ
ed. 
 
All SUSARs (as determined by the IND Sponsor) will be reported to the FDA as IND Safety 
Reports
 
per 21 CFR 312.32 as soon as possible but not exceeding 7 calendar days for unexpected 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
32
 
of 
73
 
fatal or life
-
threatening events, and not exceeding 15 calendar days
 
for other qualifying events.
 
IND Safety Reports will also be provided to the IRB. 
 
The IND Sponsor will also submit an IND Annual Report of the progress of the investigation to 
the FDA as defined in 21 CFR 312.33.
 
5.5.
 
Reporting to the Institutional Review Boa
rd
 
The following information is consistent with NIH IRB Policy 801: Reporting Research Events, 
Version 1, effective July 1, 2019. 
 
Reportable Event
:
 
 
An event that occurs during the course of human subject research that 
requires notification to the IRB.
 
For the purposes of this policy, reportable events include the following:
 
•
 
Unanticipated 
P
roblems 
(UPs) 
involving risks to subjects or others
 
•
 
Non
-
compli
ance (including major protocol deviations and noncompliance that is not 
related to a protocol deviation)
 
•
 
Deaths related or possibly related to research activities
 
•
 
New information that might affect the willingness of subjects to enroll or continue 
participa
tion in the study
 
5.5.1.
 
Unanticipated Problem
 
An Unanticipated Problem (UP) is defined as any incident, experience, or outcome that meets 
all
 
the following criteria:
 
•
 
Unexpected (in terms of nature, severity, or frequency) given (a) the research procedures 
that are described in the protocol
-
related documents, such as the IRB approved research 
protocol and informed consent document; and (b) the characteristics of the sub
ject 
population being studied; 
and
 
•
 
Related or possibly related to participation in the research (possibly related means there is 
a reasonable possibility that the incident, experience, or outcome may have been caused 
by the procedures involved in the resea
rch); 
and
 
•
 
Suggests that the research places subjects, or others (which may include research staff, 
family members or other individuals not directly participating in the research) at a greater 
risk of harm (including physical, psychological, economic, or so
cial harm) related to the 
research than was previously known or expected.
 
A UP must be reported within 7 calendar days of an investigator becoming aware of the actual or 
suspected UP.
 
5.5.2.
 
Non
-
Compliance 
 
Non
-
compliance is the failure 
of investigator(s) to foll
ow the applicable laws, regulations, or 
institutional policies governing the protection of human subjects in research, or the requirements 
or determinations of the IRB, whether intentional or not.  
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
33
 
of 
73
 
Non
-
compliance may be unintentional (e.g. due to lack of 
understanding, knowledge, or 
commitment), or intentional (e.g. due to deliberate choice to ignore or compromise the 
requirements of any applicable regulation, organizational policy, or determination of the IRB).
 
Non
-
compliance is further characterized as s
erious or continuing as follows:
 
•
 
Serious non
-
compliance
 
–
 
Non
-
compliance, whether intentional or not, that results in 
harm or otherwise materially compromises the rights, welfare and/or safety of the subject. 
Non
-
compliance that materially effects the scie
ntific integrity or validity of the research 
may be considered serious non
-
compliance, even if it does not result in direct harm to 
research subjects.
 
•
 
Continuing non
-
compliance
 
–
 
A pattern of recurring non
-
compliance that either has 
resulted, or, if contin
ued, may result in harm to subjects or otherwise materially 
compromise the rights, welfare and/or safety of subjects, affect the scientific integrity of 
the study or validity of the results.  The pattern may comprise repetition of the same non
-
compliant ac
tion(s), or different noncompliant events.  
 
Any actual or suspected non
-
compliance by any investigator or entity associated with the 
protocol must be reported to the IRB by the PI/designee within 7 calendar days of any 
investigator or individual associate
d with the protocol first becoming aware.
 
5.5.3.
 
Protocol Deviation 
 
A Protocol Deviation (PD) is defined as any change, divergence, or departure from the IRB
-
approved research protocol and are further characterized as major and minor as follows: 
 
•
 
Major Deviation
s
 
–
 
Deviations from the IRB approved protocol that have, or may have the 
potential to, negatively impact, the rights, welfare or safety of the subject, or to 
substantially negatively impact the scientific integrity or validity of the study. 
 
•
 
Minor Deviatio
ns 
–
 
Deviations that do not have the potential to negatively impact the 
rights, safety, or welfare of subjects or others, or the scientific integrity or validity of the 
study.  
 
For the reporting purposes, failure of subjects to comply with the research pr
otocol does not 
represent non
-
compliance unless that failure is due to an action or omission of a member of the 
research team, for example, the failure to give adequate instruction to the subject.
 
A major deviation must be reported within 7 calendar days o
f an investigator becoming aware of 
an actual or suspected deviation.  Although PDs are also non
-
compliance, these should only be 
reported once as deviations. 
 
Major deviations resulting in death must be reported within 24 
hours of the occurrence of the ev
ent or of any member of the study team becoming aware of the 
death.  
 
Researchers are responsible for monitoring their studies throughout the year for adherence to the 
IRB approved protocol.  The purpose of this monitoring is to identify major deviations a
nd to 
look for trends in minor deviations that may indicate a systemic issue in how the study is being 
conducted that could potentially negatively impact the rights, safety, or welfare of participants or 
the study’s ability to produce scientifically valid 
results.  A series of minor deviations pointing 
toward a more global issue that could affect the rights, safety or welfare of the participant or 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
34
 
of 
73
 
affect the validity of the study should be reported as a major deviation.  In all other instances, a 
summary of
 
minor deviations should be provided to the IRB at the time of continuing review.  
 
5.5.4.
 
Death
 
Any death of a research subject that is possibly, probably or definitely related to the research 
must be reported within 24 hours of an investigator becoming aware of
 
the death.
 
5.5.5.
 
New Information 
 
New information that might affect the willingness of a subject to enroll or remain in the study 
should be reported within 7 calendar days of an investigator first becoming aware. 
 
5.5.6.
 
Suspension or Termination of Research Activitie
s
 
Any suspension or termination of research activities, including holds on new enrollment, placed 
upon the research by the study sponsor, NIH or IC leadership, or any regulatory agency must be 
reported within 7 calendar days of an investigator 
becoming aware.
 
5.5.7.
 
Expedited Reporting to the IRB
 
Death
 
related to research must be reported 
within 
24 hours
.
 
The following will be reported within 
7 calendar days
 
of investigator awareness: 
 
•
 
Actual or suspected UPs;
 
•
 
Actual or suspected 
non
-
compliance;
 
•
 
Actual or suspected Major PDs;
 
•
 
SAEs that are actual or suspected UPs;
 
•
 
New information that might affect the willingness of a subject to enroll or remain in the 
study;
 
•
 
Suspension or termination of research activities, including holds on new 
enrollment, 
placed upon the research by the study sponsor, NIH or IC leadership, or any regulatory 
agency.
 
5.5.8.
 
Annual Reporting to the IRB
 
The following will be reported to the IRB in summary at the time of Continuing Review:
 
•
 
Summary of UPs and non
-
compliance;
 
•
 
AEs, including SAEs, that are not U
P
s
,
 
as
 
a narrative summary statement indicating 
whether these events were within the expected range
;
 
•
 
Minor 
PDs 
(aggregate summary)
;
 
•
 
Any trends or events which in the opinion of the investigator should be reported.
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
35
 
of 
73
 
6.
 
STATIS
TICAL CONSIDERATIONS
 
6.1.
 
Overview
 
This study is a Phase 1, dose
-
escalation study in healthy adults to assess the safety, PK and 
protective efficacy of 
L9LS
, an investigational human antimalarial mAb.  
 
6.2.
 
Sample Size and Accrual
 
Trial recruitment will target abou
t 
2
9
 
healthy adults, ages 18 to 50 years, as shown in
 
Table
 
1
.  
This includes 
18
 
subjects that receive study product and then undergo CHMI and 6 controls 
who
 
will 
only 
undergo 
the 
CHM
I
 
and
 
do not receive study product
 
and 5 subjects who will receive 
study product but not take part in the CHMI
.  The permitted accrual is 
40
 
subjects in total 
(inclusive of 2 subjects who will serve as back
-
up
s
 
to the control) 
to allow for additional 
enrollments 
to meet
 
the minimum 
number of subject 
evaluations needed 
for a dose
-
escalation 
evaluation 
or CHMI per
 
protocol criteria.  Dose escalation rules are described in 
Section
 
4.5
.  
Specifically, i
f a subject enrolls into a study product group but does not 
receive a product 
administration or withdraws before the challenge for reasons that are not safety related, or a 
control group subject withdraws before the malaria challenge occurs, then additional subjects 
may be enrolled to achieve the accrual target.  F
ollowing a withdrawal from a study product 
group, additional enrollments may be made if there is sufficient time to complete product 
administration prior to the scheduled CHMI.
 
The
 
primary
 
goal of this study is to identify safety concerns associated with 
L
9LS
 
at different 
doses
. 
 
Primary sample size 
considerations
 
are expressed in terms of the ability to detect serious 
adverse experiences. 
 
The ability of the study to identify SAEs will be expressed in terms of the 
probability of observing a certain number 
of serious adverse events. 
 
With
 
a
 
sample
 
size
 
of
 
n=
5
, 
there is over 90% chance to observe at least 1 SAE if the true rate is at least 0.3
70
 
and over 90% 
chance to observe no SAE if the true rate is no more than 0.0
20
. 
 
With 
a 
sample 
size
 
of
 
n=
23
, 
there is
 
over 90% chance to observe at least 1 SAE if
 
the true rate is no less than 0.
096
 
and over 
90% chance of observing no SAE if the true rate is no more than 0.00
4
.
  
Probabilities of 
observing 0 or more than 1 
SAE
 
within 
a
 
group are
 
presented in
 
Table
 
2
 
for a range of possible 
true event rates. 
 
Table
 
2
:
 
Probability of Events for Different Safety Scenarios (n
=
5
 
or 
23
)
 
True Event 
Rate
 
n=
5
 
n=
23
 
Pr(0)
 
Pr(>1)
 
Pr(0)
 
Pr(>1)
 
0.005
 
0.975
 
0.000
 
0.891
 
0.006
 
0.01
 
0.951
 
0.001
 
0.794
 
0.022
 
0.02
 
0.904
 
0.004
 
0.628
 
0.077
 
0.035
 
0.837
 
0.011
 
0.441
 
0.192
 
0.05
 
0.774
 
0.023
 
0.307
 
0.321
 
0.1
 
0.590
 
0.081
 
0.089
 
0.685
 
0.15
 
0.444
 
0.165
 
0.024
 
0.88
 
0.2
 
0.328
 
0.263
 
0.006
 
0.96
 
0.3
 
0.168
 
0.472
 
0.000
 
0.997
 
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
36
 
of 
73
 
Table
 
3
 
gives the upper and lower bounds for 95% exact binomial confidence intervals
 
of the 
true SAE rate at possible numbers of events within 
a
 
group. 
 
Within a group 
size
 
of
 
n=
5
, if none 
experience 
an 
SAE, the 95% exact confidence interval has 
an 
upper bound
 
of
 
0.
522
. Wi
th
 
a 
group 
size
 
of
 
n=
23
, if 2 
subjects
 
experience 
an 
SAE, the exact 
95% confidence interval has 
a 
lower 
and upper 
bound 
of 
0.
0
1
1
 
and 
0.28
, respectively
.
 
Table
 
3
:
 
95% Confidence Intervals for the True Rate at Possible Observed Number of 
Events (n=
5
 
or n=
23
)
 
Observed 
Number of 
Events
 
95% Confidence Interval
 
(n=
5)
 
95% Confidence Interval
 
(n=
23
)
 
Lower 
Bound
 
Upper 
Bound
 
Lower 
Bound
 
Upper 
Bound
 
0
 
0.000
 
0.522
 
0.000
 
0.148
 
1
 
0.005
 
0.716
 
0.001
 
0.219
 
2
 
0.053
 
0.853
 
0.01
1
 
0.28
 
3
 
0.147
 
0.947
 
0.0
28
 
0.336
 
4
 
0.284
 
0.995
 
0.0
5
 
0.388
 
5
 
0.478
 
1.000
 
0.0
75
 
0.437
 
6
 
 
 
0.
102
 
0.484
 
7
 
 
 
0.
132
 
0.529
 
8
 
 
 
0.164
 
0.573
 
9
 
 
 
0.197
 
0.615
 
 
6.3.
 
Statistical Analysis 
 
Enrollment of 
L9LS
 
recipients may occur on the same day as product administration at Visit 02 
(Day 0) or in advance of product administration at Visit 
01R 
(Day 
-
28 to Day 0)
, except in the 
case of controls
.  All subjects who receive product administration will provide safet
y data. 
 
Three analysis cohorts are involved in 
the 
statistical analysis
:
 
•
 
Intent
-
to
-
treat (ITT)
 
-
 
This
 
cohort will include all enrolled subjects who receive product 
administration and will be analyzed according to the assigned group.  
 
•
 
As
-
t
reated
 
-
 
This
 
cohort will include all enrolled subjects who receive product administration 
and will be analyzed accord
ing to the actual dose they receive. 
 
•
 
Modified intent
-
to
-
treat (mITT) 
–
 
This 
cohort will include all enrolled subjects who 
participate in the
 
CHMI challenge and will be analyzed according to the assigned group.  
 
All statistical analyses will be performed 
using SAS and R statistical software
.
 
6.3.1.
 
Analysis Variables
 
The analysis variables consist of baseline, safety parameters, PK, and presence or absence of 
malaria infection after CHMI.  Descriptive statistics will be used to summarize baseline 
characteristics,
 
inclusive of demographics and safety laboratory measurements.
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
37
 
of 
73
 
6.3.2.
 
Safety Analysis
 
Safety evaluation will be performed 
using 
the 
as
-
treated 
cohort.  The number and percentage of 
subjects with one or more AEs will be summarized by dose group along with the exac
t 95% 
confidence intervals of the AE rate.  For subjects experiencing more than one AE, they will be 
counted once under the event of highest severity.  In addition, a complete listing of AEs for each 
subject will provide details such as severity, duration,
 
and relationship to study product.  
Summaries will be provided for any solicited or unsolicited AEs. 
 
a.
 
Solicited Reactogenicity
 
Solicited AE data will be collected after product administration.  The number and percentage of 
subjects experiencing each type 
of solicited sign or symptom will be tabulated by severity and by 
dose group and overall (i.e., pooled IV dose groups and pooled SC and IV dose groups).  
Subjects with multiple occurrences of the same event will be counted once using the event of 
highest s
everity.
 
 
b.
 
Adverse Events
 
All reportable AEs will be recorded and coded by Medical Dictionary for Regulatory Activities 
(MedDRA) system organ class (SOC) and preferred term (PT).  The number and percentages of 
subjects with each unsolicited AE will be tabul
ated by severity and relationship to the study 
product, and by dose group and overall (i.e., pooled IV dose groups and pooled SC and IV dose 
groups).  Subjects with multiple occurrences of the same event will be counted once using the 
event
 
of
 
highest seve
rity or strongest relationship to the study treatment. 
 
A by
-
subject listing of all unsolicited AEs will provide details including severity, relationship to 
treatment type, seriousness, new medical condition status, onset and end date, duration, and 
outcom
e. 
 
c.
 
Local Laboratory Values
 
Boxplots of local laboratory values will be generated for baseline values and for values measured 
during the course of the study.  Each boxplot will show the 1st quartile, the median, and the 3rd 
quartile.  Outliers, or values o
utside the boxplot, will also be plotted.  If appropriate, horizontal 
lines representing boundaries for abnormal values will be plotted.
 
6.3.3.
 
Pharmacokinetics Analysis 
 
PK analysis will be performed 
using
 
the 
as
-
treated 
 
cohort
.  Blood samples for PK evaluations 
will be collected at defined time
-
points as listed in 
APPENDIX I
.  
 
Individual Subject Pharmacokinetic Analysis
:  A non
-
compartment
al (NC) PK analysis will 
be performed using Phoenix 7.0 (Certara
R
),
 
PKPlus or a similar program on the L9LS 
concentration data generated from each subject.  Individual subject and dosing group 
concentration vs time profiles will be constructed in linear an
d semi
-
log scales.  In the NC 
analysis the maximum concentration (Cmax) and time of maximal concentration (Tmax) will be 
taken directly from the observed data.  The area under the concentrations vs. time curve (AUC) 
will be calculated using the trapezoidal
 
method and determined out to the final concentration 
collected.  If a subjects L9LS concentration falls below the quantitative limit (QL) of the assay 
before the final of PK sample collection, the sample with concentration below the QL will be 
assigned a 
L9LS concentration value of “0” for AUC calculations.  Later PK samples after the 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
38
 
of 
73
 
initial concentration below the QL sample will be ignored in AUC calculations because partial 
AUC is not contributory to the total AUC.  In addition to calculation of the tot
al AUC from 
Time=0 to the last L9LS concentration (AUC
0
-
last
), Time= 0 to the CHMI challenge (AUC
0
-
CHMI
) 
and Time of CHMI to 
21 
Days post CHMI (AUC
CHMI
-
2
1
DCHMI
) will be determined.  The time 
weighted average concentrations (Cave) during these intervals wil
l be calculated as the AUC 
divided by the AUC collection interval, e.g. Cave
CHMI
-
21DCHMI
 
= (AUC
CMHI
-
2
1
DCHMI
) / 
3
weeks.  
The terminal slope, 
λ
z
 
will be determined by regression of the terminal, log
-
linear portion of the 
concentration vs. time profile.  If t
he final PK sample has measurable L9LS concentrations 
greater than the assay QL, the AUC post final PK collection (AUC
last
-
infinity
) will be estimated as 
C
last
/
λ
z
 
and AUC
0
-
infinity
 
will be calculated as sum AUC
0
-
last
 
+ AUC
last
-
infinity
. 
 
Population Pharmacokinetic Analyses
:  Population PK analyses will be performed on the PK 
data following IV and SC administration to determine compartmental PK parameters with the 
PK program NONMEM 7.3 or later (ICON
R
).  Based on preclinical PK results for 
L9LS and 
known PK behavior studies of mAbs, two
-
compartment model will be used (subroutine 
ADVAN4 TRANS4).  Both zero order and first order absorption following SC administration 
will be evaluated and a lag time included if a delay is seen in the raw data 
figures.  The First 
Order Conditional Estimation Method with Interaction (FOCEI) will be used.  The population 
analysis will generate estimates for clearance (CL) central and peripheral volumes of distribution 
(Vd
1
 
and Vd
2
), inter
-
compartmental clearance (
Q), CL and SC bioavailability (F).  Total volume 
of distribution at steady
-
state (Vdss), will be calculated as the sum of Vd
1
 
+ Vd
2
.  Alpha and beta 
half
-
lives will be calculated from CL, Q, Vd
1
 
and Vd
2
 
using standard equations
 
[
24
]
.  While the 
number of subjects is expected to be sufficient to characterize the typical PK parameters and 
their between
-
subject variabilities (BSV
s), the sample number is too small for a robust broad 
population PK covariate analysis. Therefore, the impact of subjects’ size will be accounted for 
using allometric scaling normalized to 70
 
kg with dose level and CHMI response being the only 
covariates e
xplored.  Individual subjects’ empiric Bayesian PK parameter estimates will be 
generated using the 
posthoc 
subroutine and may be used to estimate individual participant L9LS 
concentration
-
time profiles.  
 
Final model selection will be based on changes in t
he objective function, a goodness
-
of
-
fit 
statistic generated by NONMEM, and graphically by goodness of fit plots. The final population 
PK model will be assessed using bootstrap analysis.  Dosing strategies and their ability to 
achieve and maintain target L
9LS concentrations will be performed using the final population 
PK model and Monte Carlo simulations with at least 1000 replicates.
 
6.3.4.
 
Efficacy Analysis
 
Efficacy analysis will be performed 
using 
the mITT cohort.  The primary efficacy analysis will 
be based on a two
-
sided Barnard test on the proportion of 
infected 
subjects who 
receive L9LS 
compared to the controls who undergo CHMI concurrently.  The secondary efficacy analyses 
will be based on time
-
to
-
parasitemia, where 
L9LS recipients 
will be compared with the control 
participants 
via a log
-
rank test.  Kaplan
-
Meier curves will also be provided for each group. 
 
To assess how L9LS concentration impacts protection against infection,
 
a logistic regress
ion 
may
 
be performed to estimate the infection risk as a function of the 
L9LS 
concentration at the 
time of challenge. 
 
For the same reason, a Cox proportional hazards regression 
may 
be 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
39
 
of 
73
 
performed to estimate the hazard function with the 
L9LS 
concentration a
t the time of challenge
 
and Cave
CHMI
-
28DCHMI
,
 
as a regressor
.
 
In addition to the above efficacy analyses, descriptive statistics will be provided which include 
the proportion of infection post CHMI in each dose group and the control group.
  
To assess the 
comparability of challenge, salivary gland score 
(related to the quantity of sporozoites in each 
mosquito) 
will be listed for each participant and the summary statistics, such as the median and 
interquartile range of the salivary gland scor
e, will be reported for each dose group as well as the 
control group. 
 
6.3.5.
 
Interim 
A
nalyses
 
PK data 
may 
be analyzed 
for
 
each dose group.
 
 
Preliminary PK analyses may be 
performed
 
per 
dose level 
prior to CHMI which
 
may only generate a subset of the final PK par
ameters.  
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
40
 
of 
73
 
7.
 
PHARMACY PROCEDURES
 
The study groups are shown in
 
Table
 
1
.
 
7.1.
 
Study Product 
 
VRC
-
MALMAB01
14
-
00
-
AB (
L9LS
) is 
a sterile, aqueous, buffered 
solution filled into single 
dose vials at 150 + 15 mg/mL
 
in 
a 
formulation buffer composed of 10 mM Acetate Phosphate, 
10 mM Sodium Chloride, 250 mM Proline, 0.02% Polysorbate 80 at pH 5.6
; and 
to a target fill 
volume of 2.25 ml in a 3 ml vial. The 
drug pro
duct
 
container closure system consists of Type I 
glass vials, chlorobutyl rubber stoppers, and seals purchased from approved manufacturers. 
 
 
7.2.
 
Storage and Temperature Excursions
 
F
illed product 
must
 
be stored at 
-
35°C to 
-
15°C
, in a qualified,
 
continuously
-
m
onitored, 
temperature
-
controlled freezer
.
 
 
 
The site pharmacist must promptly report any storage temperature excursions outside of the 
normal allowance to the IND Sponsor
.
  
The affected product must be quarantined in a separate 
area
 
under protocol
-
specific
 
temperature ranges until further notice from the Sponsor.  If the 
excursion results in thawed material, DO NOT REFREEZE; store the thawed, vialed material at
 
2
°
C to 
8
°C
. 
 
 
When a
 
storage/shipping/handling excursion occurs, the IND Sponsor
 
designee 
must
 
send a 
notification of the occurrence of an excursion to 
VRCProductinquiries@nih.gov
. 
 
An automatic 
email reply will be sen
t
 
to the notifier, including (as an attachment) the Clinic
al Excursion 
Reporting Form, which can be filled electronically (or manually and scanned, if needed). The 
completed form and relevant attachments (e.g. temperature charts) must be emailed to the VRC 
via the same email address 
(
VRCProductinquiries@nih.gov
) 
using the “reply” function
.
 
 
The 
IND Sponsor will notify the site pharmacist if continued clinical use of the product is acceptable 
or will provide further instructions.
 
7.3.
 
Labeling of Study Product Vial
 
Vials of study product will be individually labeled wit
h the name of the material, volume, lot 
number, concentration, storage instructions, Investigational Use Statement (“Limited by Federal 
Law to Investigational Use”), and manufacturer information
.
 
7.4.
 
Preparation of Study Product for Administration
 
This section
 
describes how 
to
 
prepare study injections
 
and will be updated when information is 
available. 
For complete and detailed instructions for the preparation of the product please see 
Appendix III.
 
7.4.1.
 
Preparation for IV Administration 
 
For 
each IV infusion order, the subject’s weight, dose level, and study group code will be 
included in the pharmacy order.  To prepare an IV infusion, the pharmacist will: 1) calculate the 
total milligrams of 
L9LS
 
needed, 2) retrieve the minimum number of thaw
ed vials required to 
prepare the full dose, 3) withdraw the necessary amount of 
L9LS
, and 4) add this volume to a 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
41
 
of 
73
 
normal saline 
IV bag 
using sterile compounding techniques to maintain sterility.  
Overfill may be 
added to the IV bag to ensure proper IV admi
nistration via a volumetric pump when the total 
volume to be administered is low (e.g. less than 50 mL). The ideal L9LS concentration in the 
final product to be infused is greater than 2 mg/mL in order to maintain appropriate formulation.
 
Thaw and equilibr
ate vials for a minimum of 1 hour and 30 minutes at ambient 
temperature. If
 
thawed vials are removed from 2
°C
 
to
 
8
°C
,
 
equilibrate at ambient temperature for a minimum of 
30 min
utes
.  P
rior to preparation for administration in the IV bag, vials should be ge
ntly swirled 
for 
approximately 
30 seconds while avoiding foaming.  DO NOT SHAKE THE VIAL
S
.
 
An in
-
line filter infusion set must be used for IV product administrations and MUST comply 
with the following specifications: 1.2
-
micron PES (polyethersulfone) filter membrane, DEHP
-
free, latex
-
free (equivalent to 
B.
Braun #473994 filter extension set).  When the in
-
line filter is 
added to the tubing, the administration set must then be primed.  
 
The study product solution will typica
lly be administered IV over about 15
-
30 minutes using a 
volumetric pump.  The total time needed to administer the dose may be longer than 30 minutes 
based on factors such as subject tolerance.  The mL/hr infusion rate may vary based on the total 
volume nee
ded to administer a full dose.  
 
At the end of product administration, the IV administration set must be flushed with about 30 mL 
(or appropriate volume) of normal saline
 
unless the IV bag was prepared with overfill
. 
 
7.4.2.
 
Preparation for SC
 
or IM
 
Administratio
n 
 
For each SC
 
or IM
 
administration order, the subject’s weight, dose level, and study group code 
will be included in the pharmacy order.  To prepare a SC
 
or IM
 
administration dose, the 
pharmacist will calculate the total mg needed and retrieve the minimum
 
number of vials needed 
to prepare the full dose.  
Thaw and equilibrate vials for a minimum
 
of
 
1 hour and 30 minutes at 
ambient temperature
.
 
If thawed vials are removed from 2
°C
 
to 
8
°C
,
 
equilibrate at ambient 
temperature for a minimum 
of 
30 min
utes
. 
 
Prior
 
to preparation for administration, vials should 
be gently swirled for 
approximately 
30 seconds
 
while
 
avoiding foaming.  DO NOT SHAKE 
THE VIALS.  
 
The needed volume of 
L9LS 
must be withdrawn from the vial into 1 to 
4
 
syringes using a 5
-
micron filter needle
.  A new filter needle must be used for each syringe.  The filter needle must 
be discarded prior to dispensing and replaced with a needle suitable for SC
 
or IM
 
injection at the 
time of administration.  The product may be administered by direct SC
 
or IM
 
inj
ection with 
needle and syringe.  The clinician will use proper SC
 
or IM
 
technique to ensure administration 
into SC fatty layer
 
or 
the IM injection into muscle
 
and a slow push to minimize discomfort or the 
excessive distention of overlying skin.
 
7.4.3.
 
Handling of
 
Prepared Product for IV
, 
SC
, or
 
IM 
Administration 
 
After product preparation in an IV bag, the prepared 
L9LS
 
may be stored at 2°C to 8°C for a 
maximum of 24 hours 
and/
or at 
ambient temperature 
for a maximum of 4 hours total including 
the infusion time.  P
roduct may not be stored in direct sunlight.  
 
After preparation in syringes for SC
 
or IM
 
administration, the prepared 
L9LS 
may be stored at 
2°C to 8°C up to 24 hours 
and/
or at 
ambient
 
temperature up to 4 hours.  Product may not be 
stored in direct sunlight.
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
42
 
of 
73
 
7.5.
 
Study Product Accountability
 
The study pharmacist or designee will be responsible for maintaining an accurate record of the 
study group codes, inventory, and an accountability recor
d of study agent supplies.  Electronic 
documentation as well as paper copies may be used. 
 
7.6.
 
Study Product Disposition
 
The empty vials and the unused portion of a vial will be discarded in a biohazard containment 
bag and incinerated or autoclaved in accordan
ce with the institutional or pharmacy policy.  Any 
unopened vials that remain at the end of the study will be returned to the production facility or 
discarded at the discretion of the sponsor in accordance with policies that apply to investigational 
agents
.  Partially used vials will not be administered to other subjects or used for 
in vitro
 
experimental studies.  These vials will be disposed of in accordance with institutional or 
pharmacy policy. 
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
43
 
of 
73
 
8.
 
HUMAN SUBJECT PROTECTIONS AND ETHICAL 
OBLIGATIONS
 
This rese
arch will be conducted in compliance with the protocol, International Conference on 
Harmonisation
 
(ICH) 
Good Clinical Practice (GCP) guidelines and all applicable regulatory 
requirements.
 
8.1.
 
Institutional Review Board
 
The protocol, proposed informed consent f
orm, other written subject information, and any 
proposed advertising material will be submitted to the IRB for review and written approval.
 
The investigator must submit and, where necessary, obtain approval from the IRB for all 
subsequent protocol amendmen
ts and changes to the informed consent document.  The 
investigator will notify the IRB of research events that occur on study as described in 
Section
 
5.5
.
 
The investigator will be responsible for obtaining IRB approval of the annual Continuing Review 
throughout the duration of the study.
 
8.2.
 
Informed Consent
 
The study informed consent form (ICF) is provided as a separate 
hard copy 
and describes the 
investi
gational product to be used and all aspects involved in protocol participation.
 
The PI or designee is responsible for obtaining written informed consent from the subject after 
adequate explanation of the aims, methods, anticipated risks and benefits of the
 
study and before 
any protocol
-
specific procedures or study product is administered.  The AoU will be completed 
before the study ICF is signed.
 
The acquisition of informed consent will be documented in the subject’s medical records, as 
required by 21 CFR 3
12.62, and the ICF will be signed and personally dated by the subject and 
the person who conducted the informed consent discussion.  The signed ICF will be retained in 
the medical chart and a copy of the ICF will be provided to the subject.
 
During the cons
ent process, participants and investigators will view the same approved consent 
document 
simultaneously 
in their respective locations.
 
 
 
8.3.
 
Study Discontinuation and Closure
 
This study may be temporarily suspended or prematurely terminated if there is suffici
ent 
reasonable cause.  Written notification, documenting the reason for study suspension or 
termination, will be provided by the suspending or terminating party to study participants, 
the 
investigator
s
, the 
Investigational New Drug (
IND
) 
and regulatory aut
horities
 
as appropriate
.  If 
the study is prematurely terminated or suspended, the
 
Principal Investigator (
PI
)
 
will promptly 
inform study participants, the 
Institutional Review Board (
IRB
)
, and 
S
ponsor and will provide 
the reason(s) for the termination or 
suspension.  Study participants will be contacted, as 
applicable, and be informed of changes to study visit schedule.
 
 
Circumstances that may warrant termination or suspension include, but are not limited to:
 
•
 
Determination of unexpected, significant, or un
acceptable risk to participants
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
44
 
of 
73
 
•
 
Demonstration of efficacy that would warrant stopping   
 
•
 
Insufficient compliance to protocol requirements
 
•
 
Data that are not sufficiently complete and/or evaluable
 
•
 
Determination that
 
the primary endpoint has been met
 
•
 
Determin
ation of futility
 
The s
tudy may resume once concerns about safety, protocol compliance, 
and 
data quality are 
addressed
,
 
and satisfy the 
S
ponsor, IRB and/or FDA.
 
8.4.
 
Confidentiality and Privacy
 
Participant
 
confidentiality
 
and privacy 
is strictly held in trust by the participating investigators, 
their staff, and the 
S
ponsor(s) and their 
intervention
s. 
 
This confidentiality is extended to cover 
testing of biological samples in addition to the clinical information relating to participa
n
ts
.
  
Therefore, t
he study protocol, documentation, data, and all other information generated will be 
held in strict confidence.
 
 
No information concerning the study or the data will be released to any 
unauthorized third
-
party without prior written approval o
f the sponsor. 
 
All research activities will be conducted in as private a setting as possible.
 
The study monitor, other authorized representatives of the 
S
ponsor, representative
s
 
of the 
Institutional Review Board (
I
RB), and/or regulatory agencies
 
may inspe
ct all documents and 
records required to be maintained by the investigator, including but not limited to, medical 
records (office, clinic, or hospital) and pharmacy records for the 
participant
s in this study.
 
 
The 
clinical study site will permit access to 
such records.
 
The study participant’s contact information will be securely stored at 
the
 
clinical site for internal 
use during the study. 
 
At the end of the study, all records will continue to be kept in a secure 
location for as long a period as dictated b
y 
the reviewing
 
IRB
,
 
Institutional 
policies, or Sponsor 
requirements
.
 
Study participant research data, which is for purposes of statistical analysis and scientific 
reporting, will be transmitted to and stored 
by Emmes, the Data Coordinating Center
.
 
 
This w
ill 
not include the participant’s contact or identifying information. 
 
Rather, individual participants 
and their research data will be identified by a unique study identification number. 
 
The study data 
entry and study management systems used by 
the 
clinic
al site and by
 
Emmes re
search staff will 
be secured and password protected. 
 
At the end of the study, all study databases will be de
-
identified and archived.
 
To further protect the privacy of study participants, a Certificate of Confidentiality 
has been
 
is
sued by the National Institutes of Health (NIH).  This certificate protects identifiable research 
information from forced disclosure.
 
 
It allows the investigator and others who have access to 
research records to refuse to disclose identifying information o
n research participation in any 
civil, criminal, administrative, legislative, or other proceeding, whether at the federal, state, or 
local level. 
 
By protecting researchers and institutions from being compelled to disclose 
information that would identify r
esearch participants, Certificates of Confidentiality help achieve 
the research objectives and promote participation in studies by helping assure confidentiality and 
privacy to participants.
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
45
 
of 
73
 
8.5.
 
Risk/Benefit Assessment 
 
8.5.1.
 
Potential Risks
 
Risk of 
L9LS
:
 
The risk o
f L9LS is not yet known as this is the first in human study. 
 
A
 
similar 
malaria antibody,
 
CIS43LS
,
 
was
 
evaluated as safe and
 
well
-
tolerated
 
in the VRC 612 study
[
7
]
.
 
Investigational monoclonal antibody, L9LS, exhibited scattered membrane binding which 
localized to the epithelial cells lining the human salivary gland ducts and acini in a preclinical
 
tissue cross
-
reactivity study. Binding was rare at an antibody concentration of 1.15 µg/ml, and 
rare to occasional at 11.5 µg/ml. These findings are of unclear clinical significance. Any effect 
on the salivary glands from L9LS, if present, is expected to 
be transient due to clearance of the 
passively transferred antibody over time. Additionally, salivary gland epithelium turns over 
rapidly which would likewise be expected to decrease any potential complications. 
 
To address these findings, 
the trial will
 
e
xclude 
individuals
 
at an increased risk for salivary gland 
dysfunction and will prospectively monitor for signs and symptoms that may be indicative of 
salivary gland 
abnormality
. 
 
S
ubject matter experts in salivary gland disorders at the National 
Institute
 
of Dental and Craniofacial Research
,
 
who are board
-
certified by the American Board of 
Oral and Maxillofacial Pathology
,
 
ha
ve
 
assisted the study team in developing a risk mitigation 
strategy and ha
ve
 
agreed to participate in eligibility or adverse even
t
 
ev
aluations as needed by 
the study team
.
 
Evidence of clinically significant salivary gland toxicity will be considered at 
each dose escalation review and dose escalation would not proceed if clinical toxicity is 
identified. 
 
Risk
s
 
of
 
m
Ab
 
Administration
:  Adm
inistration of mAbs may cause immune reactions such as 
acute anaphylaxis, serum sickness and the generation of antibodies.  However, these reactions 
are rare and more often associated with mAbs targeted to human proteins or with the use of 
mouse mAbs that 
would have a risk of human anti
-
mouse antibodies 
[
25
]
.  In this regard, 
because 
L9LS
 
is targeted to a
 
malaria
 
parasite antigen and is a human mAb, it is expected to 
have a low risk of such side effects. 
 
Typically, the side effects of mAbs are mild to 
moderate and may include local reactions at the 
injection site (including pain, redness, bruising, swelling) and systemic reactions such as fever, 
chills, rigors, nausea, vomiting, pain, headache, dizziness, shortness of breath, bronchospasm, 
hypotension, 
hypertension, pruritus, rash, urticaria, angioedema, diarrhea, tachycardia or chest 
pain.  Clinical use of mAbs that are targeted to cytokines or antigens associated with human cells 
may be associated with an increased risk of infections 
[
25
]
; however, this is not expected to be a 
risk for a mAb targeted to a p
arasite antigen. 
 
Severe reactions, such as anaphylaxis, angioedema, bronchospasm, hypotension and hypoxia, are 
infrequent and more often associated with mAbs targeted to human proteins or with non
-
human 
mAb, such as a mouse mAb 
[
25
]
.  Most infusion
-
related events occur within the first 24 hours 
after initiatio
n of mAb administration.
 
Published experience with human mAbs directed against cell surface targets on lymphocytes 
shows that infusion of a mAb may be associated with cytokine release, causing a reaction known 
as cytokine release syndrome (CRS) 
[
26
]
.  CRS reactions commonly occur within the first few 
hours of infusion start and with the first mAb 
infusion received.  This is because the cytokine 
release is associated with lysis of the cells targeted by the mAb and the burden of target cells is 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
46
 
of 
73
 
greatest at the time of the first mAb treatment.  With licensed therapeutic mAbs, CRS is 
managed by tempora
rily stopping the infusion, administering histamine blockers and restarting 
the infusion at a slower rate 
[
2
7
]
.
 
 
Supportive treatment may also be indicated for some signs and 
symptoms.  
 
Delayed allergic reactions that include
 
a serum sickness type of reaction characterized by 
urticaria, fever, lymph 
node enlargement, and joint pains, typically occur several days after mAb 
exposure and are more commonly associated with chimeric types of mAbs 
[
25
]
.  In general, and 
with due consideration of the needs dictated by individual subject symptoms and treating 
clinician discretion, immediate and delayed reactions to
 
study product would be managed 
according to the principles of the American Academy of Allergy, Asthma, and Immunology 
guidelines established in the Drug Allergy: Practice Parameters (2010). 
 
Participation in this study may limit a subject’s eligibility fo
r future mAb studies. 
 
Risks of Blood Drawing
:  Blood drawing may cause pain, bruising, and a feeling of 
lightheadedness or fainting. Rarely, it may cause infection at the site where blood is taken. In this 
study, an IV line that can be used for blood 
collection may be placed in the arm and left in place 
for several hours on days when there is product administration for frequent PK blood draws.  
Problems from use of an IV for blood drawing are generally mild and may include pain, bruising, 
minor swellin
g or bleeding at the IV site and rarely, infection, vein irritation (phlebitis), or blood 
clot.
 
Risks of Mosquito Bite
s for CHMI
:  Risks
 
associated 
with CHMI
 
include local inflammatory 
reactions, lymphadenitis, persistent 
local 
pruritus and larger local re
actions involving the whole 
forearm, allergic reactions to mosquito bites
.  
Another remotely possible risk includes a systemic 
allergic reaction to the mosquit
oes
.
 
Risks of 
Acquiring 
Malaria
 
Infection
:  
There is also the possibility of complications of 
mal
aria, which are seen during naturally acquired malaria when diagnosis and treatment are 
delayed and high levels of parasitemia develop
.  
Under the carefully controlled conditions of this 
study
 
that supports early diagnosis and treatment
, the chance of such
 
complications is unlikely 
and the risk of death from malaria infection is very small. 
 
Transient abnormalities, e.g. fever, 
headache, myalgia, shaking chills, abdominal discomfort, nausea, vomiting, mild anemia, 
leukopenia, thrombocytopenia, 
hepato
splenom
egaly, hepatic tenderness and fatigue, are expected 
consequences of malaria
.  
In uncontrolled circumstances, malaria infections can lead to kidney, 
liver or brain injury (seizures, coma) and death. 
 
Risks of Anti
m
alarial Medication
:  
Additional risks inclu
de possible side effects of the 
antimalarial medication taken (chloroquine) following challenge with chloroquine
-
sensitive
 
Pf. 
These side effects include nausea, vomiting, diarrhea, abdominal pain, dizziness, headaches, 
sleep disturbances, blurred vision, 
pruritus, skin rash, exacerbation of psoriasis or porphyria, 
tinnitus, and photosensitivity
.  
Rarely, there may be changes in electrocardiogra
ms and 
hypotension.  S
ide effects 
of atovaquone/p
roguanil (Malarone
®
) include nausea, vomiting, 
abdominal pain, an
orexia, diarrhea, headache, cough and rarely, anemia, oral ulcerations, 
insomnia, fever, edema, rash and alopecia.
 
 
Another remotely possible risk includes a systemic 
allergic reaction to chloroquine (or Malarone
®
)
.  
The study team will discuss these medic
ations 
and their possible side effects in detail both as part of the informed consent process
, prior to 
CHMI,
 
and prior to initiation of treatment for 
diagnosed
 
malaria
 
infection
s
.
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
47
 
of 
73
 
Risks of Screening Procedures
: The risks of screening procedures can be fou
nd in the VRC
-
sponsored 
screening protocol VRC 500 (NIH 11
-
I
-
0164, [STUDY_ID_REMOVED]) used for all VRC IND 
studies conducted at the NIH Clinical Center.
 
8.5.2.
 
Potential Benefits
 
Study subjects will not receive direct health benefit from study participation.  Others ma
y benefit 
from knowledge gained in this study that may aid in the development of malaria prevention.
 
8.5.3.
 
Assessment of Potential Risk
s
 
and Benefits
 
This research study will be conducted in compliance with the protocol, GCP guidance, and all 
applicable regulatory requirements.  
 
The plan for reduction of
 
known and unknown
 
risks 
to participants 
includes appropriate training 
of study
 
personnel; education of study subjects for participation in care throughout the study; 
monitoring of study subject’s health status and experiences; withdrawal from study procedures 
upon evidence of difficulty, contraindication, or a significant adverse ev
ent; and referral for 
treatment, counseling or other necessary follow
-
up. 
 
The VRC CTP Risk Management Plan 
guides the reduction and mitigation strategies applied to the known and unknown risks 
associated with study participation
 
and trial management/opera
tions. 
 
As study subjects will not receive direct health benefit from study participation or product 
administration, no alternative procedures are planned. T
he alternative 
course of action 
is
 
to 
choose
 
not to participate.
 
8.6.
 
Plan for Use and Storage of Biolog
ical Samples
 
The plan for use and storage of biological samples from this protocol is outlined in the following 
sections.
 
8.6.1.
 
Use of Samples, Specimens and Data
 
Samples
, specimens
 
and data collected under this protocol may be used to 
conduct protocol
-
related s
afety, parasitology and immunogenicity evaluations, 
exploratory laboratory evaluations 
related to malaria, exploratory laboratory evaluations related to mAb, vaccine or infectious 
disease research in general and for research assay validation.  
 
Stored samp
les may also be used later for exploratory genetic factors that may influence the 
immune response. No specific results will be provided to participants or their health care 
providers because we will not be investigating genetic analyses that have known med
ical 
diagnoses (e.g. Huntington’s disease) or other medically actionable genetic information.
 
8.6.2.
 
Storage and Tracking of Blood Samples and Other Specimens 
 
All research samples use coded labels that only the VRC 
VEC
 
can link to the subject. Samples 
are stored
 
at VIP or VRC laboratories in Building 40, Bethesda, MD, which are both secure 
facilities with limited access.  Data will be kept in password
-
protected computers.  Only 
investigators or their designees will have access to the samples and data.  Samples wi
ll be 
tracked in the Laboratory Information Management System (LIMS) database or using another 
software designed for this purpose (e.g., Freezerworks).
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
48
 
of 
73
 
8.6.3.
 
Disposition of Samples, Specimens and Data at Completion of the
 
P
rotocol
 
 
I
n the future, other investiga
tors (both at NIH and outside) may wish to study these samp
les 
and/or data.  
IRB approval must be sought prior to any sharing of samples
 
with non
-
NIH 
investigators and a
ny clini
cal information shared about those samples
 
would similarly require 
prior IRB ap
proval
.  
The research use of stored, unlinked or unidentified samples 
will
 
be exempt 
from the need for prospective IRB review and approval. 
 
Exemption requests will be submitted 
in writing to the NIH Office of Human Subjects Research, which is authorized to determine 
whether a research activity is exempt. 
 
At the time of protocol termination, samples will remain in the 
VIP 
facility or VRC labor
atories 
or, after IRB approval, will be transferred to another repository.  Regulatory oversight of the 
stored samples and data may be transferred to a stored samples protocol as part of the IRB 
approved termination plan.  Data will be archived by the VRC 
in compliance with requirements 
for retention of research records, or after IRB and study sponsor approval, it may be either 
destroyed or transferred to another repository.
 
8.6.4.
 
Loss or D
estruction of S
amples, Specimens
 
or Data
  
 
Any loss or unanticipated destr
uction of samples (for example, due to freezer malfunction) or 
data (for example, misplacing a printout of data with identifiers) will be reported to the IRB.
  
The Protocol Chair or PI will also notify the IRB if the decision is made to destroy the remaini
ng 
samples.
 
Neither participation nor refusal to participate will have an effect, either beneficial or adverse, on 
the participant’s employment or work situation.
  
The NIH information sheet regarding NIH 
employee research participation will be distributed 
to all potential subjects who are NIH 
employees.
  
The employee subject’s privacy and confidentiality will be preserved in accordance 
with 
applicable
 
policies
 
at the study site
.
 
 
For any
 
employee subjects, consent will be obtained by 
an individual
 
who is 
in
dependent of the employee’s team. 
 
At NIH, if the individual obtaining 
consent is a co
-
worker to the subject, independent monitoring of the consent process will be 
included through the Bioethics Consultation Service.  P
rotocol study staff will be trained o
n 
obtaining potentially sensitive and private information from co
-
workers or subordinates. 
 
8.7.
 
Safety Oversight
 
Close cooperation between the designated members of the Protocol Team will occur to evaluate 
and respond to individual AEs in a timely manner.  The
 
VRC 
clinic 
designated Safety Officer 
(SO) for the day conducts a daily safety review of clinical data per VRC Standard Operating 
Procedures. 
A 
Protocol Safety Review Team (PSRT) comprised of the Principal Investigator 
(PI), Associate Investigators, Study 
Coordinator, Protocol Specialists, other study clinicians, and 
the IND MO, will review the summary study safety data reports per the protocol
-
defined 
frequency. In addition, an Independent 
Safety Monitor (ISM),
 
who is not associated with the 
VRC will provi
de safety oversight.
 
The designated 
ISM
 
will receive safety report
s
 
that contains a line listing of all adverse events 
that occurred to date. The 
ISM
 
will meet with the PSRT during the weekly protocol safety 
meeting to clarify, discuss, and provide an impression of the safety data acquired to date. 
Meetings
 
and safety report distribution
 
will transition to a monthly schedule beginning 4 weeks 
after the
 
last product administration to the final subject. Weekly safety meetings will resume for 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
49
 
of 
73
 
4 weeks after CHMI. All adverse events, including those that are expected, will be contained in 
the weekly safety reports and will be available for independent review
 
by the ISM. The overall 
findings and recommendations that result from the safety meetings will be documented in a 
protocol interim safety review form that will document adverse events that have occurred, 
including specifically any that may trigger pause c
riteria, serious adverse events, and comments 
from the group related to the adverse events. 
Attendance by the PI or designee, Medical Officer 
and/or ISM is documented on the form and officially signed by the PI or designee.  The signed 
interim safety revie
w form will be sent to the ISM and the PSRT so that all are aware of any 
emerging safety signals even if unable to attend a PSRT meeting.
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
50
 
of 
73
 
9.
 
ADMINISTRATIVE AND OPERATIONAL OBLIGATIONS
 
9.1.
 
Protocol Amendments and Study Termination
 
Protocol amendments must be made 
only with prior approval of the IND Sponsor and with 
agreement from the PI and MO.  All study amendments will be submitted to the IRB for 
approval.
 
The IND Sponsor, the IRB, OHRP, the PI, Protocol Chairs, and/or the FDA reserve the right to 
terminate the study.  The PI will notify the IRB in writing of the study’s completion or early 
termination.
 
9.2.
 
Study Documentation and Storage
 
The PI will delegate the study responsibilities to the study team, and a list of appropriately 
qualified persons to 
whom trial duties have been delegated will be maintained.
 
Source documents are original documents, data, and records from which the subject’s data are 
obtained.  These include but are not limited to hospital records, clinical and office charts, 
laboratory 
and pharmacy records, and correspondence.  Long
-
term storage of source documents 
may be in the form of electronic files.
 
The PI and staff are responsible for maintaining a comprehensive and centralized filing system of 
all study
-
related (essential) documen
tation, suitable for inspection at any time by representatives 
from the IND Sponsor, VRC/NIAID/NIH, IRB, NIH, FDA, and/or applicable regulatory 
authorities.  Elements include:
 
•
 
Subject files containing completed informed consent forms, and supporting copies
 
of 
source documentation.
 
•
 
Study files containing the protocol with all amendments, IBs, copies of all correspondence 
with the IRB.
 
In addition, all original source documentation must be maintained and be readily available. 
 
All essential documentation shou
ld be retained by the institution for the same period of time 
required for medical records retention.  The FDA requires study records to be retained for up to 
two years after marketing approval (21 CFR 312.62).
 
 
If no marketing 
application is filed, or if 
the application is not approved, the records will be retained for two years after the investigation 
is discontinued and the FDA is notified.
 
 
The HHS protection of human subjects’ regulations 
require that institutions retain reco
rds of IRB/EC activities an
d documentation of informed 
consent of subjects for at least 3 years after study completion (45 CFR 46).
 
No study document should be destroyed without prior written agreement between the VRC and 
the investigator.  Should the investigator wish to assign the
 
study records to another party or 
move them to another location, they must notify the VRC in writing of the new responsible 
person and/or the new location.
 
9.3.
 
Clinical Monitoring 
 
Clinical site monitoring is conducted to ensure that the rights and well
-
being
 
of 
trial participants
 
are protected, 
that 
the reported trial data are accurate, complete, and verifiable, and that the 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
51
 
of 
73
 
conduct of the trial is in compliance with the currently approved protocol/amendment(s), with 
ICH 
GCP, and with applicable regulatory re
quirement(s). 
 
Monitoring for this study will be performed by 
a designated 
contract research organization 
(
CRO
)
.
 
Details of clinical site monitoring are documented in a 
Clinical Monitoring Plan
. 
 
The 
C
linical 
M
onitoring 
P
lan
 
describes in detail who will co
nduct the monitoring, at what frequency 
monitoring will be done, at what level of detail monitoring will be performed, and the 
distribution of monitoring reports.
 
9.4.
 
Data Collection and Sharing
 
9.4.1.
 
Data Collection
 
Clinical research data will be collected in a sec
ure electronic web
-
based clinical data 
management system (CDMS) through a 
CRO
, Emmes (Rockville, MD). Extracted, anonymized 
data will be sent to the PSRT for safety review and to 
the 
Protocol Statistician for statistical 
analysis.
 
9.4.2.
 
Source Documents 
 
The sit
e will maintain appropriate medical and research records for this trial, in compliance with 
ICH E6(R2) GCP, applicable regulations, and institutional requirements for the protection of 
confidentiality of subjects.  Source data are all information, original
 
records of clinical findings, 
observations, or other activities in a clinical trial necessary for the reconstruction and evaluation 
of the trial.  Examples of these original documents and data records include, but are not limited 
to, medical records, labo
ratory reports, pharmacy records and other research records maintained 
for the clinical trial.
 
9.4.3.
 
Data Sharing
 
Data generated in this study will be shared as de
-
identified data in the government
-
funded public 
repository, www.clinicaltrials.gov.  Data may be s
hared prior to publication at approved public 
presentations or for collaborative development and will be shared at the time of publication or 
within one year of the primary completion date.
 
9.5.
 
Quality Assurance and Quality Control
 
The
 
clinical site will perform internal quality management of study conduct, data 
and biological 
specimen
 
collection, documentation and completion.  
The VEC’s Q
uality 
M
anagement 
P
lan will 
be 
used to perform
 
quality management
 
for this trial
.
 
Quality control (
Q
C)
 
procedures will be implemented beginning with the data entry system and 
data 
QC
 
checks that will be run on the database will be generated. 
 
Any missing data or data 
anomalies will be communicated to the site
 
for clarification/resolution.
 
T
he monitors w
ill verify that the clinical trial is 
conducted,
 
and data are generated
,
 
and 
biological specimens are collected
, documented (recorded), and reported in compliance with the 
protocol, 
ICH 
GCP, and applicable regulatory requirements
.
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
52
 
of 
73
 
The site will provide dir
ect access to all trial related sites, source data/documents, and reports for 
the purpose of monitoring and auditing by the sponsor, and inspection by local and regulatory 
author
ities.
 
9.6.
 
Language
 
All written information and other material to be used by subjects and investigative staff must use 
vocabulary and language that are clearly understood. 
 
9.7.
 
Research
-
Related Injuries
 
9.7.1.
 
NIH
 
The NIH Clinical Center will provide short
-
term medical care for any inju
ry resulting from 
participation in research here. In general, no long
-
term medical care or financial compensation 
for research
-
related injuries will be provided by the NIH, the NIH Clinical Center, or the Federal 
Government. However, 
subjects
 
have the righ
t to pursue legal remedy if 
they
 
believe that 
their
 
injury justifies such action.
 
9.7.2.
 
WRAIR 
 
If subjects are injured because of participation in this research during the CHMI and they are a 
DOD healthcare beneficiary (e.g., active duty in the military, militar
y spouse or dependent, 
retiree), they are entitled to medical care for their injury within the DOD healthcare system, as 
long as they remain a DOD healthcare beneficiary. 
 
If subjects are injured because of participation in this research during the CHMI an
d they are not 
a DOD healthcare beneficiary, they are entitled to medical care for their injury at a DOD hospital 
or clinic, but such care for the injury at DOD hospitals or clinics may be time
-
limited, and the 
subject’s insurance may be billed. It cannot 
be determined in advance which DOD hospital or 
clinic will provide care. If subje
c
t
s
 
obtain care for research
-
related injuries outside of a DOD 
hospital or clinic, they or their insurance will be responsible for medical expenses. 
 
For DOD healthcare benefi
ciaries and non
-
DOD healthcare beneficiaries: Transportation to and 
from hospitals or clinics will not be provided. No reimbursement is available if 
subjects
 
incur 
medical expenses to treat research
-
related injuries. No compensation is available for resear
ch
-
related injuries. 
Subjects
 
are not waiving any legal rights. If 
subjects
 
believe 
they
 
have sustained 
a research
-
related injury, 
they may
 
contact the PI. If 
subjects
 
have any questions, 
they can 
contact the PI.
 
9.8.
 
WRAIR Facility and CHMI 
Management 
 
The 
VRC
, NIAID, NIH is the coordinating center as well as the 
only clinical 
site for this 
protocol.
 
 
Dr. 
Richard Wu
,
 
VRC, NIAID, NIH, is the 
site PI
 
overseeing the management and 
monitoring of the protocol conduct overall. 
 
Investigators from W
RAIR, the facility that will be administering the CHMI, will have limited 
interaction with study subjects during the administration of the CHMI.  
Certain immediate pre
-
 
and post
-
CHMI assessments of subjects will take place in the CHMI facility with some 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
53
 
of 
73
 
pa
rticipation by CHMI facility personnel and NIH staff. All other post
-
CHMI clinical visits for 
subjects will take place at the NIH clinical site.
 
A Reliance Agreement will be established with the collaborating CHMI facility such that the 
NIH IRB is the IRB 
of Record for the conduct of the VRC 
614 
protocol.  Referring to 
Section
 
5
 
of the VRC 
614 
protocol, any Serious Adverse Events, Unanticipated Problems 
or Protocol 
Deviation which are reportable to the NIH IRB which are in relation to the conduct of the CHMI 
will also be communicated to the collaborating CHMI facility within the same reporting period 
specified in the protocol.  
 
9.8.1.
 
Roles and Responsibilities
 
for the CHMI
 
The PI will delegate responsibility for overseeing the administration of the CHMI at the 
collaborating CHMI facility (i.e., application of and assessment of the mosquito bites) to 
designated Associate Investigators from those facilities.  Fol
low
-
up and medical care of the study 
subjects after the CHMI is administered remains the responsibility of the site PI and the 
designated personnel at the clinical site.
 
 
The Authorized Representative from the CHMI facility may review research records rela
ted to 
the CHMI conducted at their own facility.  
 
The roles and responsibilities for this collaborating institution and 
facility
 
personnel for the 
conduct of CHMI 
as described above 
are delineated in 
the corresponding VRC 
614 
Study 
Personnel Page
.
 
 
 
9.8.2.
 
WRAIR Protocol Review and 
Reporting 
R
equirements
 
Initial Protocol Review
 
WRAIR will defer their IRB review to the NIH IRB once a reliance agreement is in place. 
WRAIR Human Subjects Protection Branch (HS
PB
) will still perform an administrative review 
of th
e protocol to ensure that the WRAIR reporting requirements are met.  WRAIR Commander 
Approval Authorization will be issued once the NIH IRB approval has been submitted to the 
WRAIR HSPB and the administrative WRAIR comments have been adequately addressed. 
Headquarters level review will be conducted as appropriate.
 
 
Protocol Modifications/Amendments
 
All amendments/modifications to the protocol and supporting documents (informed consent, 
recruitment materials, etc.) must be reviewed by the WRAIR HSPB and a WR
AIR Commander 
Authorization Approval issued prior to WRAIR participation on the amended/modified protocol. 
 
Continuing Reviews and Closeout Report 
 
The WRAIR Point of Contact will be responsible for preparing and submitting continuing review 
reports as per
 
UW
S
-
HP
-
618
.03
 
and a closeout report as per WRAIR Policy 
#30
. The WRAIR 
HSPB will review and acknowledge the reports in order for WRAIR personnel to continue their 
participation on the study. 
 
Once all study activities have been completed, to include data 
analysis, a closeout report will need to be submitted to the WRAIR HSPB to close the study. 
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
54
 
of 
73
 
The following reporting requirements apply
:
 
Unanticipated Problems Involving Risks to Subjects or Others 
 
Unanticipated problems, as defined in 
Section
 
5.5.1
, should be promptly reported (48 hours) by 
telephone, email, or fax to the WRAIR HSPB.  A complete written report should follow the 
initial notification within 10 working days.  All unanticipa
ted problems occurring within the 
reporting period should also be summarized in the continuing review reports submitted to the 
WRAIR HSPB
 
(contact information is below at end of section)
.  
 
Serious Adverse Events 
 
All related SAEs and deaths, as defined in
 
Section
 
5.2
, should be reported to the WRAIR HSPB 
within 48 hours by telephone, email, or fax.  A complete written report should follow the initial 
no
tification within 10 working days.  All SAEs occurring within the reporting period should also 
be summarized in the continuing review reports submitted to the WRAIR HSPB
.  
 
Protocol Deviations 
 
All major protocol deviations that adversely affect the safety
 
or rights of a subject or scientific 
integrity of the study, 
as defined in 
Section
 
5.5.3
, 
will be reported to the WRAIR HSPB within 
48 hours and a wr
itten report should be submitted within 10 working days. 
 
All protocol 
deviations occurring within the reporting period should be summarized in the continuing review 
reports that are submitted to the WRAIR HSPB. 
 
Pending Inspections/Issuance of Reports 
 
Th
e knowledge of any pending compliance inspection/visit by the FDA, Office 
for
 
Human 
Research Protections (Department of Health and Human Services), or other government agency 
concerning clinical investigation or research, the issuance of Inspection Reports
, FDA Form 483, 
warning letters, or actions taken by any regulatory agency including legal or medical actions and 
any instances of serious or continuing noncompliance with the regulations or requirements will 
be reported immediately to the WRAIR HSPB.
 
WRAI
R HSPB Contact 
I
nformatio
n
 
 
Director, Human Subjects Protection Branch 
 
 
503 Robert Grant Avenue 
 
Silver Spring, MD 20910 
 
Telephone: 301
-
319
-
9940 Fax: 301
-
319
-
9961 
 
E
-
mail: usarmy.detrick.medcom
-
wrair.mbx.hspb@mail.mil 
 
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
55
 
of 
73
 
10.
 
REFERENCES 
 
 
1.
 
Sachs, J. and P. Malaney, 
The economic and social burden of malaria.
 
Nature, 2002. 
415
(6872): p. 680
-
5.
 
2.
 
Roll Back Malaria
. Global Malaria Action Plan 2008 2008; Av
ailable from: 
http://www.rbm.who.int/keyfacts.html
.
 
3.
 
Breman, J.G., 
Eradicating malaria.
 
Sci Prog, 2009. 
92
(Pt 1): p. 1
-
38.
 
4.
 
Rts, S.C.T.P., 
Efficacy and safety of RTS,S/AS01 malaria vaccine with or wi
thout a 
booster dose in infants and children in Africa: final results of a phase 3, individually 
randomised, controlled trial.
 
Lancet, 2015. 
386
(9988): p. 31
-
45.
 
5.
 
Mahmoudi, S. and H. Keshavarz, 
Efficacy of phase 3 trial of RTS, S/AS01 malaria 
vaccine: The need for an alternative development plan.
 
Hum Vaccin Immunother, 2017. 
13
(9): p. 2098
-
2101.
 
6.
 
Wang, L.T., et al., 
A Potent Anti
-
Malarial Human Monoclonal Antibody Targets 
Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in t
he Liver.
 
Immunity, 2020. 
53
(4): p. 733
-
744 e8.
 
7.
 
Gaudinski, M.R., et al., 
A Monoclonal Antibody for Malaria Prevention.
 
New England 
Journal of Medicine, 2021. 
385
(9): p. 803
-
814.
 
8.
 
Gaudinski, M.R., et al., 
Safety and pharmacokinetics of the Fc
-
modified 
HIV
-
1 human 
monoclonal antibody VRC01LS: A Phase 1 open
-
label clinical trial in healthy adults.
 
PLoS Med, 2018. 
15
(1): p. e1002493.
 
9.
 
Ledgerwood, J.E., et al., 
Safety, pharmacokinetics and neutralization of the broadly 
neutralizing HIV
-
1 human monoclonal 
antibody VRC01 in healthy adults.
 
Clin Exp 
Immunol, 2015. 
182
(3): p. 289
-
301.
 
10.
 
Gaudinski, M.R., et al., 
Safety, tolerability, pharmacokinetics, and immunogenicity of the 
therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608)
: 
an open
-
label phase 1 study.
 
Lancet, 2019. 
393
(10174): p. 889
-
898.
 
11.
 
Gaudinski, M.R., et al., 
Safety and pharmacokinetics of broadly neutralising human 
monoclonal antibody VRC07
-
523LS in healthy adults: a phase 1 dose
-
escalation clinical 
trial.
 
Lancet 
HIV, 2019. 
6
(10): p. e667
-
e679.
 
12.
 
Chulay, J.D., et al., 
Malaria transmitted to humans by mosquitoes infected from cultured 
Plasmodium falciparum.
 
Am J Trop Med Hyg, 1986. 
35
(1): p. 66
-
8.
 
13.
 
Seder, R.A., et al., 
Protection against malaria by intravenous 
immunization with a 
nonreplicating sporozoite vaccine.
 
Science, 2013. 
341
(6152): p. 1359
-
65.
 
14.
 
Lyke, K.E., et al., 
Attenuated PfSPZ Vaccine induces strain
-
transcending T cells and 
durable protection against heterologous controlled human malaria infection
.
 
Proc Natl 
Acad Sci U S A, 2017. 
114
(10): p. 2711
-
2716.
 
15.
 
Roestenberg, M., et al., 
Experimental infection of human volunteers.
 
Lancet Infect Dis, 
2018. 
18
(10): p. e312
-
e322.
 
16.
 
Nieman, A.E., et al., 
Cardiac complication after experimental human 
malaria infection: 
a case report.
 
Malar J, 2009. 
8
: p. 277.
 
17.
 
Moorthy, V.S., et al., 
Report of a consultation on the optimization of clinical challenge 
trials for evaluation of candidate blood stage malaria vaccines, 18
-
19 March 2009, 
Bethesda, MD, USA.
 
Vaccine, 2009. 
27
(42): p. 5719
-
25.
 
18.
 
van Meer, M.P., et al., 
Idiopathic acute myocarditis during treatment for controlled 
human malaria infection: a case report.
 
Malar J, 2014. 
13
: p. 38.
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
56
 
of 
73
 
19.
 
Deye, G.A., et al., 
Prolonged protection provided by a single 
dose of atovaquone
-
proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human 
challenge model.
 
Clin Infect Dis, 2012. 
54
(2): p. 232
-
9.
 
20.
 
Stanisic, D.I., et al., 
Development of cultured Plasmodium falciparum blood
-
stage 
malaria cell ba
nks for early phase in vivo clinical trial assessment of anti
-
malaria drugs 
and vaccines.
 
Malar J, 2015. 
14
: p. 143.
 
21.
 
Mejia, R., et al., 
Peripheral blood stem cell transplant
-
related Plasmodium falciparum 
infection in a patient with sickle cell disease.
 
Transfusion, 2012. 
52
(12): p. 2677
-
82.
 
22.
 
Shokoples, S.E., et al., 
Multiplexed real
-
time PCR assay for discrimination of 
Plasmodium species with improved sensitivity for mixed infections.
 
J Clin Microbiol, 
2009. 
47
(4): p. 975
-
80.
 
23.
 
Gaziano, T.A., et al
., 
Laboratory
-
based versus non
-
laboratory
-
based method for 
assessment of cardiovascular disease risk: the NHANES I Follow
-
up Study cohort.
 
Lancet, 2008. 
371
(9616): p. 923
-
31.
 
24.
 
Ammon, H., 
Drugs and the Pharmaceutical Sciences, Vol. 1: PHARMACOKINETICS, 
v
on M. Gibaldi und D. Perrier, 360 S., Preis $. 19,50, Marcel Dekker Verlag, New York 
1975.
 
Archiv der Pharmazie, 1976. 
309
.
 
25.
 
Hansel, T.T., et al., 
The safety and side effects of monoclonal antibodies.
 
Nat Rev Drug 
Discov, 2010. 
9
(4): p. 325
-
38.
 
26.
 
Buge
lski, P.J., et al., 
Monoclonal antibody
-
induced cytokine
-
release syndrome.
 
Expert 
Rev Clin Immunol, 2009. 
5
(5): p. 499
-
521.
 
27.
 
Vogel, W.H., 
Infusion reactions: diagnosis, assessment, and management.
 
Clin J Oncol 
Nurs, 2010. 
14
(2): p. E10
-
21.
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
57
 
of 
73
 
APPENDIX I: 
SCHEDULE OF EVALUATIONS
 
 
 
 
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
58
 
of 
73
 
Schedule of Evaluations
: 
IV
 
Groups (Groups 1, 
2, 4
)
 
Visit Number
 
01
 
1
 
0
1R
 
1
 
0
2
 
0
2A
 
0
2B
 
0
2C
 
0
2D
 
0
3
 
0
4
 
0
6
 
0
7
 
0
8
 
0
9
 
10
 
11
 
1
2
 
1
3
 
1
4
 
Time After Infusion
 
 
 
Pre
 
EOI
 
1hr
 
3h
 
6h
 
24hr
 
48hr
 
Wk1
 
Wk2
 
Wk3
 
Wk4
 
Wk8
 
Wk12
 
Wk16
 
Wk20
 
Wk24
 
Day of Study
 
-
56 to 
-
1
 
-
28
 
to 
0 
D
0
 
D
0
 
D
0
 
D0
 
D0
 
D1
 
D2
 
D7
 
D14
 
D21
 
D28
 
D56
 
D84
 
D112
 
D140
 
D168
 
Study Procedures
 
Tube
 
Screen
 
Enroll
 
Day of infusion
 
 
 
 
 
 
 
 
 
 
 
 
VRC 500 Screening Consent
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VRC 
614
 
Informed
 
Consent
, AoU
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
Physical 
E
xam
 
 
X
 
X
 
X
 
X
 
 
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
3
 
Medical History 
 
 
X
 
X
 
X
 
 
 
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
EKG
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concomitant Medications
 
 
X
 
X
 
X
 
 
 
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Product
 
Administration
 
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Begin 
7
-
day Diary Card
 
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
Pregnancy 
P
revention 
C
ounseling
 
 
X
 
X
 
X
 
 
 
 
 
 
 
 
X
 
 
 
 
 
X
 
 
X
 
Clinical 
Evaluations
 
4 
Pregnancy 
T
est 
(
urine or serum
)
 
 
X
 
X
 
X
 
 
 
 
 
 
 
 
X
 
 
 
 
 
X
 
 
X
 
CBC 
with
 
differential
 
EDTA
 
3
 
 
3
 
 
 
 
 
3
 
 
3
 
3
 
 
3
 
 
3
 
 
 
 
ALT, creatinine
 
GLT
 
X
 
 
X
 
 
 
 
 
4
 
 
4
 
4
 
 
4
 
 
4
 
 
 
 
5
 
CMP
 
GLT
 
4
 
 
4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV 
Ag/Ab Combo
 
EDTA
 
3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sickle Cell Test
 
EDTA
 
3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P
arasitemia 
E
valuation (PCR)
 
EDTA
 
3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research Samples
 
6
 
PK 
 
SST
 
 
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
PBMC
 
EDTA
 
20
 
 
 
 
 
 
 
 
 
 
40
 
 
 
 
 
 
 
 
Serum
 
SST
 
8
 
 
16
†
 
 
 
 
 
 
8
 
8
†
 
8
 
8
 
8
†
 
8
 
8
†
 
8
 
8
 
8
†
 
Daily Vo
lume (mL)
 
 
44
 
0
 
27
 
4
 
4
 
4
 
4
 
11
 
12
 
19
 
59
 
12
 
19
 
12
 
19
 
12
 
12
 
12
 
Cumulative Volume (mL)
 
 
44
 
44
 
71
 
75
 
79
 
83
 
87
 
98
 
11
0
 
129
 
188
 
200
 
219
 
23
1
 
25
0
 
26
2
 
27
4
 
28
6
 
Visit windows
:
 
 
Schedule Visits 
0
2A
–
14 with respect to Visit 
0
2.  
Visit 
0
2A (
within 
10 min
 
of EOI
); Visits 
0
2B, 
0
2C (
±
10 min); Visit 
0
2D (
-
2 hrs); Visits 
0
3, 
0
4 
(±6 hrs); Visits 
0
6, 
0
7, 
0
8, 
0
9 (
±
2 
days); Visits 10, 11, 12, 13, 14 (
±
7 days). Visit 
0
5 is not applicable to this schedule.
 
Footnotes (continue to next page):
 
1 
Visit 
0
1R is the day of enrollment and may be done on the same day as Day 0. V
0
2/Day 0 is day of product administration and preferably scheduled 
within 14 days after enrollment at Visit 
0
1R but may be
 
scheduled up to 28 days after Visit 
0
1R. 
 
2 
Screening includes physical exam, vital signs (blood pressure (BP), temperature, pulse, re
spiratory rate (RR)), height, weight.  Day 0 includes vital signs 
and weight (for ordering study product dose).  At other visits, perform a targeted exam if medically indicated, otherwise onl
y vital signs are required.
 
3 
Perform full medical history at scr
eening.  At other visits, perform interim medical history
 
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
59
 
of 
73
 
4 
Pregnancy test results must be negative for women of reproductive potential before product administration. Complete Pregnancy
 
Prevention Counseling 
Form when pregnancy test is done. 
 
5
 
CMP includes 
sodium, potassium, chloride, total CO
2
, creatinine, glucos
e, urea nitrogen, albumin, alanine aminotransferase, alkaline phosphatase, 
aspartate aminotransferase, total bilirubin, calcium, total protein
 
6
 
PK blood draws, defined by time after an infusion, are relative to the exact time of the end of infusion (EOI).
  
Record the exact start / end times of product 
administration and of blood draw to ensure accurate PK analysis.  
 
† 
Anti
-
drug antibodies (ADA) assessed from serum samples at timepoints as indicated
.
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
60
 
of 
73
 
Schedule of 
Evaluations
: 
SC
 
Group (Group 
3
)
 
Visit Number
 
01
 
1
 
0
1R
 
1
 
0
2
 
0
2A
 
0
3
 
0
4
 
0
5
 
0
6
 
0
7
 
0
8
 
0
9
 
10
 
11
 
1
2
 
13
 
1
4
 
Time 
a
fter Infusion
 
 
 
Pre
 
EOI
 
24hr
 
48hr
 
72hr
 
Wk1
 
Wk2
 
Wk3
 
Wk4
 
Wk8
 
Wk12
 
Wk16
 
Wk20
 
Wk24
 
Study
 
Day
 
-
56 to 
-
1
 
-
28
 
to 
0
 
D0
 
D0
 
D1
 
D2
 
D3
 
D7
 
D14
 
D21
 
D28
 
D56
 
D84
 
D112
 
D140
 
D168
 
Study Procedures
 
Tube
 
Screen
 
Enroll
 
Day of injection
 
 
 
 
 
 
 
 
 
 
 
 
 
VRC 5
00 Screening Consent
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VRC 
614
 
Informed
 
Consent
, AoU
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
 
Physi
cal Exam
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
3
 
Medic
al History
 
 
 
X
 
X
 
X
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
EKG
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concomi
tant Medications
 
 
X
 
X
 
X
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Product
 
Administration
 
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Begin 
7
-
day Diary Card
 
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
Pregnancy 
P
revention 
C
ounseling
 
 
X
 
X
 
X
 
 
 
 
 
 
X
 
 
 
 
 
X
 
 
X
 
Clinica
l 
Evaluations
 
4
 
Pregnancy 
T
est
 
(
urine or serum
)
 
 
X
 
X
 
X
 
 
 
 
 
 
X
 
 
 
 
 
X
 
 
X
 
CBC 
wit
h
 
differential
 
EDTA
 
3
 
 
3
 
 
3
 
 
 
3
 
3
 
 
3
 
 
3
 
 
 
 
ALT, cr
eatinine
 
GLT
 
X
 
 
X
 
 
4
 
 
 
4
 
4
 
 
4
 
 
4
 
 
 
 
5
 
CMP
 
GLT
 
4
 
 
4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV 
Ag/
Ab Combo
 
EDTA
 
3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sickle 
Cell Test
 
EDTA
 
3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P
arasit
emia 
E
valuation (PCR)
 
EDTA
 
3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Researc
h Samples
 
6
 
PK 
 
SST
 
 
 
4
 
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
PBMC
 
ED
TA
 
20
 
 
 
 
 
 
 
 
40
 
 
 
 
 
 
 
 
Serum
 
S
ST
 
8
 
 
16
†
 
 
 
8
 
8
 
8
†
 
8
 
8
 
8
†
 
8
 
8
†
 
8
 
8
 
8
†
 
Daily Volume (mL)
 
 
44
 
0
 
27
 
0
 
11
 
12
 
12
 
19
 
59
 
12
 
19
 
12
 
19
 
12
 
12
 
12
 
Cumulative Volume (mL)
 
 
44
 
44
 
71
 
71
 
82
 
94
 
106
 
125
 
184
 
196
 
215
 
22
7
 
24
6
 
25
8
 
27
0
 
28
 
Visit windows
:
 
 
Schedule Visits 
02A 
–
14 with respect to Visit 
02
. 
Visit 
02A 
(
within 
10 min
 
of EOI
); Visits 
03
, 
04
, 
05 
(±6 hrs); Visits 
06
, 
07
, 
08
, 
09 
(
±
2 days); 
Visits 10, 11, 12, 13, 14 (
±
7 days). 
 
Footnotes (continue to next page): 
 
1 
Visit 
01R 
is the day of enrollment and may be done on the same day as Day 0. 
V02
/Day 0 is day of product administration and preferably scheduled within 
14 days after enrollment at Visit 
01R 
but may be scheduled up to 28 days after Visit 
01R
. 
 
2
 
Screening includes ph
ysical exam, vital signs (BP, temperature, pulse, RR), height, weight.  Day 0 includes vital signs and weight (for ordering s
tudy product 
dose).  At other visits, perform a targeted exam if medically indicated, otherwise only vital signs are required.
 
3 
Pe
rform full medical history at screening.  At other visits, perform interim medical history. 
 
4 
Pregnancy test results must be negative for women of reproductive potential before product administration. Complete Pregnancy
 
Prevention Counseling Form 
when pre
gnancy test is done. 
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
61
 
of 
73
 
5
 
CMP includes sodium, potassium, chloride, total CO
2
, creatinine, glucose, urea nitrogen, albumin, alanine aminotransferase, alkaline phosphatase, aspartate 
aminotransferase, total bilirubin, calcium, total protein
.
 
6 
PK blood draws,
 
defined by time after infusion, are relative to the exact time of the end of infusion (EOI).  Record exact start / end times 
of product 
administration and of blood draw to ensure accurate analysis. 
 
† 
ADA 
assessed
 
from serum samples at timepoints as indic
ated.
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
62
 
of 
73
 
Schedule of Evaluations
: IM Group (Group 6)
 
Visit Number
 
01
 
1
 
0
1R
 
1
 
0
2
 
0
2A
 
0
3
 
0
4
 
0
5
 
0
6
 
0
7
 
0
8
 
0
9
 
10
 
11
 
1
2
 
13
 
1
4
 
Time 
a
fter Infusion
 
 
 
Pre
 
EOI
 
24hr
 
48hr
 
72hr
 
Wk1
 
Wk2
 
Wk3
 
Wk4
 
Wk8
 
Wk12
 
Wk16
 
Wk20
 
Wk24
 
Study
 
Day
 
-
56 to 
-
1
 
-
28
 
to 
0
 
D0
 
D0
 
D1
 
D2
 
D3
 
D7
 
D14
 
D21
 
D28
 
D56
 
D84
 
D112
 
D140
 
D168
 
Study Procedures
 
Tube
 
Screen
 
Enroll
 
Day of injection
 
 
 
 
 
 
 
 
 
 
 
 
 
VRC 5
00 Screening Consent
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VRC 
614
 
Informed
 
Consent
, AoU
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
 
Physi
cal Exam
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
3
 
Medic
al History
 
 
 
X
 
X
 
X
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Concomi
tant Medications
 
 
X
 
X
 
X
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Product
 
Administration
 
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Begin 
7
-
day Diary Card
 
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
Pregn
ancy 
P
revention 
C
ounseling
 
 
X
 
X
 
X
 
 
 
 
 
 
X
 
 
 
 
 
X
 
 
X
 
Clinical 
Evaluations
 
4
 
Pregnancy 
T
est
 
(
urine or serum
)
 
 
X
 
X
 
X
 
 
 
 
 
 
X
 
 
 
 
 
X
 
 
X
 
CBC 
wit
h
 
differential
 
EDTA
 
3
 
 
3
 
 
3
 
 
 
3
 
3
 
 
3
 
 
3
 
 
 
 
ALT, cr
eatinine
 
GLT
 
X
 
 
X
 
 
4
 
 
 
4
 
4
 
 
4
 
 
4
 
 
 
 
5
 
CMP
 
G
LT
 
4
 
 
4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV 
Ag/
Ab Combo
 
EDTA
 
3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Researc
h Samples
 
6
 
PK 
 
SST
 
 
 
4
 
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
4
 
PBMC
 
ED
TA
 
20
 
 
 
 
 
 
 
 
40
 
 
 
 
 
 
 
 
Serum
 
S
ST
 
8
 
 
16
†
 
 
 
8
 
8
 
8
†
 
8
 
8
 
8
†
 
8
 
8
†
 
8
 
8
 
8
†
 
Daily Volume (mL)
 
 
44
 
0
 
27
 
0
 
11
 
12
 
12
 
19
 
59
 
12
 
19
 
12
 
19
 
12
 
12
 
12
 
Cumulative Volume (mL)
 
 
44
 
44
 
71
 
71
 
82
 
94
 
106
 
125
 
184
 
196
 
215
 
227
 
246
 
258
 
270
 
28
 
Visit windows
:
 
 
Schedule Visits 02A 
–
14 with respect to Visit 02. 
Visit 02A (within 10 min of EOI); Visits 03, 04, 05 (±6 hrs); Visits 06, 07, 08, 09 (
±
2 days); 
Visits 10, 11, 12, 13, 14 (
±
7 days). 
 
Footnotes (continue to next page): 
 
1 
Visit 01R is the day of enrollment and may be done on the same day as Day 0. V02/Day 0 is day of product administration and p
referably scheduled within 
14 days after enrollment at Visit 01R but may be scheduled up to 2
8 days after Visit 01R. 
 
2
 
Screening includes physical exam, vital signs (BP, temperature, pulse, RR), height, weight.  Day 0 includes vital signs and w
eight (for ordering study product 
dose).  At other visits, perform a targeted exam if medically indicate
d, otherwise only vital signs are required.
 
3 
Perform full medical history at screening.  At other visits, perform interim medical history. 
 
4 
Pregnancy test results must be negative for women of reproductive potential before product administration. Complete Pregnancy
 
Prevention Counseling Form 
when pregnancy test is done. 
 
5 
CMP includes sodium, potassium, chloride, total CO
2
, creatinine, glucos
e, urea nitrogen, albumin, alanine aminotransferase, alkaline phosphatase, aspartate 
aminotransferase, total bilirubin, calcium, total protein
.
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
63
 
of 
73
 
6 
PK blood draws, defined by time after infusion, are relative to the exact time of the end of infusion (EOI).  
Record exact start / end times of product 
administration and of blood draw to ensure accurate analysis. 
 
 
          
† 
ADA 
assessed
 
from serum samples at timepoints as indicated
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
64
 
of 
73
 
 
Schedule of Evaluations
: 
CHMI 
for 
Groups 1
-
4
 
Visit Number
 
C01
 
C02
 
1 
C02A
 
1 
C02B
 
C03
 
C04
 
C05
 
C06
 
C07
 
C08
 
C09
 
C10
 
Time after CHMI
 
 
 
24hr
 
72hr
 
Wk1
 
Wk1
 
Wk1
 
Wk1
 
Wk1
 
Wk1
 
Wk1
 
Wk2
 
CHMI Day
 
-
1
 
D0
 
D1
 
D3
 
D7
 
D8
 
D9
 
D10
 
D11
 
D12
 
D13
 
D14
 
Study Procedures
 
Tube
 
 
CHMI
 
 
 
Parasitemia Check 
(daily checks until 
treatment criteria met)
 
2
 
Physical Exam, Vital Signs
 
 
X
 
X
 
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
Interim
 
M
edical 
H
istory
 
 
X
 
X
 
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
CHMI
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
Phone Contact
 
 
 
 
X
 
X
 
 
 
 
 
 
 
 
 
Pregnancy 
P
revention 
C
ounseling
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
C
linical 
Evaluations
 
3
 
Pregnancy 
T
est
 
(
urine or serum
)
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
CBC with differential
 
EDTA
 
3
 
 
 
 
3
 
 
 
 
 
 
 
 
ALT
, 
creatinine
 
GLT
 
4
 
 
 
 
 
 
 
 
 
 
 
 
4 
P
arasitemia 
E
valuation (PCR)
 
EDTA
 
 
 
 
 
3
 
3
 
[
3
]
 
[
3
]
 
[
3
]
 
[
3
]
 
[
3
]
 
[
3
]
 
Research Samples
 
PK
 
SST
 
4
 
 
 
 
4
 
 
 
 
 
 
 
4
 
PBMC
 
EDTA  
 
 
 
 
40
 
 
 
 
 
 
 
*60
 
Serum
 
SST
 
 
 
 
 
1
6
†
 
 
 
 
 
 
 
*16
 
Daily Volume (mL)
 
 
11
 
0
 
0
 
0
 
66
 
3
 
3
 
3
 
3
 
3
 
3
 
83
 
Cumulative Volume (mL)
 
 
11
 
11
 
11
 
11
 
77
 
80
 
83
 
86
 
89
 
92
 
95
 
178
 
1 
After CHMI, schedule Visit C
0
2A on Day 1 or 2, Visit C
0
2B on Day 3 or 4
.
 
2 
Perform a targeted physical exam if medically indicated, otherwise only vital signs (BP, temperature, pulse, RR) are required
.
 
3 
Pregnancy test results must be negat
ive for women of reproductive potential within 2 days prior to CHMI.
 
 
Complete a Pregnancy Prevention 
Counseling Form when pregnancy test is done. 
 
4 
Parasitemia evaluations should continue daily until a subject has 
one
 
positive PCR 
or blood smear
; brackets [3] indicate optional draw as needed.  
A
 
positive result prior to Day 
21
 
is
 
required for initiation of antimalarial 
directly observed therapy (DOT)
. 
 
*
 
Research blood will be drawn at 14 days post
-
CHMI (Visit C
10
) from 
all
 
subjects.
 
† 
ADA assess
ed from serum samples at timepoints as indicated.
 
 
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
65
 
of 
73
 
Schedule of Evaluations
: 
CHMI
 
for Groups 1
-
4 (continued)
 
1 
Visit Number
 
C11
 
C12
 
C13
 
1 
C1
4
 
C1
5
 
C1
6
 
C1
7
 
2 
C
18
 
Time after CHMI
 
Wk2
 
Wk2
 
Wk2
 
Wk3
 
Wk3
 
Wk3
 
Wk4
 
Wk7
 
CHMI Day
 
D15
 
D16
 
D17
 
D21
 
D22
 
D23
 
D28
 
D49
 
Study Procedures
 
Tube
 
Parasitemia Check
 
(daily until treatment criteria met)
 
 
 
 
 
 
3 
Physical Exam, Vital Signs
 
 
X
 
X
 
X
 
X
 
X
 
X
 
 
[X]
 
Interim Medical History
 
 
X
 
X
 
X
 
X
 
X
 
X
 
 
[X]
 
Phone Contact 
 
 
 
 
 
 
 
 
X
 
[X]
 
Clinical Evaluations
 
CBC with 
differential
 
EDTA
 
 
 
 
*3
 
 
*3
 
 
[3]
 
ALT, creatinine
 
GLT
 
 
 
 
*4
 
 
*4
 
 
[4]
 
4 
Parasitemia Evaluation (PCR)
 
EDTA
 
[3]
 
[3]
 
[3]
 
[3]
 
 
 
 
[3]
 
Anti
-
Malarial Treatment
 
 
 
 
 
[X]
 
[X]
 
[X]
 
 
 
Research Samples
 
PK
 
SST
 
 
 
 
4
 
 
 
 
[4]
 
PBMC
 
EDTA
 
 
 
 
 
 
 
 
[60]
 
Serum
 
SST
 
 
 
 
8
†
 
 
 
 
[16]
 
Daily Volume (mL)
 
 
3
 
3
 
3
 
22
 
0
 
7
 
0
 
90
 
Cumulative Volume (mL)
 
 
181
 
184
 
187
 
209
 
209
 
216
 
216
 
306
 
1 
Visit C
1
4
 
is
 
only 
required for CHMI participants not previously diagnosed with malaria parasitemia to rule out a delayed case. At Visit C
1
4
 
(Day 
21
), any subject 
who has not already started antimalarial treatment will be given definitive 
DOT
.
 
 
Subjects must return for DOT
 
for 2 more days after initiation
.
 
 
B
rackets 
[X]
 
indicate optional as needed per subject 
treatment
 
status.
 
 
2
 
Visit 
C
18
 
is only required for subjects who had 
a 
positive PCR
 
or blood smear
 
to document test of cure. It is scheduled to occur 
26
±5 days after 
DOT 
completion 
and is shown at Day 
49
 
for convenience. 
 
Visit 
C
18
 
may be completed via phone for subjects who remain mal
aria negative, brackets [X] indicate optional as 
needed
 
per subject infection status
.
 
3
 
Perform a targeted physical exam if medically indicated, otherwise only vital signs (BP, temperature, pulse, RR) are required
.
 
4
 
Parasitemia evaluations should continue daily until a subject has 
one
 
positive PCR 
or blood smear
; brackets [3] indicate optional draw as needed.  
A
 
positive result 
prior to Day 
21
 
is
 
required for initiation of antimalarial 
DOT
.  Otherwise, 
initiate DOT at
 
C1
4
. 
 
*
 
Blood for CBC, ALT, 
and 
creatinine will be drawn at onset of 
DOT
 
and about 2 days later; shown at visits 
C
1
4
 
and 
C1
6 
to account for blood draw
. 
 
Parasitemia 
evaluations are not performed during treatment through to test of cure.
 
† 
ADA 
assessed from serum samples at timepoints as indicated.
 
 
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
66
 
of 
73
 
Schedule of Evaluations
: 
CHMI 
for Group 5
 
Visit Number
 
01
 
01R
 
C
0
1
 
C
0
2
 
1 
C
0
2A
 
1 
C
0
2B
 
C
0
3
 
C
0
4
 
C
0
5
 
C
0
6
 
C
0
7
 
C
0
8
 
C
0
9
 
C10
 
Time after CHMI
 
 
 
 
 
24hr
 
72hr
 
Wk1
 
Wk1
 
Wk1
 
Wk1
 
Wk1
 
Wk1
 
Wk1
 
Wk2
 
CHMI Day
 
-
56 to 
-
1
 
-
56 to 
-
1
 
-
1
 
D0
 
D1
 
D3
 
D7
 
D8
 
D9
 
D10
 
D11
 
D12
 
D13
 
D14
 
Study Procedures
 
Tube
 
 
 
 
CHMI
 
 
 
Parasitemia Check 
(daily checks until treatment criteria met)
 
VRC 500 Screening Consent
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VRC 614 Informed Consent, AoU
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
Physical Exam, Vital Signs
 
 
X
 
X
 
X
 
X
 
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
3 
Medical History
 
 
X
 
X
 
X
 
X
 
 
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
X
 
EKG
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concomitant Medications
 
 
X
 
 
X
 
 
 
 
 
 
 
 
 
 
 
 
CHMI
 
 
 
 
 
X
 
 
 
 
 
 
 
 
 
 
 
Phone Contact
 
 
 
 
 
 
X
 
X
 
 
 
 
 
 
 
 
 
4 
Pregnancy Prevention 
Counseling
 
 
X
 
X
 
X
 
 
 
 
 
 
 
 
 
 
 
 
C
linical Evaluations
 
4 
Pregnancy Test (urine or serum)
 
 
X
 
X
 
X
 
 
 
 
 
 
 
 
 
 
 
 
CBC with differential
 
EDTA
 
3
 
 
3
 
 
 
 
3
 
 
 
 
 
 
 
 
ALT, creatinine
 
GLT
 
X
 
 
4
 
 
 
 
 
 
 
 
 
 
 
 
5 
CMP
 
GLT
 
4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV Ag/Ab Combo
 
EDTA
 
3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sickle Cell Test
 
EDTA
 
3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
Parasitemia Evaluation (PCR)
 
EDTA
 
3
 
 
 
 
 
 
3
 
3
 
[3]
 
[3]
 
[3]
 
[3]
 
[3]
 
[3]
 
Research Samples
 
PBMC
 
EDTA
 
20
 
 
 
 
 
 
20
 
 
 
 
 
 
 
*20
 
Serum
 
SST
 
8
 
 
 
 
 
 
8
 
 
 
 
 
 
 
*8
 
Daily Volume (mL)
 
 
44
 
0
 
7
 
0
 
0
 
0
 
34
 
3
 
3
 
3
 
3
 
3
 
3
 
31
 
Cumulative Volume (mL)
 
 
44
 
44
 
51
 
51
 
51
 
51
 
85
 
88
 
91
 
94
 
97
 
100
 
103
 
134
 
Footnotes (continue to next page): 
 
1 
After CHMI, schedule Visit C
0
2A on Day 1 or 2, Visit C
0
2B on Day 3 or 4
.
 
2
 
Screening includes physical exam, vital signs (BP, temperature, pulse, RR), height, weight.  Day 0 includes vital signs 
and weight (for ordering study product 
dose).  At other visits, perform a targeted exam if medically indicated, otherwise only vital signs are required.
 
3
 
Perform full medical history at screening.  At other visits, perform interim medical history. 
 
4
 
Preg
nancy test results must be negative for women of reproductive potential within 2 days prior to CHMI.  Complete a Pregnancy Pr
evention Counseling Form 
when pregnancy test is done. 
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
67
 
of 
73
 
5
 
CMP includes sodium, potassium, chloride, total CO2, creatinine, glucose, 
urea nitrogen, albumin, alanine aminotransferase, alkaline phosphatase, aspartate 
aminotransferase, total bilirubin, calcium, total protein
.
 
6
 
Parasitemia evaluations should continue daily until a subject has one positive PCR or blood smear; brackets [3] i
ndicate optional draw as needed.  A positive 
result prior to Day 21 is required for initiation of antimalarial directly observed therapy (DOT). 
 
* Research blood will be drawn at 14 days post
-
CHMI (Visit C10) from 
all 
subjects.
 
 
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
68
 
of 
73
 
S
chedule of Evaluations
: 
CHMI
 
for Group 5 (continued)
 
1 
Visit Number
 
C11
 
C12
 
C13
 
1 
C1
4
 
C1
5
 
C1
6
 
C1
7
 
2 
C
18
 
Time after CHMI
 
Wk2
 
Wk2
 
Wk2
 
Wk3
 
Wk3
 
Wk3
 
Wk4
 
Wk7
 
CHMI Day
 
D15
 
D16
 
D17
 
D21
 
D22
 
D23
 
D28
 
D49
 
Study Procedures
 
Tube
 
Parasitemia Check
 
(daily until treatment criteria met)
 
 
 
 
 
 
3
 
Physical Exam, Vital Signs
 
 
X
 
X
 
X
 
X
 
X
 
X
 
 
[X]
 
Interim Medical History
 
 
X
 
X
 
X
 
X
 
X
 
X
 
 
[X]
 
Phone Contact 
 
 
 
 
 
 
 
 
X
 
[X]
 
Clinical 
Evaluations
 
CBC with differential
 
EDTA
 
 
 
 
*3
 
 
*3
 
 
[3]
 
ALT, creatinine
 
GLT
 
 
 
 
*4
 
 
*4
 
 
[4]
 
4
 
Parasitemia Evaluation (PCR)
 
EDTA
 
[3]
 
[3]
 
[3]
 
[3]
 
 
 
 
[3]
 
Anti
-
M
alarial Treatment
 
 
 
 
 
[X]
 
[X]
 
[X]
 
 
 
Research Samples
 
PBMC
 
EDTA
 
 
 
 
 
 
 
 
[20]
 
Serum
 
SST
 
 
 
 
 
 
 
 
[8]
 
Daily Volume (mL)
 
 
3
 
3
 
3
 
1
0
 
0
 
7
 
0
 
38
 
Cumulative Volume (mL)
 
 
137
 
140
 
143
 
153
 
153
 
160
 
160
 
198
 
1 
Visit C
1
4
 
is
 
only required for CHMI participants not previously diagnosed with malaria parasitemia to rule out a delayed case. 
 
At Visit 
C
14
 
(Day 
21
), any subject 
who has not already started antimalarial treatment will be given definitive 
DOT
.
 
 
Subjects must return for DOT
 
for 2 more days after initiation
.
 
 
B
rackets 
[X]
 
indicate optional as needed per subject 
treatment
 
status
.
 
 
2
 
Visit 
C
18
 
is only req
uired for subjects who had 
a 
positive PCR
 
or blood smear
 
to document test of cure. 
 
It is scheduled to occur 
26
±5 days after 
DOT 
completion 
and is shown at Day 
49
 
for convenience. 
 
Visit 
C
18
 
may be completed via phone for subjects who remain malaria negati
ve, brackets [X] indicate optional as 
needed
 
per subject infection status
.
 
3
 
Perform a targeted physical exam if medically indicated, otherwise only vital signs (BP, temperature, pulse, RR) are required
.
 
4
 
Parasitemia evaluations should continue daily until a subject has 
one
 
positive PCR 
or blood smear
; brackets [3] indicate optional draw as needed.  
A
 
positive result 
prior to Day 
21
 
is
 
required for initiation of antimalarial 
DOT
.  Otherwise, 
initiate DOT at
 
C1
4
. 
 
*
 
Blood for CBC, ALT, 
and 
creatinine will be drawn at onset of 
DOT
 
and about 2 days later; shown at visits 
C1
4
 
and 
C1
6
 
to account for blood draw
. 
 
Parasitemia 
evaluations are not performed during treatment through to test of cure.
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
69
 
of 
73
 
A
PPENDIX
 
II: ASSESSMENT OF AE RELATIONSHIP
 
AND
 
SEVERITY
 
GRADING
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
70
 
of 
73
 
Assessment of Relationship of an Adverse Event 
 
The relationship between an AE and the study product or CHMI will be assessed by the 
investigator on the 
basis of clinical judgment and the definitions below.
 
•
 
Definitely Related
:
 
 
The AE and administration of study product and/or CHMI are 
related in time, and a direct association can be demonstrated.
 
•
 
Probably Related
:
 
 
The AE and administration of study produ
ct and/or CHMI are 
reasonably related in time, and the AE is more likely explained by study agent or CHMI 
than other causes.
 
•
 
Possibly Related
:
 
 
The AE and administration of study product and/or CHMI are 
reasonably related in time, but the AE can be explain
ed equally well by causes other than 
study agent or CHMI.
 
•
 
Not Related
:
 
 
The AE is clearly explained by another cause not related to the study 
product or CHMI.
 
For purposes of preparing summary data reports in which AE attributions are simplified to 
“Relate
d” or “Not Related”, in this protocol, the “Definitely, Probably and Possibly” attributions 
above will be mapped to the “Related” category, while the “Unlikely/Probably Not Related” and 
“Not Related” attributions above will be mapped to the “Not Related” c
ategory.  The definitions 
that apply when these two attribution categories alone are used are as follows:
 
•
 
Related
:
 
 
There is a reasonable possibility that the AE may be related to the study 
product or CHMI.
 
•
 
Not Related
:
  
There is not a reasonable possibili
ty that the AE is related to the study 
product or CHMI. 
 
 
Grading the Severity of an Adverse Event
 
The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse 
Events, Corrected Version 2.1 [July 2017] will be used to determin
e the severity grades of AEs 
in this protocol and is available from: 
https://rsc.niaid.nih.gov/clinical
-
research
-
sites/daids
-
adverse
-
event
-
grading
-
tables
.
 
 
Several modifications were made to the table as follows:
 
•
 
Weight loss will be recorded as an AE only if it is considered deleterious to the 
participant’s health.
 
•
 
For severity grading of the solicited bruising parameter at the product 
administration site, 
the definitions based on size of the largest diameter and listed for the “Injection Site 
Erythema or Redness” will be used.  The severity grade definition for “Bruising” 
provided under the Dermatologic Clinical Conditions will be used 
only for unsolicited 
AEs involving bruising at other body locations.
 
•
 
Creatinine changes will be graded on the basis of the upper limit of normal provided by 
the grading table and not change from baseline.
 
•
 
Creatinine clearance changes will be graded accordi
ng to ml/min provided by the grading 
table and not change from baseline.
 
•
 
Subclinical CMP results for sodium, potassium, chloride, bicarbonate, BUN, and glucose 
will not be considered an AE unless Grade 2 or higher.
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
71
 
of 
73
 
A
PPENDIX
 
I
II
: 
STUDY PRODUCT
 
PREPARATION
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
72
 
of 
73
 
1.
 
Preparation for IV Administration
 
To prepare an IV infusion, the pharmacist will complete the sequence of steps outlined below.
 
 
 
1.
 
Obtain a pre
-
filled, DEHP
-
free
,
 
100 mL IV bag of 0.9% saline.
 
 
 
2.
 
Remove the air from the IV bag.
 
 
3.
 
Calculate the
 
total dose needed to prepare L9LS in the 0.9% saline bag in order to achieve 
the ideal concentration of
 
 
≥ 2 mg/mL.
 
 
 
The IV bag may be prepared with a higher volume than required (i.e. overfill) to ensure 
proper administration via volumetric
 
pump.
 
 
 
Maintaining
 
infusible volume of
 
L9LS at the minimum concentration of 2 mg/mL may cause 
the total L9LS dose in the bag to exceed the lower weight
-
based dose (e.g., 1 mg/kg).
 
 
Do not infuse the entire volume of the IV bag if the total amount 
exceeds the weight
-
based 
dose of the subject.
 
 
4.
 
Thaw and equilibrate vials on the bench at room temperature for 90 minutes. If vials are 
stored at 5°C ± 3°C, equilibrate for approximately 30 min at room temperature before use.
 
 
5.
 
Gently swirl the vials for 30
 
seconds to mix while avoiding foaming. Vials should never be 
shaken.
 
 
 
6.
 
Withdraw the necessary amount of L9LS and add it to the IV bag so that final concentration 
in bag is 
≥
 
2 mg/
mL.
 
 
 
7.
 
Add the syringe contents to the sterile bag of saline using good st
erile compounding 
technique.
 
 
 
8. 
 
An in
-
line filter infusion set is required for IV product administrations and must comply with 
the following specifications: 1.2 micron
 
polyethersulfone
 
filter membrane, DEHP
-
free, latex
-
free (equivalent to B. Braun #4739
94 filter extension set). After the in
-
line filter is added to 
the tubing, the administration set must be primed.
 
 
 
Note: If the compounded IV preparation has been stored at 5°C ± 3°C, equilibrate for 
approximately 30 min at room temperature before use.
 
 
T
he study product solution will typically 
be administered IV over about 15
-
30 minutes using a volumetric pump.
 
 
The total time needed to 
administer the dose may be longer than 30 minutes based on factors such as subject 
tolerance.
 
 
The mL/
hr
 
infusion rate m
ay vary based on the total volume needed to administer a 
full dose.
 
 
 
IV bag prepared without overfill:
 
 
 
At the end of product administration, the IV administration set 
must
 
be flushed with about 30 
mL (or appropriate volume) of normal saline.
 
 
IV bag p
repared
 
with overfill:
 
 
At the end of product administration, the IV administration set should 
not
 
be flushed with saline. 
 
 
 
 
L9LS
 
in
 
Healthy Adults
 
 
VRC 614, Version 2.0
 
                     
 
October 13, 2021
 
Page 
73
 
of 
73
 
2.
 
Preparation for SC
 
or IM
 
Administration
 
 
 
To prepare a SC
 
or IM
 
administration dose, the pharmacist will complete the sequence of steps 
as outlined in this section.
 
 
1.
 
Calculate the total mg DP needed.
 
2.
 
Thaw and equilibrate vials on the bench at room temperature for 90 minutes. If v
ials are 
stored at 5°C ± 3°C, equilibrate for approximately 30 min at room temperature before use.
 
 
3.
 
Gently swirl the vials for 30 seconds to mix while avoiding foaming. Vials should never be 
shaken.
 
 
 
4.
 
Withdraw the necessary amount of L9LS using a 5
-
micron 
filter needle
 
(maximum syringe 
fill volume of 2.5
 
ml for SC and 1.0
 
mL for IM)
.
 
Use a new filter needle for each syringe.
 
5.
 
Prior to dispensing, discard the filter needle and replace it with a needle suitable for SC 
or IM 
injection.
 
 
Note: 
 
If SC 
or IM 
preparations have been stored at 5°C ± 3°C, equilibrate for approximately 30 
min at room temperature before use.
 
 
 
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/03/2021 V2.0
Page 
1
 of 
19
CC ICF template v9 04.13.2021
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
PRINCIPAL INVESTIGATOR:  
Richard Wu, MD
STUDY TITLE: 
VRC 614 (000536): A Phase 1, Dose Escalation, Open-Label Clinical Trial with 
Experimental Controlled Human Malaria Infections (CHMI) to Evaluate Safety and Protective 
Efficacy of an Anti-Malaria Human Monoclonal Antibody, VRC-MALMAB0114- 00-AB (L9LS), 
in Healthy, Malaria-Naive Adults
STUDY SITE:
 NIH / NIAID / VRC / Vaccine Evaluation Clinic (VEC)
Cohort: 
Healthy volunteer 
Consent Version:  
Version 2.0, November 3, 2021
WHO DO YOU CONTACT ABOUT THIS STUDY? 
Principal Investigator: Richard Wu, MD,
Study Coordinator: Floreliz Mendoza, RN,
KEY INFORMATION ABOUT THIS RESEARCH 
The purpose of this consent form is to give you information to help you decide if you would like 
to be part of a research study at the National Institutes of Health (NIH). The decision to 
participate is your choice. This section provides information we believe is most helpful and 
important to you in making your decision. Additional information that may help you decide can 
be found in other sections of the document.
This is a study of an experimental drug called “L9LS”. L9LS is a monoclonal antibody    that 
targets malaria. 
L9LS has not been tested in humans before this study
. We do not know  if 
L9LS will protect you from malaria infection. There is no malaria in L9LS, so you cannot get 
the infection just by taking the experimental drug. You should not assume L9LS will protect 
you from malaria if you travel to a place where there is a risk of infection.
The main purpose of this study is to see if L9LS is safe and how your body responds to the 
antibody. This is the first time that L9LS will be given to people, and we do not know how your 
body will respond.  We will follow everyone who gets L9LS for about 24 weeks.
If you have side effects from L9LS, we expect them to be like those that occur with other 
antibody products. These side effects include fever, chills, shaking, nausea, diarrhea, vomiting, 
pain, headache, dizziness, and tiredness. They usually occur within the first 24 hours after the 
antibody is given. Some antibody products have a risk of serious allergic reactions that can be 
life threatening. Although rare, other side effects that may occur are trouble breathing, itchiness, 
rash, hives, swelling, or chest pain, and you must reach out to the study clinicians right away if 
you have any of these serious side effects.  
Another purpose of this study is to test if L9LS prevents you from getting malaria when you are 
bitten by mosquitoes that carry live malaria parasites.  This is called a “malaria challenge” or a 
            000 3 
                   12/01/2021
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/03/2021 V2.0
Page 
2
 of 
19
CC ICF template v9 04.13.2021
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
controlled human malaria infection (CHMI). You must be available on the day of the CHMI if 
you are in a group taking part in the CHMI. Each person who takes part in the CHMI may get 
malaria infection, and we will follow everyone afterward for about 7 weeks. The CHMI will 
include participants who get a dose of L9LS and “control” participants who do not get L9LS. 
Starting 7 days after the CHMI, you must come to the clinic every day for 11 days to be checked 
for malaria parasites through a blood test. Testing is done every day so that the level of malaria 
in your blood does not get to dangerous levels. 
After the CHMI, it is important that you come 
to the clinic for your scheduled visits so that the level of malaria parasites in your blood 
does not increase to dangerous levels
.
At the first sign of malaria infection in your blood, we will treat you with a medication that will 
cure you.  Even if the blood test is never positive, all who take part will get treated with a malaria 
medication at Day 21 after CHMI. We take this step to make sure that everyone is cured of 
malaria.  The drugs that treat malaria may cause some side effects.  Once you are treated, you 
will not be at risk for recurrence/reactivation of the infection from the CHMI. If you do not take 
part in the CHMI, you will not be at greater risk of getting malaria infection and will not need 
drugs that treat malaria. 
During the study, we will collect blood samples from you.  Some of your blood will be stored 
for future research.  You will be compensated for your time and inconvenience for taking part 
in this study.
The study will last about 2 to 6 months, depending on your study group.  During this time, you 
must use an effective form of birth control if able to become pregnant, must not travel to a 
malaria region, must not take antibiotic drugs starting 4 weeks before the beginning of the CHMI 
and during the CHMI (unless prescribed by a physician, in which case the study team must be 
notified) or donate blood for 3 years following participation in CHMI. These safety measures 
are further described below.  All clinical study visits will take place at the NIH Clinical Center 
in Bethesda, Maryland.  The CHMI will take place at the Walter Reed Army Institute of 
Research facility in Silver Spring, Maryland, and is also supported by the U.S. Department of 
Defense (DOD).
The remaining document will now describe the research study in more detail.  This information 
should be considered before you make your choice. Members of the study team will talk with you 
about the information in this document. Some people have personal, religious, or ethical beliefs 
that may limit the kinds of medical or research interventions in which they would want to 
participate.  Take the time you need to ask any questions and discuss this study with NIH staff, 
and with your family, friends, and personal health care providers.
IT IS YOUR CHOICE TO TAKE PART IN THE STUDY
You may choose not to take part in this study for any reason.  If you join this study, you may 
change your mind and stop participating in the study at any time and for any reason.  In either case, 
you will not lose any benefits to which you are otherwise entitled.  However, to be seen at the NIH, 
you must be taking part in a study or are being considered for a study.  If you do choose to leave 
the study, please inform your study team to ensure a safe withdrawal from the research.  
            000 3 
                   12/01/2021
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/03/2021 V2.0
Page 
3
 of 
19
CC ICF template v9 04.13.2021
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
WHY IS THIS STUDY BEING DONE?
Malaria is a disease that affects more than 250 million people throughout the world.  The parasites 
that cause malaria are known as 
Plasmodium
.  They live in the mosquito saliva and are injected 
into the skin when a mosquito bites a human.  This can cause malaria infection.  Malaria occurs in 
most tropical parts of the world including Africa, Southeast Asia and South America.  It is a serious 
threat to the local populations, to travelers and to military personnel stationed overseas.  Although 
there are medicines to treat malaria, there is no vaccine that fully prevents infection and treatment 
is not easy to get in many areas of the world.  If malaria is not treated right away, it can become a 
serious and sometimes deadly disease.  If it is treated right away, it can be completely cured.
The purpose of this research study is to test a drug that could prevent malaria infection in humans 
called L9LS.  L9LS is considered investigational, which means that it has not been approved by 
the U.S. Food and Drug Administration (FDA) to prevent malaria infection.  It is a monoclonal 
antibody (mAb) that targets the parasites that cause malaria.  Antibodies are naturally made by the 
immune  system  to  fight  infection  by  blocking  germs  (bacteria  and  parasites)  like  malaria.  
Monoclonal means that all the antibodies in L9LS are exactly the same.
L9LS was developed at the Vaccine Research Center (VRC) at NIH.  It was made in a laboratory 
and looks like an antibody that your own body could make.  It has shown promise for prevention 
of malaria in laboratory and animal studies, but it has not yet been studied in humans.
This is the first study to give L9LS to humans.
  We do not know if L9LS will protect you from 
malaria infection. You cannot get malaria from L9LS because there is no malaria in it. You should 
not assume L9LS will protect you from malaria.
The purpose of this research study is to see if L9LS is safe and how your body responds to it.  We 
will give you a dose of L9LS and measure how much of it stays in your body over time.  We also 
want  to  see  the  differences  between  getting  L9LS  as  an  infusion  in  a  vein  in  your  arm 
(intravenously, IV) as an injection under the skin (subcutaneously, SC) or as an injection into a 
muscle (intramuscularly, IM).
In this study, you will be exposed to malaria through bites from mosquitos infected with malaria 
parasites, if you are in Groups 1-5.  This is called a “malaria challenge” or a “Controlled Human 
Malaria Infection” (CHMI). We do this to find out if L9LS prevents you from getting malaria after 
you are bitten by the infected mosquitoes in a controlled setting.  We will monitor you closely and 
test your blood every day for many days to see if you get infected with malaria.  Even if your test 
is negative, we will give everyone malaria treatment by 21 days after CHMI.
We are asking you to join this research study because you are a healthy adult between the ages of 
18 and 50 who has never been infected with malaria.  If you are in Groups 1-5, you must be willing 
to take part in the CHMI and comply with follow-up requirements after CHMI to be in this study.  
If you take part in the CHMI, you must also agree not to travel to a malaria endemic region during 
the whole study and not to donate blood to a blood bank for 3 years after CHMI.  
WHAT WILL HAPPEN DURING THE STUDY?
This study has 6 groups as shown in the Study Schema table below. Groups 1, 2,  3, 4, and 6 will 
get different doses and/or routes of L9LS.  Most people who get L9LS will get it by infusion into 
a vein (IV).  Some people will get L9LS into the fat under the skin (SC) or into the muscle (IM).
            000 3 
                   12/01/2021
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/03/2021 V2.0
Page 
4
 of 
19
CC ICF template v9 04.13.2021
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
A group of people called “control” participants will not get the study product but will take part in 
the CHMI.  This group helps us make sure the mosquitos can infect people. 
If you decide to take part in this study, you will be asked to review and agree to this informed 
consent form and the procedures outlined within it.  You will have completed the screening process   
which includes a physical exam and review of your medical history, vital signs and laboratory 
results.  You must be healthy and qualify for enrollment before you can take part in this study.
The study will start with enrollments of people to the lowest dose of L9LS by IV and SC routes (1 
mg/kg IV (Group 1) and 5 mg/kg SC (Group 3)).  The next groups, 5 mg/kg IV (Group 2) and 20 
mg/kg IV (Group 4), will open after the study team reviews available safety data and agrees that 
there are no safety concerns at the lower IV doses.  Group 5 can be enrolled at any time. Group 6 
will enroll after  the IV and SC groups have received the study product and have undergone CHMI.  
Groups 1-5 will take part in the CHMI. 
If you are in Group 5, you will be a control participant and will not get a dose of L9LS.  After 
enrollment, we will check your health and draw your blood before the CHMI.
If you are female and able to become pregnant, you must use an effective method of birth control 
for the entire study.  You will be given a pregnancy test before you get any dose of L9LS and 
before the CHMI.  If you are pregnant, we will not give you L9LS and you cannot take part in the       
CHMI. 
L9LS ADMINISTRATION
You will be in the clinic for about 8 hours on the day L9LS is given.
·
Intravenous (IV) Dosing (Groups 1, 2, 4): We will place an IV line (thin tube) in a vein 
in your arm.  The IV line will be attached to a bag that has L9LS mixed with a liquid 
called “normal saline” or salt water.  It will flow into your vein for about 30 minutes.  
If you have side effects during the infusion, it may be slowed down or stopped as needed.  
At        the end of your infusion, we will monitor you for any side effects.  If you are the 
first person to get the first of a new dose level, you will be monitored for at least 2   
hours.  Everyone else will be monitored for at least 1 hour after getting L9LS.
We will also place an IV line in your other arm for blood collection during the visit to 
avoid sticking you with a needle multiple times.  We will draw your blood before and 
right after the infusion, and then 3 more times during the 4-6 hours after the infusion. 
VRC 614 Study Schema
L9LS Administration
Group
Subjects
Dose (mg/kg)
Route
CHMI
1
5
1
IV
X
2
4
5
IV
X
3
5
5
SC
X
4
4
20
IV
X
5
6
1
Control
X
6
5
5
IM
N/A
Total
29
1
Two (2) additional control subjects will be enrolled as CHMI back-ups
            000 3 
                   12/01/2021
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/03/2021 V2.0
Page 
5
 of 
19
CC ICF template v9 04.13.2021
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
You       will be allowed to go home about 4-6 hours after the infusion, as long as you do 
not have concerning side effects. If you have side effects, we will treat them.  You will 
need to come back to the clinic 2 times during the same week for blood draws.
·
Subcutaneous
 
(SC) Dosing (Group 3): We will use a small needle to inject L9LS into 
the fatty tissue  of your belly.  We may use your arm or thigh area instead of your belly 
if those sites are more appropriate for your body. You will get 1 or 2 injections to get 
the full dose of L9LS. If you are the first person to get L9LS in this group, you will be 
monitored for at least 2  hours. Everyone else will be monitored for at least 1 hour after 
getting L9LS. If there are no safety concerns, you will be  allowed to leave the clinic 
after the safety check. You will need to come back to the clinic 3 times during the same 
week for blood draws.
·
Intramuscular (IM) Dosing (Group 6): We will use a needle to inject L9LS into the 
muscle of your upper arm and/or thigh. You will get 2 to 4 injections to get the full 
dose of L9LS. If you are the first person to get L9LS in this group, you will be 
monitored for at least 2 hours. Everyone else will be monitored for at least 1 hour after 
getting L9LS. If there are no safety concerns, you will be allowed to leave the clinic 
after the safety check. You will need to come back to the clinic 3 times during the same 
week for blood draws.
We will give you a thermometer so that you can check your temperature every day for 7 days after 
you get L9LS. You will need to record your highest temperature daily and tell us about any 
symptoms you have.  We will also give you a measuring tool so that you can measure any redness, 
swelling, or bruising you may have at the injection site. You will get a password to a secure website 
to record this information. If you do not have internet access, you may use a paper      diary that we 
give you instead.
If you have any side effects or feel unwell after you get L9LS, you should tell a VRC nurse or 
doctor as soon as possible.  You can reach the clinic staff by phone 24 hours a day.  If you have 
symptoms, you may be asked to come into the clinic for an examination before your next scheduled 
visit.  You may also stay overnight in the hospital, if needed.  It is very important that you follow 
the instructions from the clinic staff
FOLLOW-UP AFTER L9LS ADMINISTRATION
The follow-up visits will last 30 minutes to 2 hours and allow us to check you for any health 
changes     or problems.  We will ask you how you are feeling and if you have taken any medications. 
We will measure  your vital signs, and may perform a targeted physical exam based on how you 
are feeling.  We will take about 1–11 tubes of blood (~ less than one half up to 6 tablespoons at 
each visit for safety and/or research tests.  Blood draw volumes will be within NIH Clinical Center 
limits. We will tell you right away if any of your test results show a health problem.  You might 
need to have extra clinic visits and laboratory tests if you have health changes that need to be 
checked.
Clinical studies follow a set schedule. This helps us answer the research questions. The visit 
schedule is a little flexible, but 
it is important that you follow the schedule as closely as possible
. 
You should try to not miss any visits.  
You should contact the clinic staff as soon as possible if 
            000 3 
                   12/01/2021
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/03/2021 V2.0
Page 
6
 of 
19
CC ICF template v9 04.13.2021
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
you need to change the date or time of any study visit.  When you complete this study, we may 
invite you to take part in another study for follow-up sample collection.
CONTROLLED HUMAN MALARIA CHALLENGE (CHMI) – GROUPS 1-5 ONLY
To learn if L9LS can prevent malaria infection, we will conduct a CHMI. The CHMI will be 
performed by U.S. Military scientists, physicians and other trained personnel who are experienced 
in conducting a CHMI under controlled conditions.  It will take place at the Walter  Reed Army 
Institute of Research (WRAIR) facility in Silver Spring, Maryland. The CHMI visit will last about 
4 to 6 hours and begins very early in the morning. 
During the CHMI, we will put mosquitoes carrying the malaria parasites into a cup. The cup is 
covered with nylon tulle netting and allows the mosquitoes to bite you under controlled conditions. 
They cannot escape from the cup.  No more than 5 mosquitoes are put in the cup at one time. You 
will hold the cup against your arm for 5 minutes and then the mosquitos will be checked for blood 
feeding and presence of malaria parasites. If needed, more mosquitoes may be added until we are 
sure that a total of 5 mosquitoes have fed on your blood.
Follow up after the CHMI is very important so we can check your health. We know that it takes 
anywhere from 7-15 days to find malaria parasites in the blood.  So, after the CHMI, we will call 
you by phone to check on you 2 times in the first week. Then, starting on day 7, you must come to 
the NIH Clinical Center every day for about 30-minute visits through day 17 so we can collect 
blood for diagnostic and research purposes. The visits may be longer if medical evaluation is 
needed.  If  you  test  positive  for  malaria,  you  will  be  treated  right  away  with  anti-malarial 
medication.  We will also bring you back about 8 weeks after the CHMI to make sure you are 
cured.  At  day  21,  anyone  who still  has  a  negative  malaria  test  will  be  given  antimalarial 
medication.  This way we can make sure that anyone who might have malaria infection is treated, 
even if your tests are negative.  If you are negative for malaria, we will call you by phone to check 
on you about 8 weeks after the CHMI
This type of CHMI has been done for over 35 years for many malaria studies.  The mosquitoes 
that will be used are raised in a laboratory for CHMIs.  They are infected with a specific strain of 
the malaria parasite (
Plasmodium falciparum
) that is known to be treatable with the anti-malaria 
medication we will give you.  While the mosquitos are being grown, they feed on transfusion- 
quality human donor blood that has been screened following FDA requirements to make sure that 
the blood is not carrying any other infectious diseases. This type of malaria does not cause 
recurrent infections after you are treated.
HOW LONG WILL THE STUDY TAKE?
The study will last for about  24 weeks if you are in Groups 1, 2, 3, 4, and 6 that get L9LS. You will 
visit the NIH Clinical Center for about 11 or 12 study visits based on if you get L9LS by IV or 
SC/IM, respectively, and up to 15 visits for the CHMI follow-up if you are taking part in the 
CHMI.  If you are in Group 5, which does not receive L9LS, the study       will last for about 7 weeks 
after the CHMI. We will discuss the exact schedule and location of these visits with you.  
            000 3 
                   12/01/2021
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/03/2021 V2.0
Page 
7
 of 
19
CC ICF template v9 04.13.2021
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
HOW MANY PEOPLE WILL PARTICIPATE IN THIS STUDY?
We plan to enroll about 29 people. This includes about 23 people who will get L9LS and about    6 
control participants.  We may enroll up to 40 people if needed to complete the study and this 
includes 2 back-up control participants for the CHMI.
WHAT ARE THE RISKS AND DISCOMFORTS OF BEING IN THE STUDY?
POSSIBLE RISKS OF L9LS
This study is the first time that L9LS will be given to people.  The information described below  is 
taken from studies with other antibodies that are like L9LS and may work the same.  Some of those 
antibodies are approved for use in people.  Like other drugs, monoclonal antibodies can cause side 
effects, some of which can be serious.  Most side effects occur within the first 24 hours   after an 
antibody is given.
·
Side effects to antibodies given by IV may include: fever, chills, shaking, nausea, 
vomiting, pain, headache, dizziness.  More serious but rare side effects may occur, 
including trouble   breathing, high or low blood pressure, itchiness, rash, hives, lip or 
face swelling, diarrhea, racing heart, or chest pain. These symptoms usually go away 
within a few minutes to hours after the product is given. We are giving L9LS at a 
controlled rate. If you develop symptoms while getting L9LS, tell the nurse right away. 
Slowing or stopping the flow  rate may help improve the symptoms.
·
Side effects to antibodies given by SC may include: mild itchiness, redness and/or 
swelling        at the site of injection. Tiredness, muscle pain, and headache have also been 
reported. These symptoms usually go away within 1 to 2 days.
·
Side effects to antibodies given IM include: mild itchiness, redness and/or swelling        at 
the site of injection. Tiredness, muscle pain, and headache have also been reported. 
These symptoms usually go away within 1 to 2 days.
Some antibodies have a risk of serious allergic reactions that can be life threatening including:
·
Anaphylaxis is one type of allergic reaction that may happen soon after an antibody is 
given. This reaction can include difficulty breathing, low blood pressure, hives, rash, 
or swelling in the mouth and face.  This reaction is rare but can be life threatening. 
Participants will remain under observation in the time frame that this usually occurs. 
·
Serum sickness is a type of allergic reaction that may happen several days to weeks 
after an antibody is given. This reaction may include hives, rash, fever, enlarged lymph 
nodes, muscle pains, joint pains, chest discomfort or shortness of breath.
Some antibody products can increase the risk of serious infections.  L9LS is not expected to 
increase the risk of serious infections because it attacks a parasite and does not target the human 
immune system.
In a lab study, L9LS attached to the salivary glands that produce saliva.  This was a rare finding. 
We do not know if L9LS affects your salivary glands.  We will be checking for any possible 
problems with your salivary glands during the study.  If there is a concern for salivary gland 
            000 3 
                   12/01/2021
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/03/2021 V2.0
Page 
8
 of 
19
CC ICF template v9 04.13.2021
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
problems, we may ask an oral specialist to examine you and provide a recommendation for your 
care. 
UNKNOWN RISKS
L9LS may have other side effects that are not yet known.  Taking part in this study may affect 
your eligibility for future monoclonal antibody or malaria studies.  We will give you any new 
information about risks or other information that may affect your decision to continue in the study 
as it becomes available.  You may not donate blood while taking part in this study and you may 
not donate blood for one year after the date of your last dose of L9LS or three years after your last 
CHMI.
POSSIBLE RISKS OF IV, IM, OR SC DOSING
General risks of methods that use a needle include stinging, discomfort, pain, soreness, redness, 
bruising, swelling or a tiny cut at the needle insertion site.
POSSIBLE RISKS OF BLOOD DRAWING
Blood drawing may cause pain, bruising, and may cause a feeling of lightheadedness or fainting. 
Rarely, it may cause infection at the site where the blood is taken.  An IV line will be placed in 
your vein for a few hours on a day L9LS is given by IV.  Problems at the IV site are usually mild 
and may include pain, bruising, minor swelling, or bleeding.  Rarely, there may be an infection, 
vein irritation, nerve problem, or blood clot.
POSSIBLE RISKS OF CHMI – GROUPS 1-5 ONLY 
During the CHMI, you will be bitten by mosquitoes that carry live malaria parasites which cause 
malaria infection.  We do not know if L9LS will protect people from malaria.  If you did not 
receive any L9LS and are in the control group, you are expected to get malaria.  If you get malaria, 
you may experience the        following symptoms:
·
Fever, chills, headache, dizziness, muscle aches, sweats, fatigue, insomnia
·
Nausea, vomiting, stomach cramps, diarrhea
·
Decrease in numbers of red blood cells, white blood cells, and platelets
·
Enlarged liver or spleen
Symptoms are usually mild to moderate, but you may have some severe symptoms.  You may have 
fevers for 1 to 3 days.  You may miss time from work or school due to your illness.  You will not 
be compensated for any loss of income for missing work.   If malaria is not treated right away, it 
can lead to kidney, liver, heart or brain damage and death.  The CHMI is considered to be safe 
because people are closely monitored and treated as soon as they are found to have malaria 
infection, but they must remain in close contact with the study team.
After the CHMI, it is important that you come to the clinic for your scheduled visits so that 
the level of malaria parasites in your blood does not increase to dangerous levels
. From past 
studies we know that malaria parasites can be found in the blood anywhere from about 7 to 15 
days after mosquito exposure.  About half of the people infected with malaria parasites develop 
            000 3 
                   12/01/2021
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/03/2021 V2.0
Page 
9
 of 
19
CC ICF template v9 04.13.2021
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
fever that usually lasts less than 12 hours.  Once treatment for malaria is started, the fever does not 
last longer than 48 hours.
Other symptoms of headache, nausea, vomiting, and loss of appetite may occur.  These symptoms 
may last an average of 3 days, with a range of 1 to 6 days when treatment is started soon after 
malaria parasites are identified by blood tests.  
Failure to return for testing or treatment after 
a CHMI can result in a serious case of malaria that is life-threatening.
  For this reason, you 
must give the names and phone numbers of at least two emergency contacts to the study staff. We 
will contact them before the CHMI to confirm communication with them in case we are not able 
to reach you by phone, text, or email after CHMI.
Among the 2,700+ participants who have participated in a CHMI since 1971, two serious events 
have been reported.  Both were cardiac events (chest pain) and occurred in people who got an 
investigational malaria vaccine.  The pain was thought to be due to myocarditis (inflammation of 
the heart muscle).  Myocarditis is a reported complication from vaccinations.  Rarely, myocarditis 
has also been reported in association with naturally-acquired malaria infection.
These are the only two cases we know about in which a cardiac event occurred after CHMI.  In 
the  unlikely  event that you develop myocarditis,  you will  be evaluated  and followed by  a 
cardiologist until resolution.
If you feel unwell at any time after the CHMI, you may be asked to remain in the clinic until you 
are checked by a study doctor.  You might stay in the hospital overnight if needed.
POSSIBLE RISKS FROM TREATMENT FOR MALARIA – GROUPS 1-5 ONLY
Everyone who takes part in the CHMI will get antimalarial treatment by Day 21 after CHMI. 
Standard treatment for malaria takes 72 hours to complete. We will give you the medication at the  
first sign of infection in your blood.  You should expect to have malaria symptoms for about 3 
days.  Only drugs approved by the U.S. FDA will be used for treatment of malaria. We will treat 
you with Malarone unless you have a known allergy.  In that case, we would treat you with 
chloroquine or another suitable alternative.  Any drugs given are effective in treating the type of 
malaria parasite used for the CHMI.
The drugs that treat malaria may also cause some side effects. Treatments and their side effects 
are described below:
1. The first line of treatment will be Malarone. If you get Malarone, you may have the 
following side effects:
·
Nausea, vomiting, abdominal pain, loss of appetite, diarrhea
·
Temporary elevation of liver function tests
·
Headache and coughing
·
Rarely, low blood count, oral irritation or ulcers, insomnia, fever, 
swelling, rash and hair loss
2. Another backup treatment option will be chloroquine. If you get chloroquine, you 
may have the following side effects:
·
Nausea, vomiting, abdominal pain, diarrhea, dizziness, sleep 
            000 3 
                   12/01/2021
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/03/2021 V2.0
Page 
10
 of 
19
CC ICF template v9 04.13.2021
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
disturbances and photosensitivity
·
Headache, blurred vision, ringing in ears
·
Itching, skin rash, and make conditions of psoriasis (itchy skin rash) and 
porphyria (rare disturbance of metabolism that can be seen as disorders of 
the skin or other organs) worse
·
Long term use can cause permanent eye damage or deafness, but you will 
only be receiving a short course of treatment
·
Rarely, there may be changes in electrocardiograms (test of heart’s electrical 
activity) and low blood pressure
If you need treatment with any other antimalarial drug, we will give you information about the 
side effects of that drug. You can also take over-the-counter medicine, like acetaminophen 
(Tylenol) and/or ibuprofen for fever, headache or other symptoms of malaria.
MOSQUITO BITE SITE REACTIONS – GROUPS 1-5 ONLY
Local, allergic reactions are common after mosquito bites.  You may have itching and raised, red 
swelling at the sites of the bites.  These reactions usually develop quickly, go away 1 to 4 days 
after a mosquito bite, and do not need treatment.  So far, no severe allergic reactions to mosquito 
bites have been reported in prior CHMI studies. You will be observed for 30 minutes after the last 
mosquito bite.  We will check the bite area and watch for any severe allergic signs.  We may give 
you a steroid cream to use on the skin reactions.
POSSIBLE RISKS FROM STORED SAMPLES
There is a small chance that information from your medical records could be given to someone 
who should not get it without your permission.  It is possible for someone to use that information 
to discriminate against you when you apply for insurance or employment.  Similar problems may 
occur if you give information about yourself or agree to have your medical records released.
POSSIBLE RISKS OF DATA SHARING 
Information in the shared databases could be linked back to you and used to discriminate against 
you or  your  family.    State  and  federal laws  provide  some  protections  against  genetic  and 
preexisting conditions discrimination.
POSSIBLE RISKS RELATED TO PREGNANCY
If you are able to become pregnant, we will do a pregnancy test before beginning this study.  We 
will also give you a pregnancy test before you get L9LS and before CHMI.  You must use effective 
birth control methods and try not to become pregnant while taking part in this study.  If you become 
pregnant, there may be unknown risks to the fetus or unborn child, or risks that we did not 
anticipate.  There may be long-term effects of the treatment being studied that could increase the 
risk of harm to a fetus.  You must tell the study doctor if your birth control method fails while you 
are in the study.  If you think or know you have become pregnant while taking part in this research 
study, please contact the research team member identified at the top of this document as soon as 
possible.  You should not plan to become pregnant until you have completed participation in this 
study.
            000 3 
                   12/01/2021
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/03/2021 V2.0
Page 
11
 of 
19
CC ICF template v9 04.13.2021
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
SAFETY MEASURES YOU SHOULD USE AS A PARTICIPANT IN THE STUDY
You should not expect L9LS to protect you from malaria in the future. You should assume that 
you are not protected from malaria.  After leaving the study, you should follow your physician’s 
instructions to prevent malaria infection.  We also ask that you follow our instructions below:
·
Travel:  Do not travel outside the local area from the CHMI through 28 days after. 
Before or after this point, please let the study staff know about planned travels so we 
can schedule  your visits and have contact information before you travel.  We ask that 
you not travel to any areas with malaria during the entire period of the study.  
Country-specific information can be provided. This does not apply to Group 6.
·
Use of Antibiotics:  Avoid taking antibiotics starting 4 weeks before the CHMI and 
during the CHMI unless prescribed by a physician.  Please notify the study team 
immediately if an antibiotic is prescribed for you or if you consider taking an 
antibiotic during the course of the study. This does not apply to Group 6.
·
Blood Donation: You will not be permitted to donate blood for transfusion purposes 
while  in the study, for 1 year after your L9LS administration and for 3 years after the 
CHMI.  To make sure that blood is safe for donation, blood banks will not accept 
blood donations for 1 year after exposure to an investigational product (L9LS) and 
for 3 years from anyone who is infected with or treated for malaria .
·
Mosquito Avoidance: For two weeks after the CHMI you should practice mosquito 
avoidant  behaviors.  This  includes  covering  your  skin  when  outside,  avoiding 
outdoors at times mosquitoes are active (dusk, evening, dawn), using insect repellants 
appropriately on yourself and your clothes, and maintaining effective mosquito 
barriers in your home such as screen doors and windows. Clinical staff will cover 
these with you again in detail during the CHMI process. This does not apply to Group 
6.
WHAT ARE THE BENEFITS OF BEING IN THE STUDY?
You will not benefit from being in this study.
Are there any potential benefits to others that might result from the study?
In the future, other people might benefit from this study because the information may help us learn 
more about preventing and treating malaria infection. Results from this study may also be used to 
help develop new products that target malaria or other infectious diseases in the future.
WHAT OTHER OPTIONS ARE THERE FOR YOU?
Before you decide whether or not to be in this study, we will discuss other options that are 
available to you.  Instead of being in this study, you could choose not to take part.  You may be 
eligible for other VRC studies.
 
            000 3 
                   12/01/2021
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/03/2021 V2.0
Page 
12
 of 
19
CC ICF template v9 04.13.2021
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
DISCUSSION OF FINDINGS
New information about the study
If we find out any new information that may affect your choice to participate in this study, we 
will get in touch with you to explain what we have learned.  This may be information we have 
learned while doing this study here at the NIH or information we have learned from other 
scientists doing similar research in other places.
Return of research results
At each visit you will be checked for any health changes or problems. Blood will be drawn at 
almost every study visit to either check on your health or collect samples for research. You will be 
told right away by phone call, text, or in person in the clinic if any of your test results show a health 
problem.
After the CHMI, we will draw your blood to test for malaria parasites. You will be told right away 
by phone, or in person in the clinic if we find that you have malaria infection.
We will use some of the blood samples to study how long L9LS remains in your body and if your 
body develops an immune response to L9LS and to the CHMI.  We will also study the malaria 
parasites that we may find in your bloodstream after the CHMI if you get malaria infection.  These 
tests are for research purposes only and are not for checking on your health. We will not give you 
these results.
The results of this study may be reported in medical journals, on the internet or at scientific 
meetings. We will give you information about how to find the study results once they are available.
EARLY WITHDRAWAL FROM THE STUDY 
You may be removed from the research study by the researcher for any of the following reasons:
·
Not keeping appointments or following study procedures;
·
Getting a serious illness that needs ongoing medical care;
·
Enrolling in another research study at the same time you are in this study;
·
Becoming pregnant;
·
The study is stopped or cancelled;
·
The researcher believes that it is in your best interest to remove you from the study.
·
The study is stopped by regulatory agencies, the study sponsor or study 
investigators. If this happens, we will tell you why.
You can stop taking part in the study at any time.  However, if you decide to stop taking part in 
this study, you will be asked to keep follow up visits so we can check your health, especially if 
you got a dose of L9LS or take part in the CHMI.  We may stop collecting samples that are for 
research purposes only.
We don’t know if you will get malaria after the CHMI. If you choose to stop the study after the 
CHMI and before completion of monitoring for malaria infection, you will need to be treated for 
malaria by the study doctor regardless of whether you develop symptoms of malaria or parasites 
in your blood.
            000 3 
                   12/01/2021
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/03/2021 V2.0
Page 
13
 of 
19
CC ICF template v9 04.13.2021
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
STORAGE, SHARING AND FUTURE RESEARCH USING YOUR SPECIMENS AND 
DATA
Will your specimens or data be saved for use in other research studies?
As part of this study, we are obtaining specimens and data from you.  We will remove all the 
identifiers, such as your name, date of birth, address, or medical record number and label your 
specimens and data with a code so that you cannot easily be identified. However, the code will 
be linked through a key to information that can identify you.  We plan to store and use these 
specimens and data for studies other than the ones described in this consent form that are going 
on right now, as well as studies that may be conducted in the future.  These studies may provide 
additional  information  that will  be  helpful  in  understanding  malaria,  or  other  diseases  or 
conditions. This could include studies to develop other research tests, treatments, drugs, or 
devices, that may lead to the development of a commercial product by the NIH and/or its research 
or commercial partners.  There are no plans to provide financial compensation to you if this 
happens.  Also, it is unlikely that we will learn anything from these studies that may directly 
benefit you.
By agreeing to take part in this study, you give permission for your coded specimens and data to 
be stored and used for future research as described above.
Will your specimens or data be shared for use in other research studies?
We may share your coded specimens and data with other researchers.  If we do, while we will 
maintain the code key, we will not share it, so the other researchers will not be able to identify 
you.  They may be doing research in areas that are similar to this study or in other unrelated 
areas.  These researchers may be at NIH, other research centers and institutions, or commercial 
entities.
By agreeing to take part in this study, you give permission for your coded specimens and data to 
be shared with other researchers and used by these researchers for future research as described 
above.
If you change your mind and do not want us to store and use your specimens and data for future 
research, you should contact the research team member identified at the top of this document. 
We will do our best to comply with your request but cannot guarantee that we will always be 
able to destroy your specimens and data.  For example, if some research with your specimens 
and data has already been completed, the information from that research may still be used.  Also, 
for example, if the specimens and data have been shared already with other researchers, it might 
not be possible to withdraw them. 
In addition to the planned use and sharing described above, we might remove all identifiers and 
codes from your specimens and data and use or share them with other researchers for future 
research at the NIH or other places.  When we or the other researchers access your anonymized 
data, there will be no way to link the specimens or data back to you.  We will not contact you to 
ask your permission or otherwise inform you before we do this.  We might do this even if you 
answered "no" to the above questions.  If we do this, we would not be able to remove your 
specimens or data to prevent their use in future research studies, even if you asked, because we 
will not be able to tell which are your specimens or data.
            000 3 
                   12/01/2021
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/03/2021 V2.0
Page 
14
 of 
19
CC ICF template v9 04.13.2021
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
NIH policies require that your clinical and other study data be placed in an internal NIH database 
that is accessible to other NIH researchers for future research. Usually, these researchers will not 
have access to any of your identifiers, such as your name, date of birth, address, or medical 
record number; and your data will be labeled with only a code. We cannot offer you a choice of 
whether your data to be placed in this database or not.  If you do not wish to have your data 
placed in this database, you should not enroll in this study.  
GENETIC TESTING
 
Some of the blood drawn from you during this study will be used for genetic tests.  Some genetic 
tests are done in research studies to see if there are genetic difference in immune responses.  Your 
blood sample used in these genetic tests will not have your name on it, and the results will not 
be in your medical record.
How long will your specimens and data be stored by the NIH?
Your specimens and data may be stored by the NIH
 
indefinitely
.
Risks of storage and sharing of specimens and data
When we store your specimens and data
,
 we take precautions to protect your information from 
others that should not have access to it.  When we share your specimens and data, we will do 
everything we can to protect your identity, for example, when appropriate, we remove information 
that can identify you.  Even with the safeguards we put in place, we cannot guarantee that your 
identity will never become known, or someone may gain unauthorized access to your information. 
New methods may be created in the future that could make it possible to re-identify your specimens 
and data.
PAYMENT
Will you receive any type of payment for taking part in this study?
You will be compensated for your time and inconvenience by the NIH Clinical Research Volunteer 
Program per NIH policies and guidelines.  It is possible that you may have some expenses that are 
not covered by the compensation provided.
The compensation for specific study visits is as follows:
·
$430 for the study visit that includes IV administration of L9LS 
·
$375 for the study visit that includes SC or IM administration of L9LS $455 
for the malaria challenge (CHMI) with pre-CHMI clinic visit and activities 
·
$25 total for the timely completion of all 7 days of an electronic diary
·
$200 for a scheduled follow-up visit that includes blood draw
·
$85 for all other clinic visits that do not include blood draws
Total compensation for completion of all study visits including CHMI is between $4195 and $5950 
if you get L9LS by IV and between $4340 and $6140 if you get L9LS by SC. Compensation for 
the IM group is around $2800. Compensation for CHMI visits for the control group is between 
about $1625 and $3425.  The total compensation you get is based on the number and type of study 
            000 3 
                   12/01/2021
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/03/2021 V2.0
Page 
15
 of 
19
CC ICF template v9 04.13.2021
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
visits you complete.  If you are unable to finish the study, you will get compensation only for the 
study visits you completed. 
You will get the compensation about 2 weeks after each completed visit by direct deposit into a 
bank account that you specify to the Volunteer Payment Office.
The study team will collect social security numbers from research participants for purposes of 
compensation.  Participants can withhold their social security numbers and still participate in the 
research study; however you may not be able to receive compensation if you do so.
With few exceptions, study compensation is considered taxable income that is reportable to the 
Internal Revenue Service (IRS).  A “Form 1099-Other Income” will be sent to you if your total 
payments for research participation are $600 or more in a calendar year.  If you have unpaid debt 
to the federal government, please be aware that some or all of your compensation may be 
automatically reduced to repay that debt on your behalf.
REIMBURSEMENT
Will you receive reimbursement or direct payment by NIH as part of your participation?
This study does not offer reimbursement for participants, or payment of, hotel, travel, or meals. 
COSTS
Will taking part in this research study cost you anything?
NIH does not bill health insurance companies or participants for any research or related clinical 
care that you receive at the NIH Clinical Center. 
CONFLICT OF INTEREST (COI) 
The NIH reviews NIH staff researchers at least yearly for conflicts of interest.  This process is 
detailed in a COI Guide.  You may ask your research team for a copy of the COI Guide or for more 
information.  Members of the research team who do not work for NIH are expected to follow these 
guidelines or the guidelines of their home institution, but they do not need to report their personal 
finances to the NIH.
The NIH and the research team for this study have developed the investigational product, L9LS, 
being used in this study. This means it is possible that the results of this study could lead to 
payments to NIH.  By law, the government is required to share such payments with the employee 
inventors.  You will not receive any money from the development of L9LS.
CLINICAL TRIAL REGISTRATION AND RESULTS REPORTING 
A description of this clinical trial will be available on 
http://www.ClinicalTrials.gov, as required 
by U.S. Law.  This website will not include information that can identify you.  At most, the website 
will include a summary of the results, once they are available.  You can search this website at any 
time.
            000 3 
                   12/01/2021
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/03/2021 V2.0
Page 
16
 of 
19
CC ICF template v9 04.13.2021
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
CONFIDENTIALITY PROTECTIONS PROVIDED IN THIS STUDY  
Will your medical information be kept private? 
We will do our best to make sure that the personal information in your medical record will be kept 
private.  However, we cannot guarantee total privacy.  Organizations that may look at and/or copy 
your medical records for research, quality assurance, and data analysis include:
·
The NIH and other government agencies, like the Food and Drug Administration (FDA), 
which are involved in keeping research safe for people.
·
NIH Intramural Institutional Review Board
·
The study Sponsor (VRC) or their agent(s) 
·
United  States  Army  Medical  Research  and  Development  Command  (USAMRDC) 
representatives
The researchers conducting this study and the NIH follow applicable laws and policies to keep 
your identifying information private to the extent possible.  However, there is always a chance 
that, despite our best efforts, your identity and/or information about your participation in this 
research may be inadvertently released or improperly accessed by unauthorized persons.
In most cases, the NIH will not release any identifiable information collected about you without 
your written permission.  However, your information may be shared as described in the section of 
this document on sharing of specimens and data, and as further outlined in the following sections.  
Further, the information collected for this study is protected by NIH under a Certificate of 
Confidentiality and the Privacy Act. 
Certificate of Confidentiality
To help us protect your privacy, the NIH Intramural Program has received a Certificate of 
Confidentiality (Certificate). With this certificate, researchers may not release or use data or 
information about you except in certain circumstances.  
NIH researchers must not share information that may identify you in any federal, state, or local 
civil, criminal, administrative, legislative, or other proceedings, for example, if requested by a 
court.  
The Certificate does not protect your information when it:  
1. is disclosed to people connected with the research, for example, information may be used 
for auditing or program evaluation internally by the NIH; or 
2. is required to be disclosed by Federal, State, or local laws, for example, when information 
must  be  disclosed  to  meet  the  legal  requirements  of  the  federal  Food  and  Drug 
Administration (FDA); 
3. is for other research;
4. is disclosed with your consent. 
The Certificate does not prevent you from voluntarily releasing information about yourself or your 
involvement in this research. 
            000 3 
                   12/01/2021
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/03/2021 V2.0
Page 
17
 of 
19
CC ICF template v9 04.13.2021
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
The Certificate will not be used to prevent disclosure to state or local authorities of harm to self or 
others including, for example, child abuse and neglect, and by signing below you consent to those 
disclosures. Other permissions for release may be made by signing NIH forms, such as the Notice 
and Acknowledgement of Information Practices consent.
Privacy Act
The Federal Privacy Act generally protects the confidentiality of your NIH medical information 
that we collect under the authority of the Public Health Service Act.  In some cases, the Privacy 
Act protections differ from the Certificate of Confidentiality.  For example, sometimes the Privacy 
Act allows release of information from your record without your permission, for example, if it is 
requested by Congress.  Information may also be released for certain research purposes with due 
consideration and protection, to those engaged by the agency for research purposes, to certain 
federal and state agencies, for HIV partner notification, for infectious disease or abuse or neglect 
reporting,  to tumor registries, for quality assessment and medical audits, or when the NIH is 
involved in a lawsuit.  However, NIH will only release information from your medical record if it 
is permitted by both the Certificate of Confidentiality and the Privacy Act.
POLICY REGARDING RESEARCH-RELATED INJURIES  
The NIH Clinical Center will provide short-term medical care for any injury resulting from your 
participation in research here.  In general, no long-term medical care or financial compensation for 
research-related injuries will be provided by the NIH, the NIH Clinical Center, or the Federal 
Government.  However, you have the right to pursue legal remedy if you believe that your injury 
justifies such action.
FOR INJURIES RELATED TO CHMI
If you are injured because of your participation in this research during the CHMI and you are a 
DOD healthcare beneficiary (e.g., active duty in the military, military spouse or dependent, 
retiree), you are entitled to medical care for your injury within the DOD healthcare system, as long 
as you remain a DOD healthcare beneficiary.
If you are injured because of your participation in this research during the CHMI and you are not 
a DOD healthcare beneficiary, you are entitled to medical care for your injury at a DOD hospital 
or clinic, but such care for your injury at DOD hospitals or clinics may be time-limited, and your 
insurance may be billed.  It cannot be determined in advance which DOD hospital or clinic will 
provide care.  If you obtain care for research-related injuries outside of a DOD hospital or clinic, 
you or your insurance will be responsible for medical expenses.
For DOD healthcare beneficiaries and non-DOD healthcare beneficiaries: Transportation to and 
from hospitals or clinics will not be provided.  No reimbursement is available if you incur medical 
expenses to treat research-related injuries. No compensation is available for research-related 
injuries.  You are not waiving any legal rights.  If you believe you have sustained a research-related 
injury, please contact the Principal Investigator (PI). If you have any questions, please contact the 
PI.
            000 3 
                   12/01/2021
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/03/2021 V2.0
Page 
18
 of 
19
CC ICF template v9 04.13.2021
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
PROBLEMS OR QUESTIONS
If you have any problems or questions about this study, or about your rights as a research 
participant, or about any research-related injury, contact the Principal Investigator, Richard Wu, 
MD at   Other researchers you may call are: Floreliz 
Mendoza, RN or Lasonji Holman, FNP at    You may also call the NIH Clinical 
Center Patient Representative at   or the NIH Office of IRB Operations at 
 if you have a research-related complaint or concern.
CONSENT DOCUMENT 
Please keep a copy of this document in case you want to read it again.
            000 3 
                   12/01/2021
PATIENT IDENTIFICATIONConsent to Participate in a Clinical Research StudyNIH-2977 (4-17)
File in Section 4: Protocol Consent (1)
Version Date: 11/03/2021 V2.0
Page 
19
 of 
19
CC ICF template v9 04.13.2021
MEDICAL RECORD
CONSENT TO PARTICIPATE IN AN NIH CLINICAL RESEARCH STUDY
Adult Research Participant: 
I have read the explanation about this study and have been given the opportunity 
to discuss it and to ask questions. I consent to participate in this study.
Signature of Research Participant
Print Name of Research Participant
Date
Investigator:
Signature of Investigator
Print Name of Investigator
Date
Witness should sign below if either:
1. A short form consent process has been used to enroll a non-English speaking subject or
2. An oral presentation of the full consent has been used to enroll a blind or illiterate subject
Signature of Witness
Print Name of Witness
Date
NIH  ADMINISTRATIVE  SECTION  TO  BE  COMPLETED  REGARDING  THE  USE  OF  AN 
INTERPRETER:
An interpreter, or other individual, who speaks English and the participant’s preferred language facilitated
the administration of informed consent and served as a witness.
 
The investigator obtaining consent may not 
also serve as the witness.
An interpreter, or other individual, who speaks English and the participant’s preferred language facilitated
the administration of informed consent but did not serve as a witness. The name or ID code of the person 
providing interpretive support is:
.
            000 3 
                   12/01/2021